JC07 Rec'd PCT/PTO 04 DEC 2001

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER **PF-0709 USN** U.S. APPLICATION NO. (If known, see 37 CFR 1.5) TO BE ASSIGNED 10/009328
INTERNATIONAL APPLICATION NO **PCT/US00/16668**	INTERNATIONAL FILING DATE **16 June 2000**	PRIORITY DATE CLAIMED **17 June 1999**

TITLE OF INVENTION
HUMAN TRANSPORT PROTEINS

APPLICANT(S) FOR DO/EO/US
INCYTE GENOMICS, INC.; LAL, Preeti; YANG, Junming; YUE, Henry; HILLMAN, Jennifer L.; TANG, Y. Tom; BANDMAN, Olga; BURFORD, Neil; BAUGHN, Mariah R.; AZIMZAI, Yalda; LU, Dyung Aina M.; AU-YOUNG, Janice; PATTERSON, Chandra

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is the **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to promptly begin national examination procedures (35 U.S.C. 371 (f)).
4. ☐ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. ☐ is attached hereto (required only if not communicated by the International Bureau)
   b. ☐ has been communicated by the International Bureau.
   c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. ☐ are attached hereto (required only if not communicated by the International Bureau).
   b. ☐ have been communicated by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 16 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.27 and 3.31 is included.
13. ☒ A FIRST preliminary amendment, as follows: Cancel in this application original claims 12, 14, 18, 20, 21, 23, 24, 25, 28 - 230 before calculating the filing fee, without prejudice or disclaimer. Applicants submit that these claims were included in the application as filed in the interest of providing notice to the public of certain specific subject matter intended to be claimed, and are being canceled at this time in the interest of reducing filing costs. Applicants expressly state that these claims are not being canceled for reasons related to patentability, and are in fact fully supported by the specification as filed. Applicants expressly reserve the right to reinstate these claims or to add other claims during prosecution of this application or a continuation or divisional application. Applicants expressly do not disclaim the subject matter of any invention disclosed herein which is not set forth in the instantly filed claims.
    ☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

1) Transmittal Letter (2 pp, in duplicate)
2) Return Postcard
3) Express Mail Label No.: **EL 697 344 232 US**
4) Article 34 Amendment

JC07 Rec'd PCT/PTO 04 DEC 2001

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) TO BE ASSIGNED	INTERNATIONAL APPLICATION NO. PCT/US00/16668	ATTORNEY'S DOCKET NUMBER PF-0709 USN

10/009328

17 ☒ The following fees are submitted:
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5):
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....$1000.00
☐International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..$860.00
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....$710.00
☒**International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....$710.00**
☐International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)..... .....$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =				$710.00	
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	20 =	0	X **$ 18.00**	$	
Independent Claims	3 =	1	X **$ 80.00**	$ 80.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ **$270.00**	$	
TOTAL OF ABOVE CALCULATIONS =				$790.00	
☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				$	
SUBTOTAL =				$790.00	
Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1492(f)). +				$	
TOTAL NATIONAL FEE =				$790.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by the appropriate cover sheet (37 CFR 3.28, 3.31). **$40.00** per property +				$	
TOTAL FEES ENCLOSED =				$790.00	
				Amount to be Refunded	$
				Charged	$

a. ☐ A check in the amount of $_____ to cover the above fees is enclosed.
b. ☒ Please charge my Deposit Account No. 09-0108 in the amount of $790.00 to cover the above fees.
c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

INCYTE GENOMICS, INC.
3160 Porter Drive
Palo Alto, CA 94304

SIGNATURE

NAME: Diana Hamlet-Cox

REGISTRATION NUMBER: 33,302

DATE: 4 December 2001

10/009328

Docket No.: PF-0709 USN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Preeti Lal, Junming Yang, Henry Yue, Jennifer L. Hillman, Y. Tom Tang, Olga Bandman, Neil Burford, Mariah R. Baughn, Yalda Azimzai, Dyung Aina M. Lu, Janice Au-Young & Chandra Patterson

Title: HUMAN TRANSPORT PROTEINS

PCT Serial No.: PCT/US00/16668 International Filing Date: 16 June 2000

Examiner: To Be Assigned Group Art Unit: To Be Assigned

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

SUBMISSION UNDER 37 CFR § 1.821-1.825 SEQUENCE LISTING

Sir:

In accordance with the requirements of 37 CFR § 1.821-1.825, Applicants hereby submit one (1) diskette(s) containing the computer-readable information for the Sequence Listing of the above-identified application. The content of the Sequence Listing paper copy is identical to the computer-readable copy filed with the US Receiving Office. The USPTO is authorized to add whatever is necessary to update the CRF with the current application information.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 4 December 2001

Diana Hamlet-Cox
Reg. No. 33,302
Direct Dial Telephone: (650) 845-4639

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

HUMAN TRANSPORT PROTEINS

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of human transport proteins and to the use of these sequences in the diagnosis, treatment, and prevention of transport, metabolic, neurological, cardiovascular, reproductive, and immune disorders, and cell proliferative disorders including cancer.

BACKGROUND OF THE INVENTION

Eukaryotic cells are surrounded and subdivided into functionally distinct organelles by hydrophobic lipid bilayer membranes. These membranes act as a barrier to most molecules, and maintain the essential differences between the cytosol, the extracellular environment, and the contents of each intracellular organelle. Transport of essential nutrients, certain metal ions, metabolic waste products, cell signaling molecules, macromolecules, and proteins across lipid membranes and between organelles must be mediated by a variety of transport molecules. Transport between the cytoplasm and the extracellular environment, and between the cytoplasm and lumenal spaces of cellular organelles requires specific transport proteins. Each transport protein carries a particular class of molecule, such as ions, sugars, or amino acids, and often is specific to a certain molecular species of the class.

Cells and organelles require transport molecules to import and export essential nutrients and metal ions including K^+, NH_4^+, P_i, SO_4^{2-}, sugars, and vitamins, as well as various metabolic waste products. Transport proteins also play roles in antibiotic resistance, toxin secretion, ion balance, synaptic neurotransmission, kidney function, intestinal absorption, tumor growth, and other diverse cell functions (Griffith, J. and C. Sansom (1998) The Transporter Facts Book, Academic Press, San Diego CA, pp. 3-29). Transport can occur by a passive concentration-dependent mechanism, or can be linked to an energy source such as ATP hydrolysis or an ion gradient. Proteins that function in transport include carrier proteins, which bind to a specific solute and undergo a conformational change that transfers the bound solute across the membrane, and channel proteins, which form hydrophilic pores that allow specific solutes to diffuse through the membrane down an electrochemical solute gradient.

Transport proteins are often multi-pass transmembrane proteins, which either actively transport molecules across the membrane or passively allow them to cross. Active transport involves directional pumping of a solute across the membrane, usually against an electrochemical gradient. Active transport is tightly coupled to a source of metabolic energy, such as ATP hydrolysis or an electrochemically favorable ion gradient. Passive transport involves the movement of a solute down

its electrochemical gradient. Transport proteins can be further classified as either carrier proteins or channel proteins. Carrier proteins, which can function in active or passive transport, bind to a specific solute to be transported and undergo a conformational change which transfers the bound solute across the membrane. Channel proteins, which only function in passive transport, form hydrophilic pores across the membrane. When the pores open, specific solutes, such as inorganic ions, pass through the membrane and down the electrochemical gradient of the solute. Examples include facilitative transporters, the secondary active symporters and antiporters driven by ion gradients, and active ATP binding cassette transporters involved in multiple-drug resistance and targeting of antigenic peptides to MHC Class I molecules. Transported substrates range from nutrients and ions to a broad variety of drugs, peptides and proteins.

Information on the action of ARL-6 (ADP-ribosylation like factor), an endoplasmic reticulum transmembrane protein, can be found in Greenfield, J.J. and S. High (1999; J. Cell Sci. 112:1477-1486). Information on reduced folate carrier transporter proteins can be found in Dixon, K.H. et al. (1994; J. Biol. Chem. 269:17-20) and Moscow, J.A. et al. (1995; Cancer Res. 55:5983-5987).

Carrier proteins which transport a single solute from one side of the membrane to the other are called uniporters. In contrast, coupled transporters link the transfer of one solute with simultaneous or sequential transfer of a second solute, either in the same direction (symport) or in the opposite direction (antiport). For example, intestinal and kidney epithelia contain a variety of symporter systems driven by the sodium gradient that exists across the plasma membrane. Sodium moves into the cell down its electrochemical gradient and brings the solute into the cell with it. The sodium gradient that provides the driving force for solute uptake is maintained by the ubiquitous Na^+/K^+ ATPase. Sodium-coupled transporters include the mammalian glucose transporter (SGLT1), iodide transporter (NIS), and multivitamin transporter (SMVT). All three transporters have twelve putative transmembrane segments, extracellular glycosylation sites, and cytoplasmically-oriented N- and C-termini.

Mitochondrial carrier proteins are transmembrane-spanning proteins which transport ions and charged metabolites between the cytosol and the mitochondrial matrix. Examples include the ADP, ATP carrier protein; the 2-oxoglutarate/malate carrier; the phosphate carrier protein; the brown fat uncoupling protein which transports protons from the cytosol into the matrix; the pyruvate carrier; the dicarboxylate carrier which transports malate, succinate, fumarate, and phosphate; the tricarboxylate carrier which transports citrate and malate; and the Grave's disease carrier protein, a protein recognized by IgG in patients with active Grave's disease, an autoimmune disorder resulting in hyperthyroidism (Stryer, L. (1995) Biochemistry, W.H. Freeman and Company, New York NY, p. 551; PROSITE PDOC00189 Mitochondrial energy transfer proteins signature; Online Mendelian Inheritance in Man (OMIM) *275000 Graves Disease).

This class of transporters also includes the mitochondrial uncoupling proteins, which create

proton leaks across the inner mitochondrial membrane, thus uncoupling oxidative phosphorylation from ATP synthesis. The result is energy dissipation in the form of heat. Mitochondrial uncoupling proteins have been implicated as modulators of thermoregulation and metabolic rate, and have been proposed as potential targets for drugs against metabolic diseases such as obesity (Ricquier, D. et al. (1999) J. Int. Med. 245:637-642).

A number of metal ions such as iron, zinc, copper, cobalt, manganese, molybdenum, selenium, nickel, and chromium are important as cofactors for a number of enzymes. For example, zinc is required for the function of enzymes such as the extracellular matrix metalloproteinases, and zinc ions stabilize several motifs commonly found in transcription factors, including zinc fingers, zinc clusters, and LIM domains. Zinc and other metal ions must be provided in the diet, and are absorbed by transporters in the gastrointestinal tract. Plasma proteins transport the metal ions to the liver and other target organs, where specific transporters move the ions into cells and cellular organelles as needed. Imbalances in metal ion metabolism have been associated with a number of disease states (Danks, D.M. (1986) J. Med. Genet. 23:99-106).

The largest and most diverse family of transport proteins known are the ATP-binding cassette (ABC) transporters. As a family, ABC transporters can transport substances that differ markedly in chemical structure and size, ranging from small molecules such as ions, sugars, amino acids, peptides, and phospholipids, to lipopeptides, large proteins, and complex hydrophobic drugs. ABC proteins consist of four modules: two nucleotide-binding domains (NBD), which hydrolyze ATP to supply the energy required for transport, and two membrane-spanning domains (MSD), each containing six putative transmembrane segments. These four modules may be encoded by a single gene, as is the case for the cystic fibrosis transmembrane regulator (CFTR), or by separate genes. When encoded by separate genes, each gene product contains a single NBD and MSD. These "half-molecules" form homo- and heterodimers, such as Tap1 and Tap2, the endoplasmic reticulum-based major histocompatibility (MHC) peptide transport system. Several genetic diseases are attributed to defects in ABC transporters, such as the following diseases and their corresponding proteins: cystic fibrosis (CFTR, an ion channel), adrenoleukodystrophy (adrenoleukodystrophy protein, ALDP), Zellweger syndrome (peroxisomal membrane protein-70, PMP70), and hyperinsulinemic hypoglycemia (sulfonylurea receptor, SUR). Overexpression of the multidrug resistance (MDR) protein, another ABC transporter, in human cancer cells makes the cells resistant to a variety of cytotoxic drugs used in chemotherapy (Taglicht, D. and S. Michaelis (1998) Methods Enzymol. 292:131-163).

The nuclear pore complex (NPC) is a large multiprotein complex spanning the nuclear envelope which mediates the transport of proteins and RNA molecules between the nucleus and the cytoplasm, thus contributing to the regulation of gene expression. The NPC allows passive diffusion of ions, small molecules, and macromolecules under about 60kD, while larger macromolecules are transported by facilitated, energy-dependent pathways. Nuclear localization signals (NLS), consisting

of short stretches of amino acids enriched in basic residues, are found on proteins that are targeted to the nucleus, such as the glucocorticoid receptor. The NLS is recognized by the NLS receptor, importin, which then interacts with the monomeric GTP-binding protein Ran. This NLS protein/receptor/Ran complex navigates the nuclear pore with the help of the homodimeric protein nuclear transport factor 2 (NTF2) (Nakielny, S. and G. Dreyfuss (1997) Curr. Opin. Cell Biol. 9:420-429; Gorlich, D. (1997) Curr. Opin. Cell Biol. 9:412-419). Four O-linked glycoproteins, p62, p58, p54, and p45, exist as a stable "p62 complex" that forms a ring localized on both nucleoplasmic and cytoplasmic surfaces of the NPC. The p62, p58, and p54 proteins all interact directly with the cytosolic transport factors p97 and NTF2, suggesting that the p62 complex is an important ligand binding site near the central gated channel of the NPC (Hu, T. et al. (1996) J. Cell Biol. 134:589-601).

Transport can also occur through intercellular bridges which connect the cytoplasms of sister cells, for example in the male and female germline of species ranging from fruit flies to humans. These bridges allow passage of cytoplasmic materials between cells during development. Intercellular bridges have also been found to connect somatic cells. The nurse cells and oocyte of a Drosophila egg chamber, which are derived from a single precursor cell through four rounds of mitosis, are connected to each other through intercellular bridges called ring canals. The cells do not completely separate after mitosis; the mitotic cleavage furrows are transformed into ring canals by the addition of an actin cytoskeleton lining the tunnels between the cells. The Drosophila kelch protein functions in organizing actin in the ring canal. Mutations in kelch cause female sterility in Drosophila. Kelch contains four protein domains: the NTR domain at the N-terminus, the BTB or POZ domain, the IVR or intervening region; and the kelch repeat domain, which contains six 50-amino acid kelch repeats. The BTB or POZ domain, a 120-amino acid motif that is also found in several zinc-finger containing transcription factors, may be important in dimerization of kelch. Kelch repeats are found in other proteins as well and may be important for actin binding (Robinson, D.N. and L. Cooley (1997) J. Cell Biol. 138:799-810; Cooley, L. (1998) Cell 93:913-915).

Ion Channels

The electrical potential of a cell is generated and maintained by controlling the movement of ions across the plasma membrane. The movement of ions requires ion channels, which form an ion-selective pore within the membrane. Ion channels share common structural and mechanistic themes. The channel consists of four or five subunits or protein monomers that are arranged like a barrel in the plasma membrane. Each subunit typically consists of six potential transmembrane segments (S1, S2, S3, S4, S5, and S6). The center of the barrel forms a pore lined by α-helices or β-strands. The side chains of the amino acid residues comprising the α-helices or β-strands establish the charge (cation or anion) selectivity of the channel. The degree of selectivity, or what specific ions are allowed to pass through the channel, depends on the diameter of the narrowest part of the pore. There

are two basic types of ion channels, ion transporters and gated ion channels. Ion transporters utilize the energy obtained from ATP hydrolysis to actively transport an ion against the ion's concentration gradient. Gated ion channels allow passive flow of an ion down the ion's electrochemical gradient under restricted conditions. Together, these types of ion channels generate, maintain, and utilize an electrochemical gradient that is used in 1) electrical impulse conduction down the axon of a nerve cell, 2) transport of molecules into cells against concentration gradients, 3) initiation of muscle contraction, and 4) endocrine cell secretion.

Transmembrane ATPases are divided into three families. The phosphorylated (P) class ion transporters, including Na^+-K^+ ATPase, Ca^{2+} ATPase, H^+ ATPase, and Cu^{++} ATPase, are activated by a phosphorylation event. P-class ion transporters are responsible for maintaining resting potential distributions such that cytosolic concentrations of Na^+ and Ca^{2+} are low and cytosolic concentration of K^+ is high. The vacuolar (V) class of ion transporters include H^+ pumps on intracellular organelles, such as lysosomes and Golgi. V-class ion transporters are responsible for generating the low pH within the lumen of these organelles that is required for function. The coupling factor (F) class consists of H^+ pumps in the mitochondria. F-class ion transporters utilize a proton gradient to generate ATP from ADP and inorganic phosphate (P_i).

Cu^{++} ATPases export copper from cells (PROSITE PDOC00139 E1-E2 ATPases phosphorylation site). Mutations in one Cu^{++} ATPase cause Wilson disease, in which toxic amounts of copper accumulate in a number of organs, particularly the liver and brain (Tanzi, R.E. et al. (1993) Nat. Genet. 5:344-350). Mutations in another Cu^{++} ATPase cause Menkes disease and occipital horn syndrome. Menkes disease mutations block export of copper from the gastrointestinal tract, leading to skeletal abnormalities, severe mental retardation, neurologic degeneration, and mortality in early childhood (Harrison, M.D. and C.T. Dameron (1999) J. Biochem. Mol. Toxicol. 13:93-106). Occipital horn syndrome mutations cause connective tissue defects (Harrison, supra; Levinson, B. et al. (1996) Hum. Mol. Genet. 5:1737-1742).

The coupling factor (F) class of ion transporters consists of H^+ pumps in mitochondria, chloroplasts, and bacteria. For example, the F_oF_1 ATPase utilizes a proton gradient across the inner mitochondrial membrane to generate ATP from ADP and inorganic phosphate (P_i). The F_oF_1 ATPase is composed of the F_o complex, which is the transmembrane channel through which protons flow, and the F_1 complex, where ATP synthesis activity resides. F_o has three subunits, A (also known as protein 6), B, and C (Lodish, H. et al. (1995) Molecular Cell Biology, Scientific American Books, New York NY, pp. 752-756; PROSITE PDOC00420 ATP synthase a subunit signature).

Voltage-gated Ca^{2+} channels are involved in presynaptic neurotransmitter release, and heart and skeletal muscle contraction. The voltage-gated Ca^{2+} channels from skeletal muscle (L-type) and brain (N-type) have been purified and, though their functions differ dramatically, they have similar subunit compositions. The channels are composed of three subunits. The α_1 subunit forms the

membrane pore and voltage sensor, while the $\alpha_2\delta$ and β subunits modulate the voltage-dependence, gating properties, and the current amplitude of the channel. These subunits are encoded by at least six α_1, one $\alpha_2\delta$, and four β genes. A fourth subunit, γ, has been identified in skeletal muscle (Walker, D. et al. (1998) J. Biol. Chem. 273:2361-2367; and Jay, S.D. et al. (1990) Science 248:490-492). The human β4 subunit is homologous to the mouse epilepsy gene lethargic, and is a candidate for involvement in neurological disorders including ataxia and absence epilepsy (Escayg, A. et al. (1998) Genomics 50:14-22).

Ligand-gated channels open their pores when an extracellular or intracellular mediator binds to the channel. Neurotransmitter-gated channels are channels that open when a neurotransmitter binds to their extracellular domain. These channels exist in the postsynaptic membrane of nerve or muscle cells. There are two types of neurotransmitter-gated channels. Sodium channels open in response to excitatory neurotransmitters, such as acetylcholine, glutamate, and serotonin. This opening causes an influx of Na^+ and produces the initial localized depolarization that activates the voltage-gated channels and starts the action potential. Chloride channels open in response to inhibitory neurotransmitters, such as γ-aminobutyric acid (GABA) and glycine, leading to hyperpolarization of the membrane and the subsequent generation of an action potential.

Ion channels are expressed in a number of tissues where they are implicated in a variety of processes. CNG channels, while abundantly expressed in photoreceptor and olfactory sensory cells, are also found in kidney, lung, pineal, retinal ganglion cells, testis, aorta, and brain. Calcium-activated K^+ channels may be responsible for the vasodilatory effects of bradykinin in the kidney and for shunting excess K^+ from brain capillary endothelial cells into the blood. They are also implicated in repolarizing granulocytes after agonist-stimulated depolarization (Ishi, T.M. et al. (1997) Proc. Natl. Acad. Sci. USA 94:11651-11656). Another transmembrane protein, the leukotrine B4 receptor (BLT) appears to be involved in inflammation responses and host cell defense against infection. BLT also functions as an HIV coreceptor (Izumi, T. et al. (1997) Nature 387:620-624; Martin, V. et al. (1999) J. Biol. Chem. 274:8597-8603).

Ion channels have been the target for many drug therapies. Neurotransmitter-gated channels have been targeted in therapies for treatment of insomnia, anxiety, depression, and schizophrenia. Voltage-gated channels have been targeted in therapies for arrhythmia, ischemic stroke, head trauma, and neurodegenerative disease (Taylor, C.P. and L.S. Narasimhan (1997) Adv. Pharmacol. 39:47-98).

K^+ channels are located in all cell types, and may be regulated by voltage, ATP concentration, or second messengers such as Ca^{++} and cAMP. In non-excitable tissue, K^+ channels are involved in protein synthesis, control of endocrine secretions, and the maintenance of osmotic equilibrium across membranes. In neurons and other excitable cells, in addition to regulating action potentials and repolarizing membranes, K^+ channels are responsible for setting resting membrane potential. The cytosol contains non-diffusible anions and, to balance this net negative charge, the cell

contains a Na^+-K^+ pump and ion channels that provide the redistribution of Na^+, K^+, and Cl^-. The pump actively transports Na^+ out of the cell and K^+ into the cell in a 3:2 ratio. Ion channels in the plasma membrane allow K^+ and Cl^- to flow by passive diffusion. Because of the high negative charge within the cytosol, Cl^- flows out of the cell. The flow of K^+ is balanced by an electromotive force pulling K^+ into the cell, and a K^+ concentration gradient pushing K^+ out of the cell. Thus, the resting membrane potential is primarily regulated by K^+ flow (Salkoff, L. and T. Jegla (1995) Neuron 15:489-492). Information on NY-REN-45, a K+ channel integral membrane protein, can be found in Scanlan, M.J. et al. (1998; Int. J. Cancer 76:652-658). The emopamil-binding protein (EBP) shares structural features with both pro- and eukaryotic drug transport proteins (Hanner, M. et al. (1995) J. Biol. Chem. 270:7551-7557). The Na+ channel, transmembrane protein myelin protein zero (MPZ) may be responsible for some sporadic cases of Dejerine-Scottas disease (hereditary motor and sensory neuropathy type III) (Hayasaka, K. et al. (1993) Nat. Genet. 5:266-268).

K^+ pore-forming subunits generally have six transmembrane-spanning domains with a short region between the fifth and sixth transmembrane regions that senses membrane potential; and the amino and carboxy termini are located intracellularly. In mammalian heart, the duration of ventricular action potential is controlled by a K^+ current. Thus, the K^+ channel is central to the control of heart rate and rhythm. K^+ channel dysfunctions are associated with a number of renal diseases including hypertension, hypokalemia, and the associated Bartter's syndrome and Getelman's syndrome, as well as neurological disorders including epilepsy. K^+ channels have been implicated in Alzheimer's disease by observations that a significant component of senile plaques, beta amyloid or A beta, also blocks voltage-gated potassium channels in hippocampal neurons (Antes, L.M. et al. (1998) Seminar Nephrol. 18:31-45; Stoffel, M. and L.Y. Jan (1998) Nat. Genet. 18:6-8; Madeja, M. et al. (1997) Eur. J. Neurosci. 9:390-395; Good, T.A. et al. (1996) Biophys. J. 70:296-304).

Gated ion channels control ion flow by regulating the opening and closing of pores. These channels are categorized according to the manner of regulating the gating function. Mechanically-gated channels open pores in response to mechanical stress, voltage-gated channels open pores in response to changes in membrane potential, and ligand-gated channels open pores in the presence of a specific ion, nucleotide, or neurotransmitter.

Voltage-gated Na^+ channels are responsible for electrical excitability of neurons, skeletal muscle, heart, and neuroendocrine tissues. For example, the sequential opening and closing of voltage-gated Na^+ channels results in the propagation of action potentials down neuronal axons. Na^+ channels isolated from rat brain tissue are heterotrimeric complexes composed of a 260 kDa pore forming α subunit that associates with two smaller auxiliary subunits, $\beta 1$ and $\beta 2$. The $\beta 2$ subunit is an integral membrane glycoprotein that contains an extracellular Ig domain, and its association with α and $\beta 1$ subunits correlates with increased function of the channel, a change in the channel's gating properties, as well as an increase in whole cell capacitance (Isom, L.L. et al. (1995) Cell 83:433-442).

Integral Membrane Proteins

The majority of known integral membrane proteins are transmembrane proteins (TM) which are characterized by an extracellular, a transmembrane, and an intracellular domain. TM domains are typically comprised of 15 to 25 hydrophobic amino acids which are predicted to adopt an α-helical conformation. TM proteins are classified as bitopic (Types I and II) and polytopic (Types III and IV) (Singer, S.J. (1990) Annu. Rev. Cell Biol. 6:247-96). Bitopic proteins span the membrane once while polytopic proteins contain multiple membrane-spanning segments. TM proteins that act as cell-surface receptor proteins involved in signal transduction include growth and differentiation factor receptors, and receptor-interacting proteins such as Drosophila pecanex and frizzled proteins, LIV-1 protein, NF2 protein, and GNS1/SUR4 eukaryotic integral membrane proteins. TM proteins also act as transporters of ions or metabolites, such as gap junction channels (connexins) and ion channels, and as cell anchoring proteins, such as lectins, integrins, and fibronectins. TM proteins act as vesicle organelle-forming molecules, such as calveolins, or as cell recognition molecules, such as cluster of differentiation (CD) antigens, glycoproteins, and mucins. Information on connexin can be found in Kanter, H.L. et al. (1994; J. Mol. Cell. Cardiol. 26:861-868).

Many membrane proteins (MPs) contain amino acid sequence motifs that target these proteins to specific subcellular sites. Examples of these motifs include PDZ domains, KDEL, RGD, NGR, and GSL sequence motifs, von Willebrand factor A (vWFA) domains, and EGF-like domains. RGD, NGR, and GSL motif-containing peptides have been used as drug delivery agents in cancer treatments which target tumor vasculature (Arap, W. et al. (1998) Science, 279:377-380.) Furthermore, MPs may also contain amino acid sequence motifs, such as the carbohydrate recognition domain (CRD), also known as the C-type lectin domain, that mediate interactions with extracellular or intracellular molecules.

G-protein coupled receptors (GPCR) comprise a superfamily of integral membrane proteins which transduce extracellular signals. GPCRs include receptors for biogenic amines, lipid mediators of inflammation, peptide hormones, and sensory signal mediators. The structure of these highly-conserved receptors consists of seven hydrophobic transmembrane regions, an extracellular N-terminus, and a cytoplasmic C-terminus. Three extracellular loops alternate with three intracellular loops to link the seven transmembrane regions. The most conserved parts of these proteins are the transmembrane regions and the first two cytoplasmic loops. Cysteine disulfide bridges connect the second and third extracellular loops. A conserved, acidic-Arg-aromatic residue triplet present in the second cytoplasmic loop may interact with G proteins. A GPCR consensus pattern is characteristic of most proteins belonging to this superfamily (ExPASy PROSITE document PS00237; and Watson, S. and S. Arkinstall (1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp 2-6). Mutations and changes in transcriptional activation of GPCR-encoding genes have been

associated with neurological disorders such as schizophrenia, Parkinson's disease, Alzheimer's disease, drug addiction, and feeding disorders.

Cytochromes are electron-transferring proteins that contain a heme prosthetic group, a porphyrin ring containing a tightly bound iron atom. Cytochromes act as oxidoreductases in such diverse cellular processes as respiration, photosynthesis, fatty acid metabolism, and neurotransmitter biosynthesis. The heme iron atom serves as the actual electron carrier by changing from the ferric to the ferrous oxidation state when accepting an electron. Cytochromes accept electrons from one substrate such as NADH or ascorbate and donate them to other electron carriers such as other cytochromes, ubiquinone, or semidehydroascorbic acid (Lodish, H. et al. (1995) Molecular Cell Biology, Scientific American Books, New York NY, pp. 759-770, 786-797; Sperling, P. et al. (1995) Eur. J. Biochem. 232:798-805; and Online Mendelian Inheritance in Man (OMIM) *600019 Cytochrome b561, CYB561).

Cytochrome b5 is an electron donor in membrane-linked redox enzyme systems involved in lipid and drug metabolism. Cytochrome b5 has been found in Golgi, plasma, outer mitochondrial, endoplasmic reticulum (ER), and microbody membranes. Conserved amino acids in cytochrome b5 include eight invariant amino acids at W34, H51, P52, G53, G54, G63, F70, and H74, and fifteen conserved amino acids at L24, I35, S36, V41, Y42, N43, T45, W47, A48, L58, D65, T67, L85, T87, and G88 (numbering based on the sunflower cytochrome b5/delta-6 desaturase fusion protein; GI 1040729, Sperling, supra). The invariant residues H51PGG are involved in heme-binding. Cytochrome b5-like domains have also been found linked to other enzymes. For example, cytochrome b5-like domains are part of delta-9 fatty acid desaturases in yeast and Histoplasma capsulatum, nitrate reductase, sulfite reductase, flavocytochrome b2, Arabidopsis thaliana acyl lipid desaturase, and Borago officinalis (borage) and Helianthus annuus (sunflower) delta-6 desaturases (Sperling, supra; Sayanova, O. et al (1997) Proc. Natl. Acad. Sci. USA 94:4211-4216; and Mitchell, A.G. and C.E. Martin (1997) J. Biol. Chem. 272:28281-28288).

Signal peptides are found on proteins that are targeted to the endoplasmic reticulum (ER). Signal peptides consist of stretches of amino acids enriched in hydrophobic residues. Signal peptides are usually found at the extreme N-terminus of the protein and are recognized by a cytosolic signal-recognition peptide (SRP). The SRP binds to the signal peptide and to an SRP receptor, an integral membrane protein in the ER. Once bound to the SRP receptor, the newly formed protein containing the signal peptide is translocated across the ER membrane. Proteins containing signal peptides may end up inserted into the lipid bilayer, or they may end up in the lumen of an organelle or secreted from the cell.

Disease Correlation

The etiology of numerous human diseases and disorders can be attributed to defects in the

transport of molecules across membranes. Defects in the trafficking of membrane-bound transporters and ion channels are associated with several disorders, e.g. cystic fibrosis, glucose-galactose malabsorption syndrome, hypercholesterolemia, von Gierke disease, and certain forms of diabetes mellitus. Single-gene defect diseases resulting in an inability to transport small molecules across membranes include, e.g., cystinuria, iminoglycinuria, Hartup disease, and Fanconi disease (van't Hoff, W.G. (1996) Exp. Nephrol. 4:253-262; Talente, G.M. et al. (1994) Ann. Intern. Med. 120:218-226; and Chillon, M. et al. (1995) New Engl. J. Med. 332:1475-1480).

Cystinuria is an inherited disease that results from the inability to transport cystine, the disulfide-linked dimer of cysteine, from the urine into the blood. Accumulation of cystine in the urine leads to the formation of cystine stones in the kidneys.

Transthyretin (TTR), present in human plasma, binds to and transports the thyroid hormone thyroxine. Mutations in TTR result in the conversion of TTR to amyloid, an insoluble fibrillar structure. The resulting amyloid plaques have been shown to be the causative agent in the development of familial amyloid polyneuropathy and senile systemic amyloidosis (Miroy, G.J. et al. (1996) Proc. Natl. Acad. Sci. USA 93:15051-15056).

Stomatin, a 31-kDa erythrocyte integral membrane protein has been linked to the hereditary anemia stomatocytosis. This anemia is characterized by red blood cells that lack stomatin and leak Na+ and K+. Thus, stomatin is presumed to play a role in the regulation of ion transport. Red blood cell ion transport defects are also linked to other disorders such as hypertension (Stewart, G.W. (1997) Int. J. Biochem. Cell Biol. 29:271-274).

The discovery of new human transport proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of transport, metabolic, neurological, cardiovascular, reproductive, and immune disorders, and cell proliferative disorders including cancer.

SUMMARY OF THE INVENTION

The invention features purified polypeptides, human transport proteins, referred to collectively as "TPPT" and individually as "TPPT-1," "TPPT-2," "TPPT-3," "TPPT-4," "TPPT-5," "TPPT-6," "TPPT-7," "TPPT-8," "TPPT-9," "TPPT-10," "TPPT-11," "TPPT-12," "TPPT-13," "TPPT-14," "TPPT-15," "TPPT-16," "TPPT-17," "TPPT-18," "TPPT-19," "TPPT-20," "TPPT-21," "TPPT-22," "TPPT-23," "TPPT-24," "TPPT-25," "TPPT-26," "TPPT-27," "TPPT-28," "TPPT-29," "TPPT-30," "TPPT-31," "TPPT-32," "TPPT-33," "TPPT-34," "TPPT-35," "TPPT-36," "TPPT-37," "TPPT-38," "TPPT-39," "TPPT-40," "TPPT-41," "TPPT-42," and "TPPT-43." In one aspect, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-

43, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-43.

The invention further provides an isolated polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-43. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:44-86.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a

polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43.

The invention further provides an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:44-86, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:44-86, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:44-86, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:44-86, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:44-86, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:44-86, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a pharmaceutical composition comprising an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, and a pharmaceutically acceptable excipient. In one embodiment, the pharmaceutical composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-43. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional TPPT, comprising administering to a patient in need of such treatment the pharmaceutical composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a pharmaceutical composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional TPPT, comprising administering to a patient in need of such treatment the pharmaceutical composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a pharmaceutical composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional TPPT, comprising administering to a patient in

need of such treatment the pharmaceutical composition.

The invention further provides a method of screening for a compound that specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-43. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:44-86, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

BRIEF DESCRIPTION OF THE TABLES

Table 1 shows polypeptide and nucleotide sequence identification numbers (SEQ ID NOs), clone identification numbers (clone IDs), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding TPPT.

Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods, algorithms, and searchable databases used for analysis of TPPT.

Table 3 shows selected fragments of each nucleic acid sequence; the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis; diseases, disorders, or conditions associated with these tissues; and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding TPPT were isolated.

Table 5 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"TPPT" refers to the amino acid sequences of substantially purified TPPT obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of TPPT. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of TPPT either by directly interacting with

TPPT or by acting on components of the biological pathway in which TPPT participates.

An "allelic variant" is an alternative form of the gene encoding TPPT. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding TPPT include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as TPPT or a polypeptide with at least one functional characteristic of TPPT. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding TPPT, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding TPPT. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent TPPT. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of TPPT is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of TPPT. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of TPPT either by directly interacting with TPPT or by acting on components of the biological pathway in which TPPT

participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, $F(ab')_2$, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind TPPT polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic TPPT, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or

amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding TPPT or fragments of TPPT may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (PE Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

Original Residue	Conservative Substitution
Ala	Gly, Ser
Arg	His, Lys
Asn	Asp, Gln, His
Asp	Asn, Glu
Cys	Ala, Ser
Gln	Asn, Glu, His
Glu	Asp, Gln, His
Gly	Ala
His	Asn, Arg, Gln, Glu
Ile	Leu, Val
Leu	Ile, Val
Lys	Arg, Gln, Glu
Met	Leu, Ile
Phe	His, Met, Leu, Trp, Tyr
Ser	Cys, Thr
Thr	Ser, Val
Trp	Phe, Tyr
Tyr	His, Phe, Trp
Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

A "fragment" is a unique portion of TPPT or the polynucleotide encoding TPPT which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50% of a polypeptide) as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:44-86 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:44-86, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:44-86 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:44-86 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:44-86 and the region of SEQ ID NO:44-86 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-43 is encoded by a fragment of SEQ ID NO:44-86. A fragment of SEQ ID NO:1-43 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-43. For example, a fragment of SEQ ID NO:1-43 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-43. The precise length of a fragment of SEQ ID NO:1-43 and the region of SEQ ID NO:1-43 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended

purpose for the fragment.

A "full-length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full-length" polynucleotide sequence encodes a "full-length" polypeptide sequence.

"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/bl2.html. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties
Gap x drop-off: 50
Expect: 10
Word Size: 11
Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (Apr-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62
Open Gap: 11 and Extension Gap: 1 penalties
Gap x drop-off: 50

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for chromosome replication, segregation and maintenance.

The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 μg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of TPPT which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of TPPT which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of TPPT. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of TPPT.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide,

polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an TPPT may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of TPPT.

"Probe" refers to nucleic acid sequences encoding TPPT, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al.,1987, Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al., 1990, PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs

can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is

expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding TPPT, or fragments thereof, or TPPT itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants, and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide

polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

The invention is based on the discovery of new human transport proteins (TPPT), the polynucleotides encoding TPPT, and the use of these compositions for the diagnosis, treatment, or prevention of transport, metabolic, neurological, cardiovascular, reproductive, and immune disorders, and cell proliferative disorders including cancer.

Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding TPPT. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte clones in which nucleic acids encoding each TPPT were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. In some cases, GenBank sequence identifiers are also shown in column 5. The Incyte clones and GenBank cDNA sequences, where indicated, in column 5 were used to assemble the consensus nucleotide sequence of each TPPT and are useful as fragments in hybridization technologies.

The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3 shows potential phosphorylation sites; column 4 shows potential glycosylation sites; column 5 shows the amino acid residues comprising signature sequences and motifs; column 6 shows homologous sequences as identified by BLAST analysis; and column 7 shows analytical methods and in some cases, searchable databases to which the analytical methods were applied. The methods of column 7 were used to characterize each polypeptide through sequence homology and protein motifs.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding TPPT. The first column of Table 3 lists the nucleotide SEQ ID NOs. Column 2 lists fragments of the nucleotide sequences of column 1. These fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:44-86

and to distinguish between SEQ ID NO:44-86 and related polynucleotide sequences. The polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express TPPT as a fraction of total tissues expressing TPPT. Column 4 lists diseases, disorders, or conditions associated with those tissues expressing TPPT as a fraction of total tissues expressing TPPT. Column 5 lists the vectors used to subclone each cDNA library.

Of particular interest is the expression of SEQ ID NO:50 exclusively in cardiovascular tissue, the expression of SEQ ID NO:56 in nervous and gastrointestinal tissues, the expression of SEQ ID NO:57 in gastrointestinal tissues, and the expression of SEQ ID NO:66 in nervous system tissues. Of particular note is the tissue-specific expression of SEQ ID NO:75. Over 71% of the cDNA libraries expressing SEQ ID NO:75 are derived from lung tissue.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding TPPT were isolated. Column 1 references the nucleotide SEQ ID NOs, column 2 shows the cDNA libraries from which these clones were isolated, and column 3 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

SEQ ID NO:44 maps to chromosome 7 within the interval from 38.80 to 42.10 centiMorgans. SEQ ID NO:48 maps to chromosome X within the interval from 107.90 to 122.80 centiMorgans. SEQ ID NO:60 maps to chromosome 2 within the interval from 157.0 to 167.0 centiMorgans. SEQ ID NO:65 maps to chromosome 2 within the interval from 17.4 to 40.7 centiMorgans and to chromosome 5 within the interval from 61.1 to 69.6 centiMorgans. The interval on chromosome 5 from 61.1 to 69.6 centiMorgans also contains genes associated with Cockayne syndrome. SEQ ID NO:69 maps to chromosome 3 within the interval from 157.40 to 162.00 centiMorgans. SEQ ID NO:70 maps to chromosome 3 within the interval from 176.40 to 179.80 centiMorgans. SEQ ID NO:71 maps to chromosome 18 within the interval from the p-terminus to 52.30 centiMorgans. SEQ ID NO:73 maps to chromosome 17 within the interval from 75.70 to 84.20 centiMorgans, and to chromosome 2 within the interval from 204.70 to 209.30 centiMorgans. SEQ ID NO:76 maps to chromosome 20 within the interval from 79.00 to 94.40 centiMorgans. SEQ ID NO:80 maps to chromosome 18 within the interval from 1.60 to 6.20 centiMorgans, and to chromosome 11 within the interval from 117.90 to 126.00 centiMorgans. SEQ ID NO:83 maps to chromosome 17 within the interval from 67.60 to 69.30 centiMorgans, and from 83.8 centiMorgans to the q-terminus, and to chromosome 7 within the interval from 105.20 to 114.50 centiMorgans.

The invention also encompasses TPPT variants. A preferred TPPT variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the TPPT amino acid sequence, and which contains at least one functional or structural characteristic of TPPT.

The invention also encompasses polynucleotides which encode TPPT. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected

from the group consisting of SEQ ID NO:44-86, which encodes TPPT. The polynucleotide sequences of SEQ ID NO:44-86, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding TPPT. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding TPPT. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:44-86 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:44-86. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of TPPT.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding TPPT, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring TPPT, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode TPPT and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring TPPT under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding TPPT or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding TPPT and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode TPPT and TPPT derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding TPPT or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:44-86 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (PE Biosystems, Foster City CA), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (PE Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (PE Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding TPPT may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo

Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, PE Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode TPPT may be cloned in recombinant DNA molecules that direct expression of TPPT, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express TPPT.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter TPPT-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or

improve the biological properties of TPPT, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding TPPT may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, TPPT itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (PE Biosystems). Additionally, the amino acid sequence of TPPT, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

In order to express a biologically active TPPT, the nucleotide sequences encoding TPPT or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding TPPT. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding TPPT. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding TPPT and its initiation codon and upstream regulatory sequences are inserted into

the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding TPPT and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding TPPT. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; Scorer, C.A. et al. (1994) Bio/Technology 12:181-184; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al., (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding TPPT. For example, routine cloning,

subcloning, and propagation of polynucleotide sequences encoding TPPT can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding TPPT into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of TPPT are needed, e.g. for the production of antibodies, vectors which direct high level expression of TPPT may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of TPPT. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, supra; and Scorer, supra.)

Plant systems may also be used for expression of TPPT. Transcription of sequences encoding TPPT may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, supra; Broglie, supra; and Winter, supra.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding TPPT may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses TPPT in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet.

15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of TPPT in cell lines is preferred. For example, sequences encoding TPPT can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk*⁻ and *apr*⁻ cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), ß glucuronidase and its substrate ß-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding TPPT is inserted within a marker gene sequence, transformed cells containing sequences encoding TPPT can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding TPPT under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding TPPT and that express TPPT may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or

chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of TPPT using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on TPPT is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding TPPT include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding TPPT, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding TPPT may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode TPPT may be designed to contain signal sequences which direct secretion of TPPT through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the

American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural. modified, or recombinant nucleic acid sequences encoding TPPT may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric TPPT protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of TPPT activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the TPPT encoding sequence and the heterologous protein sequence, so that TPPT may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled TPPT may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ^{35}S-methionine.

TPPT of the present invention or fragments thereof may be used to screen for compounds that specifically bind to TPPT. At least one and up to a plurality of test compounds may be screened for specific binding to TPPT. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of TPPT, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which TPPT binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express TPPT, either as a secreted

protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing TPPT or cell membrane fractions which contain TPPT are then contacted with a test compound and binding, stimulation, or inhibition of activity of either TPPT or the compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with TPPT, either in solution or affixed to a solid support, and detecting the binding of TPPT to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

TPPT of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of TPPT. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for TPPT activity, wherein TPPT is combined with at least one test compound, and the activity of TPPT in the presence of a test compound is compared with the activity of TPPT in the absence of the test compound. A change in the activity of TPPT in the presence of the test compound is indicative of a compound that modulates the activity of TPPT. Alternatively, a test compound is combined with an in vitro or cell-free system comprising TPPT under conditions suitable for TPPT activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of TPPT may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding TPPT or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent No. 5,175,383 and U.S. Patent No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred

to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

Polynucleotides encoding TPPT may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

Polynucleotides encoding TPPT can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding TPPT is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress TPPT, e.g., by secreting TPPT in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of TPPT and human transport proteins. In addition, the expression of TPPT is closely associated with neurological, cardiovascular, reproductive, gastrointestinal, and hematopoietic/immune tissues, and inflammation, cell proliferation, and cancer. Therefore, TPPT appears to play a role in transport, metabolic, neurological, cardiovascular, reproductive, and immune disorders, and cell proliferative disorders including cancer. In the treatment of disorders associated with increased TPPT expression or activity, it is desirable to decrease the expression or activity of TPPT. In the treatment of disorders associated with decreased TPPT expression or activity, it is desirable to increase the expression or activity of TPPT.

Therefore, in one embodiment, TPPT or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TPPT. Examples of such disorders include, but are not limited to, a transport disorder such as akinesia, amyotrophic lateral sclerosis, ataxia telangiectasia, cystic fibrosis, Becker's muscular dystrophy, Bell's palsy, Charcot-Marie Tooth disease, diabetes mellitus, diabetes insipidus, diabetic neuropathy, Duchenne muscular dystrophy, hyperkalemic periodic paralysis, normokalemic periodic paralysis, Parkinson's disease, malignant hyperthermia, multidrug resistance, myasthenia gravis, myotonic dystrophy, catatonia, tardive dyskinesia, dystonias, peripheral neuropathy, cerebral neoplasms, prostate cancer; cardiac disorders associated with transport, e.g., angina, bradyarrythmia, tachyarrythmia, hypertension, Long QT syndrome, myocarditis, cardiomyopathy, nemaline

myopathy, centronuclear myopathy, lipid myopathy, mitochondrial myopathy, thyrotoxic myopathy, ethanol myopathy, dermatomyositis, inclusion body myositis, infectious myositis, polymyositis; neurological disorders associated with transport, e.g., Alzheimer's disease, amnesia, bipolar disorder, dementia, depression, epilepsy, Tourette's disorder, paranoid psychoses, and schizophrenia; and other disorders associated with transport, e.g., neurofibromatosis, postherpetic neuralgia, trigeminal neuropathy, sarcoidosis, sickle cell anemia, Wilson's disease, cataracts, infertility, pulmonary artery stenosis, sensorineural autosomal deafness, hyperglycemia, hypoglycemia, Grave's disease, goiter, Cushing's disease, Addison's disease, glucose-galactose malabsorption syndrome, hypercholesterolemia, adrenoleukodystrophy, Zellweger syndrome, Menkes disease, occipital horn syndrome, von Gierke disease, cystinuria, iminoglycinuria, Hartup disease, and Fanconi disease; a metabolic disorder such as Addison's disease, cerebrotendinous xanthomatosis, congenital adrenal hyperplasia, coumarin resistance, cystic fibrosis, diabetes, fatty hepatocirrhosis, fructose-1,6-diphosphatase deficiency, galactosemia, goiter, glucagonoma, glycogen storage diseases, hereditary fructose intolerance, hyperadrenalism, hypoadrenalism, hyperparathyroidism, hypoparathyroidism, hypercholesterolemia, hyperthyroidism, hypoglycemia, hypothyroidism, hyperlipidemia, hyperlipemia, lipid myopathies, lipodystrophies, lysosomal storage diseases, mannosidosis, neuraminidase deficiency, obesity, pentosuria phenylketonuria, and pseudovitamin D-deficiency rickets; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cardiovascular disorder such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins,

thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation, congenital lung anomalies, atelectasis, pulmonary congestion and edema, pulmonary embolism, pulmonary hemorrhage, pulmonary infarction, pulmonary hypertension, vascular sclerosis, obstructive pulmonary disease, restrictive pulmonary disease, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, bronchial asthma, bronchiectasis, bacterial pneumonia, viral and mycoplasmal pneumonia, lung abscess, pulmonary tuberculosis, diffuse interstitial diseases, pneumoconioses, sarcoidosis, idiopathic pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia bronchiolitis obliterans-organizing pneumonia, diffuse pulmonary hemorrhage syndromes, Goodpasture's syndromes, idiopathic pulmonary hemosiderosis, pulmonary involvement in collagen-vascular disorders, pulmonary alveolar proteinosis, lung tumors, inflammatory and noninflammatory pleural effusions, pneumothorax, pleural tumors, drug-induced lung disease, radiation-induced lung disease, and complications of lung transplantation; a reproductive disorder such as a disorder of prolactin production, infertility, including tubal disease, ovulatory defects, and endometriosis, a disruption of the estrous cycle, a disruption of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, an endometrial or ovarian tumor, a uterine fibroid, autoimmune disorders, an ectopic pregnancy, and teratogenesis; cancer of the breast, fibrocystic breast disease, and galactorrhea; a disruption of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, and gynecomastia; an immune disorder such as inflammation, actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis,

pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, trauma, and hematopoietic cancer including lymphoma, leukemia, and myeloma; and a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus.

In another embodiment, a vector capable of expressing TPPT or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TPPT including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified TPPT in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TPPT including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of TPPT may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TPPT including, but not limited to, those listed above.

In a further embodiment, an antagonist of TPPT may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of TPPT. Examples of such disorders include, but are not limited to, those transport, metabolic, neurological, cardiovascular, reproductive, and immune disorders, and cell proliferative disorders including cancer described above. In one aspect, an antibody which specifically binds TPPT may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express TPPT.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding TPPT may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of TPPT including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made

by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of TPPT may be produced using methods which are generally known in the art. In particular, purified TPPT may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind TPPT. Antibodies to TPPT may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with TPPT or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to TPPT have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of TPPT amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to TPPT may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce TPPT-specific single

chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for TPPT may also be generated. For example, such fragments include, but are not limited to, $F(ab')_2$ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between TPPT and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering TPPT epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for TPPT. Affinity is expressed as an association constant, K_a, which is defined as the molar concentration of TPPT-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple TPPT epitopes, represents the average affinity, or avidity, of the antibodies for TPPT. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular TPPT epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the TPPT-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of TPPT, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to

determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of TPPT-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al., supra.)

In another embodiment of the invention, the polynucleotides encoding TPPT, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding TPPT. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding TPPT. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) J. Allergy Clin. Immunol. 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) Blood 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) Br. Med. Bull. 51(1):217-225; Boado, R.J. et al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morris, M.C. et al. (1997) Nucleic Acids Res. 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding TPPT may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, I.M. and Somia, N. (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated

cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in TPPT expression or regulation causes disease, the expression of TPPT from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in TPPT are treated by constructing mammalian expression vectors encoding TPPT and introducing these vectors by mechanical means into TPPT-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H. Récipon (1998) Curr. Opin. Biotechnol. 9:445-450).

Expression vectors that may be effective for the expression of TPPT include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). TPPT may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen; the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and H.M. Blau, supra)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding TPPT from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to TPPT expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding TPPT under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., $CD4^+$ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding TPPT to cells which have one or more genetic abnormalities with respect to the expression of TPPT. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544; and Verma, I.M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding TPPT to target cells which have one or more genetic abnormalities with respect to the expression of TPPT. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing TPPT to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has

been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res.169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding TPPT to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotech. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full-length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for TPPT into the alphavirus genome in place of the capsid-coding region results in the production of a large number of TPPT-coding RNAs and the synthesis of high levels of TPPT in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of TPPT into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have

been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding TPPT.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding TPPT. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding TPPT. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular

chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased TPPT expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding TPPT may be therapeutically useful, and in the treament of disorders associated with decreased TPPT expression or activity, a compound which specifically promotes expression of the polynucleotide encoding TPPT may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding TPPT is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding TPPT are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding TPPT. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5.932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved

using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such pharmaceutical compositions may consist of TPPT, antibodies to TPPT, and mimetics, agonists, antagonists, or inhibitors of TPPT.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

Pharmaceutical compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of pharmaceutical compositions may be prepared for direct intracellular delivery of macromolecules comprising TPPT or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, TPPT or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell

culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example TPPT or fragments thereof, antibodies of TPPT, and agonists, antagonists or inhibitors of TPPT, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind TPPT may be used for the diagnosis of disorders characterized by expression of TPPT, or in assays to monitor patients being treated with TPPT or agonists, antagonists, or inhibitors of TPPT. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for TPPT include methods which utilize the antibody and a label to detect TPPT in human body fluids

or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring TPPT, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of TPPT expression. Normal or standard values for TPPT expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibody to TPPT under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of TPPT expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding TPPT may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of TPPT may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of TPPT, and to monitor regulation of TPPT levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding TPPT or closely related molecules may be used to identify nucleic acid sequences which encode TPPT. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding TPPT, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the TPPT encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:44-86 or from genomic sequences including promoters, enhancers, and introns of the TPPT gene.

Means for producing specific hybridization probes for DNAs encoding TPPT include the cloning of polynucleotide sequences encoding TPPT or TPPT derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding TPPT may be used for the diagnosis of disorders

associated with expression of TPPT. Examples of such disorders include, but are not limited to, a transport disorder such as akinesia, amyotrophic lateral sclerosis, ataxia telangiectasia, cystic fibrosis, Becker's muscular dystrophy, Bell's palsy, Charcot-Marie Tooth disease, diabetes mellitus, diabetes insipidus, diabetic neuropathy, Duchenne muscular dystrophy, hyperkalemic periodic paralysis, normokalemic periodic paralysis, Parkinson's disease, malignant hyperthermia, multidrug resistance, myasthenia gravis, myotonic dystrophy, catatonia, tardive dyskinesia, dystonias, peripheral neuropathy, cerebral neoplasms, prostate cancer; cardiac disorders associated with transport, e.g., angina, bradyarrythmia, tachyarrythmia, hypertension, Long QT syndrome, myocarditis, cardiomyopathy, nemaline myopathy, centronuclear myopathy, lipid myopathy, mitochondrial myopathy, thyrotoxic myopathy, ethanol myopathy, dermatomyositis, inclusion body myositis, infectious myositis, polymyositis; neurological disorders associated with transport, e.g., Alzheimer's disease, amnesia, bipolar disorder, dementia, depression, epilepsy, Tourette's disorder, paranoid psychoses, and schizophrenia; and other disorders associated with transport, e.g., neurofibromatosis, postherpetic neuralgia, trigeminal neuropathy, sarcoidosis, sickle cell anemia, Wilson's disease, cataracts, infertility, pulmonary artery stenosis, sensorineural autosomal deafness, hyperglycemia, hypoglycemia, Grave's disease, goiter, Cushing's disease, Addison's disease, glucose-galactose malabsorption syndrome, hypercholesterolemia, adrenoleukodystrophy, Zellweger syndrome, Menkes disease, occipital horn syndrome, von Gierke disease, cystinuria, iminoglycinuria, Hartup disease, and Fanconi disease; a metabolic disorder such as Addison's disease, cerebrotendinous xanthomatosis, congenital adrenal hyperplasia, coumarin resistance, cystic fibrosis, diabetes, fatty hepatocirrhosis, fructose-1,6-diphosphatase deficiency, galactosemia, goiter, glucagonoma, glycogen storage diseases, hereditary fructose intolerance, hyperadrenalism, hypoadrenalism, hyperparathyroidism, hypoparathyroidism, hypercholesterolemia, hyperthyroidism, hypoglycemia, hypothyroidism, hyperlipidemia, hyperlipemia, lipid myopathies, lipodystrophies, lysosomal storage diseases, mannosidosis, neuraminidase deficiency, obesity, pentosuria phenylketonuria, and pseudovitamin D-deficiency rickets; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial

nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cardiovascular disorder such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation, congenital lung anomalies, atelectasis, pulmonary congestion and edema, pulmonary embolism, pulmonary hemorrhage, pulmonary infarction, pulmonary hypertension, vascular sclerosis, obstructive pulmonary disease, restrictive pulmonary disease, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, bronchial asthma, bronchiectasis, bacterial pneumonia, viral and mycoplasmal pneumonia, lung abscess, pulmonary tuberculosis, diffuse interstitial diseases, pneumoconioses, sarcoidosis, idiopathic pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia bronchiolitis obliterans-organizing pneumonia, diffuse pulmonary hemorrhage syndromes, Goodpasture's syndromes, idiopathic pulmonary hemosiderosis, pulmonary involvement in collagen-vascular disorders, pulmonary alveolar proteinosis, lung tumors, inflammatory and noninflammatory pleural effusions, pneumothorax, pleural tumors, drug-induced lung disease, radiation-induced lung disease, and complications of lung transplantation; a reproductive disorder such as a disorder of prolactin production, infertility, including tubal disease, ovulatory defects, and endometriosis, a disruption of the estrous cycle, a disruption of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, an endometrial or ovarian tumor, a uterine fibroid, autoimmune disorders, an ectopic pregnancy, and teratogenesis; cancer of the breast, fibrocystic breast disease, and galactorrhea; a disruption of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, and gynecomastia; an immune disorder such as inflammation, actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome,

allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, trauma, and hematopoietic cancer including lymphoma, leukemia, and myeloma; and a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. The polynucleotide sequences encoding TPPT may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered TPPT expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding TPPT may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding TPPT may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding TPPT in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of TPPT, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding TPPT, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding TPPT may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding TPPT, or a fragment of a polynucleotide complementary to the polynucleotide encoding TPPT, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding TPPT may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding TPPT are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are

detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

Methods which may also be used to quantify the expression of TPPT include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described in Seilhamer, J.J. et al., "Comparative Gene Transcript Analysis," U.S. Patent No. 5,840,484, incorporated herein by reference. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, antibodies specific for TPPT, or TPPT or fragments thereof may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-

2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding TPPT may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, e.g., Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding TPPT on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, TPPT, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug

screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between TPPT and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with TPPT, or fragments thereof, and washed. Bound TPPT is then detected by methods well known in the art. Purified TPPT can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding TPPT specifically compete with a test compound for binding TPPT. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with TPPT.

In additional embodiments, the nucleotide sequences which encode TPPT may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, in particular U.S. Ser. No. 60/139,923, U.S. Ser. No. 60/148,177, U.S. Ser. No. 60/149,357, and U.S. Ser. No. 60/162,287, are hereby expressly incorporated by reference.

EXAMPLES

I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated

using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), pcDNA2.1 plasmid (Invitrogen, Carlsbad CA), or pINCY plasmid (Incyte Genomics, Palo Alto CA). Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5α, DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (PE Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ

Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (PE Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (PE Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VI.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programing, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and PFAM to acquire annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and Hidden Markov Model (HMM)-based protein family databases such

as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:44-86. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

IV. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score x Percent Identity}}{5 \times \text{minimum } \{\text{length(Seq. 1)}, \text{length(Seq. 2)}\}}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding TPPT occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous,

reproductive, and urologic. The disease/condition categories included cancer, inflammation, trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

V. Chromosomal Mapping of TPPT Encoding Polynucleotides

The cDNA sequences which were used to assemble SEQ ID NO:44-49 and SEQ ID NO:54-86 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:44-49 and SEQ ID NO:54-86 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 5). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

The genetic map locations of SEQ ID NO:44, SEQ ID NO:48, SEQ ID NO:60, SEQ ID NO:65, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:76, SEQ ID NO:80,and SEQ ID NO:83 are described in The Invention as ranges, or intervals, of human chromosomes. More than one map location is reported for SEQ ID NO:65, SEQ ID NO:73, SEQ ID NO:80, and SEQ ID NO:83, indicating that previously mapped sequences having similarity, but not complete identity, to SEQ ID NO:65, SEQ ID NO:73, SEQ ID NO:80, and SEQ ID NO:83 were assembled into their respective clusters. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Diseases associated with the public and Incyte sequences located within the indicated intervals are also reported in the Invention section where applicable. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (http://www.ncbi.nlm.nih.gov/genemap/), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

VI. Extension of TPPT Encoding Polynucleotides

The full length nucleic acid sequences of SEQ ID NO:44-86 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this

fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68 °C to about 72 °C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+}, $(NH_4)_2SO_4$, and β-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94 °C, 3 min; Step 2: 94 °C, 15 sec; Step 3: 60 °C, 1 min; Step 4: 68 °C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68 °C, 5 min; Step 7: storage at 4 °C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94 °C, 3 min; Step 2: 94 °C, 15 sec; Step 3: 57 °C, 1 min; Step 4: 68 °C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68 °C, 5 min; Step 7: storage at 4 °C.

The concentration of DNA in each well was determined by dispensing 100 µl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 µl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 µl to 10 µl aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37 °C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (PE Biosystems).

In like manner, the polynucleotide sequences of SEQ ID NO:44-86 are used to obtain 5' regulatory sequences using the procedure above, along with oligonucleotides designed for such extension, and an appropriate genomic library.

VII. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:44-86 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μCi of [γ-^{32}P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

VIII. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers.

Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorbtion and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

Tissue or Cell Sample Preparation

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)$^+$ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)$^+$ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/µl oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/µl RNase inhibitor, 500 µM dATP, 500 µM dGTP, 500 µM dTTP, 40 µM dCTP, 40 µM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)$^+$ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)$^+$ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37 °C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85 °C to the stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 µl 5X SSC/0.2% SDS.

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification

uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μg. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incorporated herein by reference. 1 μl of the array element DNA, at an average concentration of 100 ng/μl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60 °C followed by washes in 0.2% SDS and distilled water as before.

Hybridization

Hybridization reactions contain 9 μl of sample mixture consisting of 0.2 μg each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65 °C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm^2 coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μl of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45 °C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45 °C in a second wash buffer (0.1X SSC), and dried.

Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

IX. Complementary Polynucleotides

Sequences complementary to the TPPT-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring TPPT. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of TPPT. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the TPPT-encoding transcript.

X. Expression of TPPT

Expression and purification of TPPT is achieved using bacterial or virus-based expression systems. For expression of TPPT in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express TPPT upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of TPPT in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding TPPT by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, TPPT is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from TPPT at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified TPPT obtained by these methods can be used directly in the assays shown in Examples XI and XV.

XI. Demonstration of TPPT Activity

TPPT transport activity is assayed by measuring uptake of labeled substrates into Xenopus laevis oocytes. Oocytes at stages V and VI are injected with TPPT mRNA (10 ng per oocyte) and incubated for 3 days at 18°C in OR2 medium (82.5mM NaCl, 2.5 mM KCl, 1mM $CaCl_2$, 1mM $MgCl_2$, 1mM Na_2HPO_4, 5 mM Hepes, 3.8 mM NaOH , 50μg/ml gentamycin, pH 7.8) to allow expression of TPPT. Oocytes are then transferred to standard uptake medium (100mM NaCl, 2 mM KCl, 1mM $CaCl_2$, 1mM $MgCl_2$, 10 mM Hepes/Tris pH 7.5). Uptake of various substrates (e.g., amino acids,

sugars, drugs, ions, and neurotransmitters) is initiated by adding labeled substrate (e.g. radiolabeled with ^3H, fluorescently labeled with rhodamine, etc.) to the oocytes. After incubating for 30 minutes, uptake is terminated by washing the oocytes three times in Na^+-free medium, measuring the incorporated label, and comparing with controls. TPPT activity is proportional to the level of internalized labeled substrate.

XII. Functional Assays

TPPT function is assessed by expressing the sequences encoding TPPT at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT plasmid (Life Technologies) and pCR3.1 plasmid (Invitrogen), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of TPPT on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding TPPT and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding TPPT and other genes of interest can be analyzed by northern analysis or microarray techniques.

XIII. Production of TPPT Specific Antibodies

TPPT substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the TPPT amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (PE Biosystems) using FMOC chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-TPPT activity by, for example, binding the peptide or TPPT to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XIV. Purification of Naturally Occurring TPPT Using Specific Antibodies

Naturally occurring or recombinant TPPT is substantially purified by immunoaffinity chromatography using antibodies specific for TPPT. An immunoaffinity column is constructed by covalently coupling anti-TPPT antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing TPPT are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of TPPT (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/TPPT binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and TPPT is collected.

XV. Identification of Molecules Which Interact with TPPT

TPPT, or biologically active fragments thereof, are labeled with ^{125}I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled TPPT, washed, and any wells with labeled TPPT complex are assayed. Data obtained using different concentrations of TPPT are used to calculate values for the number, affinity, and association of TPPT with the candidate molecules.

Alternatively, molecules interacting with TPPT are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989, Nature 340:245-246), or using commercially

available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

TPPT may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	44	264114	HNT2AGT01	028972R6 (SPLNFET01), 028972T6 (SPLNFET01), 264114H1 (HNT2AGT01), 452387R6 (TLIVNOT02), 736580R1 (TONSNOT02), 747955R6 (BRATTUT01), 936731R1 (CERVNOT02), 3206282H1 (PENCNOT03), 3344943H1 (SPLNNOT09), 3742964H1 (THYMNOT08), 4028320H1 (BRAINOT23), 4726757H1 (GBLADTT01), 5473562H1 (MCLRUNT01)
2	45	1455669	COLNFET02	1455669H1 (COLNFET02), 2877376F6 (THYRNOT10), 3536452F6 (KIDNNOT25)
3	46	2084989	PANCNOT04	1281527H1 (COLNNOT16), 1412985H1 (BRAINOT12), 2084989H1 (PANCNOT04), 2084989R6 (PANCNOT04), 2084989T6 (PANCNOT04), 2470048F6 (THPINOT03), 2539015F7 (BONRTUT01), 3109754F6 (BRSTTUT15), 3694831H1 (PANCNOT19), 3700647H1 (SINTNOT05)
4	47	2501034	ADRETUT05	1114665F1 (PITUNOT01), 1114665R1 (PITUNOT01), 414042R6 (BRSTNOT01), 687891H1 (UTRSNOT02), 2501034H1 (ADRETUT05)
5	48	2745212	LUNGTUT11	000802H1 (U937NOT01), 008963H1 (HMC1NOT01), 009314H1 (HMC1NOT01), 135428F1 (BMARNOT02), 723168X19 (SYNOOAT01), 1000842R1 (BRSTNOT03), 1370189H1 (BSTMMON02), 1374329H1 (BSTMMON02), 2745212H1 (LUNGTUT11), 4920466H1 (TESTNOT11), SAIA021822F1
6	49	4833111	BRAVTXT03	864776T1 (BRATUT03), 1911267F6 (CONNTUT01), 4833111H1 (BRAVTXT03), SARA02608F1, SARA02002F1
7	50	876677	LUNGAST01	876677H1 (LUNGAST01), 876677R6 (LUNGAST01), SCDA08642V1
8	51	2326143	OVARNOT02	867305R1 (BRATTUT03), 963058R2 (BRSTTUT03), 1715155F6 (UCMCNOT02), 1727927T6 (PROSNOT14), 2326143H1 (OVARNOT02), 2326143R6 (OVARNOT02), 3360563H1 (PROSTUT16)
9	52	2786302	BRSTNOT13	2786302H1 (BRSTNOT13), 2958321X03D1 (ADRENOT09), 2958321X05D1 (ADRENOT09), 2958321X08D1 (ADRENOT09)
10	53	3735780	SMCCNOS01	551126H1 (BEPINOT01), 2808373H1 (BLADTUT08), 3735780F6 (SMCCNOS01), 3735780H1 (SMCCNOS01), 3735780T6 (SMCCNOS01), 4760604T6 (BRAMNOT01)
11	54	039026	HUVENOB01	039026H1 (HUVENOB01), 159164F1 (ADENINB01), 159164R1 (ADENINB01)
12	55	260607	HNT2RAT01	063159R6 (PLACNOB01), 260607R6 (HNT2RAT01), 1272850T1 (TESTTUT02), 1273069H1 (TESTTUT02), 2867453F6 (KIDNNOT20), 3082466H1 (BRAIUNT01), 4796739H1 (LIVRTUT09), 4799318F6 (MYEBUNT01), g1424405

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
13	56	1429651	SINTBST01	1429651F1 (SINTBST01), 1429651H1 (SINTBST01), 1501096F6 (SINTBST01), 1989621T6 (CORPNOT02), SXLA01343V1, SXLA01183V1, SXLA01559V1, SXLA00812V1
14	57	2069971	ISLTNOT01	2069606F6 (ISLTNOT01), 2069971H1 (ISLTNOT01), 2374634F6 (ISLTNOT01), 2383754F6 (ISLTNOT01), 4171186T6 (ISNTNOT21), SXLA01128V1, SXLA01348V1, SXLA01219V1, SXLA00260V1, SXLA00074V1
15	58	2329339	COLNNOT11	658662H1 (BRAINOT03), 1544110R1 (PROSTUT04), 1657742F6 (URETUT01), 1750523F6 (SPCWTUT02), 2329339H1 (COLNNOT11), 2329339R6 (COLNNOT11), 3858671H1 (LNODNOT03), g1494061, g1891451
16	59	2540219	BONRTUT01	2540219H1 (BONRTUT01), 2540219T6 (BONRTUT01), 2554869F6 (THYMNOT03), g869197
17	60	2722462	LUNGTUT10	883601R1 (PANCNOT05), 1525902F6 (UCMCL5T01), 1525902X18C1 (UCMCL5T01), 1525902X311D1 (UCMCL5T01), 1527325T6 (UCMCL5T01), 1554770X311D1 (BLADTUT04), 2417265H1 (HNT3AZT01), 2444786F6 (THP1NOT03), 2722462H1 (LUNGTUT10), 4293114H1 (BRABDIR01), 5070268T6 (PANCNOT23), SANA01850F1, SAJA01078R1, SANA02081F1, SAJA01813F1
18	61	2739264	OVARNOT09	000573H1 (U937NOT01), 494409F1 (HNT2NOT01), 494409R1 (HNT2NOT01), 2506506F6 (CONUTUT01), 2681059H1 (SINTUCT01), 2744648F6 (BRSTTUT14), 2805590F6 (BLADTUT08), 3770643H1 (BRSTNOT25), 4204278H1 (BRAITUT29), SAEA02093F1
19	62	2758310	THP1AZS08	487309R7 (HNT2AGT01), 1361439F1 (LUNGNOT12), 2758310H1 (THP1AZS08), SCFA05584V1, SCFA05940V1, SCFA05166V1, SCFA05135V1
20	63	2762348	BRSTNOT12	632097R6 (KIDNNOT05), 632097T6 (KIDNNOT05), 2762348H1 (BRSTNOT12), SCCA02837V1, SCCA05356V1, SCCA01377V1, SCCA05963V1, SCCA05364V1, SCCA02307V1, SCCA04327V1, SCCA02009V1
21	64	3715961	PENCNOT09	961523H1 (BRSTTUT03), 1863723F6 (PROSNOT19), 2265329H1 (UTRSNOT02), 2360619R6 (LUNGFET05), 2360619T6 (LUNGFET05), 2821718H1 (ADRETUT06), 3715961H1 (PENCNOT09), 5016160H1 (BRAXNOT03), 5499583H1 (BRABDIR01)
22	65	5108194	PROSTUS19	1322651X35 (BLADNOT04), 1322651X36 (BLADNOT04), 3494841H1 (ADRETUT07), 4958978F6 (TLYMNOT05), 5108194H1 (PROSTUS19), g1379009, g1527417
23	66	5503122	BRABDIR01	5503122F6 (BRABDIR01), 5503122H1 (BRABDIR01), 5503122R6 (BRABDIR01)

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
24	67	5517972	LIVRDIR01	805957R1 (BSTMNOT01), 953622R1 (SCORNON01), 1501080F1 (SINTNBST01) 1547318l86 (PROSTUT04) 2081843r6 (UTRSNOT08), 2811524F6 (OVARNOT10), 3212921H1 (BLADNOT08), 3250443H1 (SEMVNOT03), 3269479H1 (BRAINOT20), 3699955F6 (SINTNOT05), 3700368H1 (SININOT05), 4944050H1 (BRAIFEN05), 5517972H1 (LIVRDIR01)
25	68	5593114	COLCDIT03	2859465F6 (SININOT03), 2859465r6 (SININOT03), 3555656F6 (LUNGNOT31), 3555656r6 (LUNGNOT31), 4345952H1 (TLYMTXT01), 5593114H1 (COLCDIT03), 5874544H1 (COLTDIT04)
26	69	044775	TBLYNOT01	044775H1 (TBLYNOT01), 044775X3 (TBLYNOT01), 455640R1 (KERANOT01), 950702R1 (PANCNOT05), 2418550H1 (HNT3AZT01), 2798917H1 (NPOLNOT01), 2844696H1 (DRGLNOT01), g1718929
27	70	116588	KIDNNOT01	699714R6 (SYNORAT03), 831423R1 (PROSTUT04), 978875R1 (BRSTNOT02), 1350569F1 (LATRTUT02), 1447681R1 (PLACNOT02), 3177382F6 (UTRSTUT04), 3688796H1 (HEAANOT01), 3929008H1 (KIDNNOT19), g2106455, g2163092
28	71	875369	LUNGAST01	571573F1 (OVARNON01), 571573R1 (OVARNON01), 875369H1 (LUNGAST01), 875369R1 (LUNGAST01), 3569021H1 (HEAPNOT01)
29	72	1325518	LPARNOT02	1325518H1 (LPARNOT02), 1325518r6 (LPARNOT02), 1825553F6 (LSUBNOT03), SBAAC2035F1
30	73	2060987	OVARNOT03	1378947T1 (LUNGNOT10), 1453290F1 (PENITUT01), 1459818R1 (COLNFET02), 1967477H1 (BRSTNOT04), 2060987H1 (OVARNOT03), 2455371F6 (ENDANOT01), 2499967F7 (ADRETUT05), 3093055T6 (BRSTNOT19), 3213366H1 (BLADNOT08), 4934158H1 (BRSTTUT20), SBIA01942D1
31	74	2172064	ENDCNOT03	2172064CT1 (ENDCNOT03), 2172064H1 (ENDCNOT03), SBLA01269F1
32	75	2219267	LUNGNOT18	2219267F6 (LUNGNOT18), 2219267H1 (LUNGNOT18), 3117478T6 (LUNGTUT13), 3126288T6 (LUNGTUT12), 3558495H1 (LUNGNOT31)
33	76	2308629	NGANNOT01	469862F1 (MMLR1DT01), 469862R1 (MMLR1DT01), 1594203X11C1 (BRAINOT14), 2191933H1 (THYATUT03)
34	77	2660038	LUNGTUT09	1326594F1 (LPARNOT02), 2256143H1 (OVARTUT01), 2278689R6 (PROSNON01), 2528425H1 (SBLANOT02), 2660038H1 (LUNGTUT09), 2660038T6 (LUNGTUT09), 3449596H1 (UTRSNOR03), 5099879H1 (PROSTUS20), g1885680, g1893369

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
35	78	2670745	ESOGTUT02	259200X12 (HNT2RAT01), 1266477F1 (BRAINOT09), 2383364F6 (ISLTNOT01), 2670745H1 (ESOGTUT02), 3181526H1 (TLYJNOT01)
36	79	2676443	KIDNNOT19	607375R6 (BRSTTUT01), 1728626X15C1 (PROSNOT14), 1751773F6 (LIVRTUT01), 1751994T6 (LIVRTUT01), 1796032X14C1 (PROSTUT05), 2010172H1 (TESTNOT03), 2676443H1 (KIDNNOT19)
37	80	3295764	TLYJINT01	063264H1 (PLACNOB01), 434468T6 (THYRNOT01), 487721H1 (HNT2AGT01), 907796R2 (COLNNOT09), 1212556R7 (BRSTTUT01), 1251889H1 (LUNGFET03), 1653370F6 (PROSTUT08), 1653370X30901 (PROSTUT08), 2192762F6 (THYRTUT03), 2226786F6 (SEMVNOT01), 3295764H1 (TLYJOINT01), 338447IH1 (ESOGNOT04), SASA01137F1
38	81	3438320	PENCNOT06	343832OH1 (PENCNOT06), 350143BH1 (PROSTUT13), 3745542H1 (THYMNOT08), 3751060H1 (UTRSNOT18), 4979750F6 (HELATXT04), SADA00043F1, SADA00087F1
39	82	3986488	UTRSTUT05	1634141F6 (COLNNOT19), 1692115X12C1 (PROSTUT10), 1731310F6 (BRSTTUT08), 2046232H1 (THP1NT7T01), 3557951H1 (LUNGNOT31), 4726788H1 (GBLADIT01)
40	83	4378816	LUNGNOT37	1318962H1 (BLADNOT04), 1520864F1 (BLADTUT04), 1684381F6 (PROSNOT15), 2055747R6 (BEPINOT01), 4378816H1 (LUNGNOT37)
41	84	4797137	LIVRTUT09	4797137F6 (LIVRTUT09), 4797137H1 (LIVRTUT09), 4797137T6 (LIVRTUT09)
42	85	5470806	MCLRUNT01	5470806H1 (MCLRUNT01), 5470806T6 (MCLRUNT01)
43	86	5473242	MCLRUNT01	5473242H6 (MCLRUNT01), 5473242T6 (MCLRUNT01)

Table 2

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
1	623	S521 S2 T3 S16 S99 S138 S144 T193 T264 T404 S448 S589 S151 T229 T337 T457 S562 S568	N97 N333	BTB domain: C44-F56 POZ domain: N10-Q211 Kelch repeat signature: E379-G392, T398-V412, L438-M452, T498-A512 Ring canal protein repeat: E122-P254	Ring canal protein [Drosophila melanogaster] g577276	MOTIFS BLIMPS-PFAM BLIMPS-PRINTS BLAST-GenBank BLAST-PRODOM BLAST-DOMO
2	99	T17	N15	Signal peptide: M1-G36 Transmembrane region: S25-W45 MRP(2) MRP(1) repeat: C30-V74	Multi-drug resistance-associated protein (MRP)-like protein-1 (MLP-1) [Rattus norvegicus] g3242458	MOTIFS BLAST-GenBank BLAST-PRODOM SPScan HMMER
3	374	T334 T33 S137 T146 S291 S311 T346	N103 N127 N135 N138	Signal peptide: M1-N52	Tricarboxylate carrier [Rattus sp.] g545998	MOTIFS BLAST-GenBank SPScan
4	271	S234 T126 T169 Y141		Signal peptide: M1-C30 Transmembrane region: L233-F252	Weak similarity with honeybee ATP synthase A chain [Caenorhabditis elegans] g3878801	MOTIFS BLAST-GenBank SPScan HMMER
5	323	S99 S125 S192 T277 S307 S309 T110 Y212		Leucine zipper: L284-L305	Cu²-transporting ATPase homolog [Arabidopsis thaliana] g2464854	BLAST-GenBank MOTIFS
6	274	S96 T198 S215 T29 S121 S164 S170		Mitochondrial energy transfer proteins: G5-L266 Signal peptide: M1-G17	Pet8p [Saccharomyces cerevisiae] g495307	BLAST-GenBank HMMER-PFAM MOTIFS ProfileScan BLIMPS-BLOCKS BLIMPS-PRINTS BLAST-PRODOM BLAST-DOMO SPScan

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
7	291	S6 T113 T173 T147 S230 T258	N226 N261	Signal peptide: M1-T42 Transmembrane domain: W29-I54 Band 7 protein family: C50-V62, K90-E224 Membrane stomatin: E14-N283	Stomatin [Homo sapiens] g1161562	MOTIFS BLAST-GenBank SPScan HMMER BLIMPS-BLOCKS BLAST-DOMO BLAST-PRODOM
8	381	S2 S35 T57 S92 T104 S191 S302 S334 S335 S336 T43 T250 T255 T304 S311 S370 Y65	N218 N253 N259		K' channel modulatory factor DEPT-91 [Mus musculus] g4838557	MOTIFS BLAST-GenBank
9	190	T160 S17 T71 S77 T78 S111 S134 S142	N87	ABC transporter family: R79-K177 ATP/GTP-binding site motif A (P-loop): G102-S109	ABC2 transporter [Mus musculus] g495259	MOTIFS BLAST-GenBank BLAST-DOMO
10	297	S17 S114 T136 S16	N287	Mitochondrial carrier protein signature: E117-I297 Graves Disease carrier protein: P137-T157, L259-S279	Similar to human ADP/ATP carrier protein [C. elegans] g3879938	MOTIFS BLAST-GenBank HMMER-PFAM BLIMPS-PRINTS
11	89	T37 T47 T60 S64			Mitochondrial import protein Tim9p [Saccharomyces cerevisiae] g3747026	BLAST-GenBank MOTIFS
12	115	T108 T84		Signal peptide: M1-G24 Transmembrane domain: G35-F57 Sodium neurotransmitter symporter signature: R7-S61		MOTIFS SPScan HMMER ProfileScan

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
13	675	T54 T50 S99 T127 S413 T558 S645 T654 T47 S242 T602 T611 Y501	N243 N247 N301 N601	Transmembrane domains: I29-V48, L103-I121, L177-G196, I210-M229, L417-W435, F481-Y501, Y521-W541 Sodium symporter family domain: Y58-G487 Sodium:solute symporter signature: Y35-G89, M111-R140, L173-G227, P460-G469	Sodium-glucose cotransporter [Oryctolagus cuniculus] g473969	BLAST-GenBank MOTIFS HMMER HMMER-PFAM BLIMPS-BLOCKS ProfileScan BLAST-PRODOM BLAST-DOMO
14	320	T84 S304 T11 S75 S80 S164 Y20	N162 N234	Transmembrane domains: I92-L112, I201-K219 Zinc transporter signature: A28-V142, D199-E303 Cation transporter domain: S48-L74	Zinc transporter ZnT-2 [Rattus norvegicus] g1256378	BLAST-GenBank MOTIFS HMMER BLIMPS-PRODOM BLAST-PRODOM BLAST-DOMO
15	462	S111 S145 S183 S233 T26 T185 S202 T243	N24 N279	Kelch repeat motifs: C299-N349; F350-R399 Y400-G446 BTB domain: F50-L117 POZ domain: Y27-E215	Ring canal protein [Drosophila melanogaster] g577276	BLAST-GenBank MOTIFS HMMER-PFAM BLIMPS-PRINTS BLAST-DOMO
16	98	T22 Y37		Signal peptide: M1-S17 Mitochondrial carrier proteins domain: C4-T89 Mitochondrial carrier proteins signature sequence: G19-A33, G63-E83	Carrier protein (c1) [Caenorhabditis elegans] g472902	BLAST-GenBank MOTIFS SPScan HMMER-PFAM ProfileScan BLIMPS-BLOCKS BLIMPS-PRINTS BLAST-DOMO

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
17	748	S55 S196 T254 S307 S327 T491 T534 T550 T571 S635 S648 S677 T696 S283 S291 T314 S629 S701 Y556	N531 N543 N548 N627	Signal peptide: M1-A61 Transmembrane domains: L39-L56, I167-F186, C229-F252, G438-L455, M492-F509, L598-I618 Ion transport proteins signature: F85-V251, L369-I618	Voltage-gated calcium channel [Rattus norvegicus] g4586963	BLAST-GenBank MOTIFS SPScan HMMER HMMER-PFAM BLIMPS-PRINTS
18	507	T200 S183 T232 T284 T349 T150 T252 S253 S319 S383 Y454	N220 N250 N364 N496	Signal peptide: M1-G26	Nucleoporin p54 [Rattus norvegicus] g1537070	BLAST-GenBank MOTIFS SPScan
19	592	S460 S104 T178 S320 S321 T498 T531 Y365		ABC1 precursor signature: N153-Q162, F210-A229, G234-I254, V312-G332, T366-V378	ABC transporter [Methanobacterium thermo.] g2622773	BLAST-GenBank MOTIFS BLIMPS-PRODOM BLAST-PRODOM
20	841	T98 S120 S203 T214 T276 S388 T438 T700 T838 T167 T179 S280 T370 S435 S531 S539 S666 S693 S830	N368 N490 N624	Transmembrane domains: Y451-D469, M544-F562, F577-F597, G775-W797 Vacuolar ion transport subunit signature: M10-F831	Vacuolar H+/ATPase subunit [Rattus norvegicus] g206430	BLAST-GenBank MOTIFS HMMER BLIMPS-PRODOM BLAST-PRODOM BLAST-DOMO
21	253	S50 T139 T152 T177 S202 T143 Y55		Mitochondrial carrier proteins domain: Y31-S248 Mitochondrial energy transfer proteins signature sequence: I62-Q86, I110-Q122	Mitochondrial uncoupling protein UCP-4 [Homo sapiens] g4324701	BLAST-GenBank MOTIFS HMMER-PFAM BLIMPS-BLOCKS ProfileScan BLAST-PRODOM BLAST-DOMO

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
22	229	S69 S26 S109 T162 S178 S25 S64 S65 T210 S219		Signal peptide: M1-A47 Mitochondrial carrier proteins domain: Q32-G220 Mitochondrial carrier proteins signature sequence: S36-T49, T49-V63, G92-E112, T144-T162, Y187-F205	Grave's disease carrier protein [Bos taurus] g387	BLAST-GenBank MOTIFS SPScan HMMER-PFAM BLIMPS-BLOCKS ProfileScan BLIMPS-PRINTS BLAST-PRODOM BLAST-DOMO
23	170	S26 S31 S149 S164 T22 T157	N66 N145	Dihydroxipyridine-sensitive L-type calcium channel signature: Y2-A47, I49-V77, A83-M100, R106-E131 SH3 domain: V59-R122	Voltage-dependent calcium channel beta-4 subunit [Homo sapiens] g2058727	BLAST-GenBank MOTIFS HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS BLIMPS-PFAM BLAST-PRODOM BLAST-DOMO
24	655	T194 S195 S232 T362 S655 S4 S88 T135 T153 S187 T214 S322 T345 S353 S443 T609 S261 S381 S384	N338 N418 N557 N596	Transmembrane domains: I396-K417, Y494-S522, T538-V556 ABC transporters domain: P73-G262 ABC transporter family signature sequence: I78-L89, V186-D217	Breast cancer resistance protein (multidrug transporter) [Homo sapiens] g4038352	BLAST-GenBank MOTIFS HMMER HMMER-PFAM BLIMPS-BLOCKS ProfileScan BLAST-PRODOM BLAST-DOMO
25	184	T51 S29 T100 S138 S151 Y78	N27		Cation transport protein [E. coli] g495778	BLAST-GenBank MOTIFS
26	154	S54 S42 S62 T78 Y104		Mitochondrial energy transfer proteins signatures: P89-L97, M1-E41, M73-L152 Mitochondrial carrier protein domain: G2-K152	Similar to carrier protein C2 (C. elegans] g3879669	MOTIFS HMMER-PFAM BLAST-PRODOM BLAST-DOMO BLAST-GenBank

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
27	438	S170 T5 T51 T265 T300 S425	N50 N423	Transmembrane domains: C91-L111, L237-I257, I305-M332, M332-L354, L391-V408, I186-A204	Multidrug efflux transporter [Bacillus subtilis] g2635104	MOTIFS HMMER BLAST-GenBank
28	237	S10 S47 T72 S28 S96 S148 T173 T222 S6 S21 T32 T61 T192	N35	Nucleic acid-binding protein E5.1 domain: S6-K128	ARL-6 interacting protein-4 [Mus musculus] g4927204	MOTIFS BLAST-DOMO BLAST-GenBank
29	219	T66 S194 T200		Signal peptide: M1-R19 or M1-K15 Caseins alpha/beta signature: M1-N39	Surface antigen [Trypanosoma cruzi] g161956	MOTIFS HMMER SPScan ProfileScan BLAST-GenBank
30	707	S31 T6 T55 T263 T328 T546 T580 T594 S662 S673 T32 S50 S231 T244 T306 T385 S439 S476 S533 S553 S624	N343 N570 N638 N703	Potassium channel signature: K62-T81 Potassium channel integral membrane protein domain: S13-D117	NY-REN-45 antigen (similar to potassium channel protein) [Homo sapiens] g5360115	MOTIFS BLIMPS-PRINTS BLAST-DOMO BLAST-GenBank
31	279	T18 T245 T206	N181	Signal cleavage: M1-G45 Connexin domains: M1-V99. V20-Y44 Connexin signatures: L33-V86, L152-F205, F51-P73, S76-L96, L133-Y159, C169-T189, I190-L218 Gap junction protein connexin transmembrane regions: F5-Y97, L133- K223, M1-S130	Gap junction protein (similar to connexin) [Homo sapiens] g3006230	MOTIFS SPScan HMMER BLIMPS-BLOCKS BLIMPS-PRINTS BLAST-PFAM ProfileScan BLAST-PRODOM BLAST-DOMO BLAST-GenBank

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
32	154	S114		Signal peptide: M1-A35 or M1-A14 Transmembrane domain: F83-L102	mBOCT (potent organic cation transporter) [Mus musculus] g4589468	MOTIFS HMMER SPScan BLAST-GenBank
33	289	T83 T205 S269 T279	N60	Mitochondrial energy transfer proteins signatures: M1-G147, P17, P115, N185-K280, A101-Q181, Y184-I278 Mitochondrial carrier protein domains: M1-E176, N185-K280 Mitochondrial transmembrane transport protein regions: P17-R182, P180-I278	Mitochondrial solute carrier [Onchocerca volvulus] g1518458	MOTIFS HMMER-PFAM BLAST-DOMO BLAST-PRODOM ProfileScan BLAST-GenBank
34	300	S189 S195 S204 T257		Mitochondrial energy transfer proteins signatures: P19-W27, D2-I53, L209-L295 Mitochondrial carrier protein domain: D2-Y295 Transport protein domain: P122-Y295	YKL522=mitochondria l ADP/ATP carrier protein homolog [Saccharomyces cerevisiae] g254449	MOTIFS HMMER-PFAM ProfileScan BLAST-PRODOM BLAST-DOMO BLAST-GenBank
35	382	S34 S207 T221 S312 T40 S53 T112 T117 T277 S337	N96 N372	Kelch motifs: H191-G249, E250-D301	Similarity to Human host cell factor C1 [Homo sapiens] g3875291	MOTIFS HMMER BLAST-PFAM BLAST-GenBank

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
36	287	T36 T118 S180 S230 T84 S168 T244		Mitochondrial energy transfer proteins signatures: P26-L34, P219-L227, L97-G193, W10-V89, D197-F281, P96-Y194 Mitochondrial carrier protein domain: A5-F281 Mitochondrial brown fat region: Y82-Q94, V151-S168, Y194-C212	Mitochondrial dicarboxylate carrier [Rattus norvegicus] g3646426	MOTIFS HMMER-PFAM BLIMPS-PRINTS BLAST-DOMO BLAST-GenBank
37	497	T65 T135 S147 T360 S8 T22 S45 S291	N63 N314 N414	Transmembrane domains: M114-T137, M364-M380, Y390-A413, A421-D444, F456-V478 Folate transporter domains: W30-H218, I253-K484	Reduced folate carrier [Homo sapiens] g1041934	MOTIFS HMMER BLAST-PRODOM BLAST-DOMO SPScan BLAST-GenBank
38	228	T21 S124 T145 S158 T190 T95 S132 S137 T177		Heme-binding domain in Cytochrome b5: Y19-G98 Cytochrome b5 family domain: H28-P75	cytochrome b5 containing fusion protein [Helianthus annuus] g1040729 P=1.2e-07	MOTIFS HMMER-PFAM BLAST-GenBank ProfileScan
39	273	T63 S158 T48	N214	Transmembrane domains: L85-N105, F180-Y200 Intermembrane space domain: I30-I251	Sqv-7-like protein (similar to nucleotide-sugar transporters) [Homo sapiens] g4008517	MOTIFS HMMER BLAST-DOMO BLAST-GenBank

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
40	206	S187 S201	N158	Signal peptide: M1-G29 or M1-A27 Emopamil binding protein: G37-S187, L15-K203 Transmembrane domain: Y164-L183	C-8,7 sterol isomerase, aSI1 [Arabidopsis thaliana] g2772934	MOTIFS HMMER ProfileScan BLAST-DOMO BLAST-GenBank
41	235	S192 S200 S56 T95 T146 S199 T207 S229 T53 T61 T69 T119 T148 Y70	N123	Transmembrane domain: F15-I34, M155-V174 Channel myelin protein: L18-M181 Sodium channel beta-2 subunit precursor: F15-E210 Immunoglobulin domain: I34-V136	Myelin protein zero (Mpz) [Homo sapiens] g2160399	MOTIFS HMMER BLIMPS-PRINTS BLAST-PRODOM BLAST-DOMO BLAST-GenBank
42	147	T79 T116 S3 S66 Y89 Y98	N118	Signal peptide: M1-G23 or M1-A20 Transthyretin signature: S28-S132 Transthyretin domain: G21-Q146	Transthyretin precursor [Sus scrofa] g1009702	MOTIFS HMMER ProfileScan BLAST-PRODOM BLAST-DOMO BLAST-GenBank BLIMPS-BLOCKS BLIMPS-PRINTS
43	147	T5 S88 T39		Globin domain: V2-H147 Heme oxygen transport protein domain: L32-H147	III beta-3 globin [Rattus norvegicus] g395943	MOTIFS HMMER-PFAM BLAST-PRODOM BLAST-DOMO BLIMPS-BLOCKS BLIMPS-PRINTS

Table 3

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
44	1567-1611 2107-2151	Gastrointestinal (0.203) Hematopoietic/Immune (0.188) Nervous (0.156)	Cell Proliferation and Cancer (0.547) Inflammation (0.422)	PBLUESCRIPT
45	1-92 351-434	Endocrine (0.333) Developmental (0.167) Gastrointestinal (0.167) Musculoskeletal (0.167) Reproductive (0.167)	Cell Proliferation and Cancer (0.833) Inflammation (0.167)	pINCY
46	920-964 1352-1396	Reproductive (0.304) Gastrointestinal (0.174) Cardiovascular (0.130) Hematopoietic/Immune (0.130) Nervous (0.130)	Cell Proliferation and Cancer (0.478) Inflammation (0.391)	PSPORT1
47	1-80 768-848	Nervous (0.273) Reproductive (0.273) Gastrointestinal (0.127) Hematopoietic/Immune (0.127)	Cell Proliferation and Cancer (0.564) Inflammation (0.400)	pINCY
48	111-194 687-758	Reproductive (0.221) Nervous (0.185) Gastrointestinal (0.124)	Cell Proliferation and Cancer (0.552) Inflammation (0.343)	pINCY
49	1-97	Nervous (0.234) Hematopoietic/Immune (0.191) Gastrointestinal (0.149)	Cell Proliferation and Cancer (0.617) Inflammation (0.340)	pINCY
50	218-262	Cardiovascular (1.000)	Cancer (0.333) Inflammation/Trauma (0.333) Cell Proliferation (0.333)	PSPORT1
51	811-855	Hematopoietic/Immune (0.180) Gastrointestinal (0.146) Reproductive (0.281)	Cancer (0.393) Inflammation/Trauma (0.515) Cell Proliferation (0.146)	PSPORT1
52	595-639	Gastrointestinal (0.286) Reproductive (0.714)	Cancer (0.429) Inflammation/Trauma (0.429)	pINCY
53	96-140	Cardiovascular (0.167) Hematopoietic/Immune (0.167) Nervous (0.250) Reproductive (0.167)	Cancer (0.250) Inflammation/Trauma (0.167) Cell Proliferation (0.167)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
54	507-551	Reproductive (0.323) Gastrointestinal (0.154) Nervous (0.123)	Cancer (0.446) Inflammation/Trauma (0.308) Cell Proliferation (0.185)	PBLUESCRIPT
55	455-499	Urologic (0.333) Nervous (0.222) Reproductive (0.222)	Cancer (0.667) Cell Proliferation (0.333)	PBLUESCRIPT
56	1835-1879	Nervous (0.625) Gastrointestinal (0.375)	Inflammation/Trauma (0.375) Cancer (0.250) Neurological (0.250)	pINCY
57	811-855	Gastrointestinal (1.000)	Inflammation/Trauma (0.667)	pINCY
58	390-434	Reproductive (0.320) Nervous (0.240) Urologic (0.120)	Cancer (0.520) Inflammation/Trauma (0.240) Cell Proliferation (0.160)	PSPORT1
59	413-457	Gastrointestinal (0.333) Musculoskeletal (0.333) Nervous (0.333)	Cancer (0.333) Neurological (0.333)	pINCY
60	2021-2084	Nervous (0.197) Gastrointestinal (0.184) Reproductive (0.184)	Cancer (0.461) Inflammation/Trauma (0.316) Cell Proliferation (0.118)	pINCY
61	65-109	Nervous (0.226) Reproductive (0.208) Cardiovascular (0.113) Gastrointestinal (0.113)	Cancer (0.528) Inflammation/Trauma (0.301) Cell Proliferation (0.208)	pINCY
62	379-423 1867-1911	Reproductive (0.282) Gastrointestinal (0.205) Nervous (0.154)	Cancer (0.538) Inflammation/Trauma (0.282) Cell Proliferation (0.103)	PSPORT1
63	362-406 1193-1237	Urologic (0.500) Reproductive (0.333) Cardiovascular (0.167)	Cancer (0.667) Inflammation/Trauma (0.333)	pINCY
64	394-438	Nervous (0.294) Reproductive (0.265) Cardiovascular (0.118)	Cancer (0.382) Inflammation/Trauma (0.235) Cell Proliferation (0.118)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
65	768-812	Reproductive (0.300) Endocrine (0.200) Gastrointestinal (0.200) Hematopoietic/Immune (0.200)	Inflammation/Trauma (0.500) Cancer (0.400)	pINCY
66	77-121	Nervous (1.000)	Neurological (1.000)	pINCY
67	1999-2043	Reproductive (0.324) Nervous (0.265) Gastrointestinal (0.235)	Cancer (0.500) Inflammation/Trauma (0.294) Cell Proliferation (0.118)	pINCY
68	561-605	Hematopoietic/Immune (0.455) Gastrointestinal (0.182) Nervous (0.182)	Inflammation/Trauma (0.546) Cell Proliferation (0.182)	pINCY
69	679-729	Nervous (0.292) Gastrointestinal (0.208) Hematopoietic/Immune (0.125)	Cancer (0.250) Cell Proliferation (0.375) Inflammation/Trauma (0.416)	PBLUESCRIPT
70	95-366 1078-1185	Reproductive (0.206) Hematopoietic/Immune (0.186) Cardiovascular (0.127)	Cancer (0.373) Inflammation/Trauma (0.382) Cell Proliferation (0.176)	PBLUESCRIPT
71	33-152	Reproductive (0.275) Nervous (0.163) Gastrointestinal (0.137)	Cancer (0.438) Inflammation/Trauma (0.314) Cell Proliferation (0.176)	PSPORT1
72	81-779	Gastrointestinal (1.000)	Cancer (1.000)	pINCY
73	719-817 1202-1414	Reproductive (0.311) Hematopoietic/Immune (0.203) Gastrointestinal (0.122)	Cancer (0.459) Inflammation/Trauma (0.379) Cell Proliferation (0.203)	PSPORT1
74	1-848	Nervous (0.750) Dermatologic (0.250)	Cancer (0.250) Cell Proliferation (0.250) Inflammation/Trauma (0.500)	pINCY
75	1-478	Cardiovascular (0.714) Developmental (0.143) Hematopoietic/Immune (0.143)	Cancer (0.571) Cell Proliferation (0.286) Inflammation (0.143)	pINCY
76	1-134	Reproductive (0.253) Nervous (0.241) Gastrointestinal (0.127) Hematopoietic (0.127)	Cancer (0.494) Inflammation (0.215) Cell Proliferation (0.127)	PSPORT1

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
77	510-719 960-1100	Reproductive (0.467) Cardiovascular (0.133) Gastrointestinal (0.133)	Cancer (0.467) Inflammation/Trauma (0.467)	pINCY
78	180-293	Reproductive (0.230) Nervous (0.225) Gastrointestinal (0.124)	Cancer (0.478) Inflammation/Trauma (0.292) Cell Proliferation (0.191)	pINCY
79	192-653 795-935	Reproductive (0.417) Gastrointestinal (0.292) Urologic (0.125)	Cancer (0.750) Cell Proliferation (0.125) Inflammation/Trauma (0.167)	pINCY
80	139-1044	Reproductive (0.245) Nervous (0.143) Developmental (0.122)	Cancer (0.490) Inflammation/Trauma (0.286) Cell Proliferation (0.224)	pINCY
81	233-916	Reproductive (0.667) Cardiovascular (0.167) Nervous (0.167)	Cancer (0.500) Cell Proliferation (0.333) Inflammation (0.167)	pINCY
82	1-153 760-816	Gastrointestinal (0.282) Hematopoietic/Immune (0.205) Reproductive (0.205)	Inflammation/Trauma (0.461) Cancer (0.308) Cell Proliferation (0.205)	pINCY
83	57-299	Nervous (0.179) Reproductive (0.179) Gastrointestinal (0.128)	Cancer (0.564) Cell Proliferation (0.256) Inflammation/Trauma (0.180)	pINCY
84	1-707	Gastrointestinal (0.500) Hematopoietic/Immune (0.500)	Cancer (0.500) Inflammation (0.500)	pINCY
85	451-594	Hematopoietic/Immune (1.000)	Cell Proliferation (1.000)	pINCY
86	8-124 161-187 407-472	Developmental (1.000)	Cell Proliferation (1.000)	pINCY

Table 4

SEQ ID NO:	Library	Library Comment
44	HNT2AGT01	Library was constructed at Stratagene (STR937233), using RNA isolated from the hNT2 cell line derived from a human teratocarcinoma that exhibited properties characteristic of a committed neuronal precursor. Cells were treated with retinoic acid for 5 weeks and with mitotic inhibitors for two weeks and allowed to mature for an additional 4 weeks in conditioned medium.
45	COLNFET02	Library was constructed using RNA isolated from the colon tissue of a Caucasian female fetus, who died at 20 weeks' gestation.
46	PANCNOT04	Library was constructed using RNA isolated from the pancreatic tissue of a 5-year-old Caucasian male, who died in a motor vehicle accident. Serology was positive for cytomegalovirus (CMV).
47	ADRETUT05	Library was constructed RNA isolated from adrenal tumor tissue removed from a 52-year-old Caucasian female during a unilateral adrenalectomy. Pathology indicated a pheochromocytoma.
48	LUNGTUT11	Library was constructed using RNA isolated from lung tumor tissue removed from the right lower lobe a 57-year-old Caucasian male during a segmental lung resection. Pathology indicated an infiltrating grade 4 squamous cell carcinoma. Multiple intrapulmonary peribronchial lymph nodes showed metastatic squamous cell carcinoma. Patient history included a benign brain neoplasm and tobacco abuse. Family history included spinal cord cancer, type II diabetes, cerebrovascular disease, and malignant prostate neoplasm.
49	BRAVTXT03	Library was constructed using RNA isolated from treated astrocytes removed from the brain of a female fetus who died after 22 weeks' gestation. The cells were treated with tumor necrosis factor (TNF) alpha and interleukin 1 (IL-1), 10ng/ml each for 24 hours.
50	LUNGAST01	Library was constructed using RNA isolated from the lung tissue of a 17-year-old Caucasian male, who died from head trauma. Patient history included asthma.
51	OVARNOT02	Library was constructed using RNA isolated from ovarian tissue removed from a 59-year-old Caucasian female who died of a myocardial infarction. Patient history included cardiomyopathy, coronary artery disease, previous myocardial infarctions, hypercholesterolemia, hypotension, and arthritis.
52	BRSTNOT13	Library was constructed using RNA isolated from breast tissue removed from the left medial lateral breast of a 36-year-old Caucasian female during bilateral simple mastectomy and total breast reconstruction. Pathology indicated benign breast tissue. Patient history included a breast neoplasm, depressive disorder, hyperlipidemia, chronic bronchitis, and an ectopic pregnancy. Family history included myocardial infarction, cerebrovascular disease, atherosclerotic coronary artery disease, hyperlipidemia, skin cancer, breast cancer, depressive disorder, esophageal cancer, bone cancer, Hodgkin's lymphoma, bladder cancer, and a heart condition.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
53	SMCCNOS01	Library was constructed using 7.56 X 10e6 clones from a coronary artery smooth muscle cell library and was subjected to two rounds of subtraction hybridization for 48 hours with 6.12 X 10e6 clones from a control coronary artery smooth muscle cell library. The starting library for subtraction was constructed using RNA isolated from coronary artery smooth muscle cells removed from a 3-year-old Caucasian male. The cells were treated with TNF alpha & IL-1 beta 10ng/ml each for 20 hours. The hybridization probe for subtraction was derived from a similarly constructed library from RNA isolated from untreated coronary artery smooth muscle cells from the same donor.
54	HUVENOB01	Library was constructed using RNA isolated from HUV-EC-C (ATCC CRL 1730) cells.
55	HNT2RAT01	Library was constructed at Stratagene (STR937231), using RNA isolated from the hNT2 cell line (derived from a human teratocarcinoma that exhibited properties characteristic of a committed neuronal precursor). Cells were treated with retinoic acid for 24 hours.
56	SINTBST01	Library was constructed using RNA isolated from ileum tissue obtained from an 18-year-old Caucasian female during bowel anastomosis. Pathology indicated Crohn's disease of the ileum, involving 15 cm of the small bowel. Family history included cerebrovascular disease and atherosclerotic coronary artery disease.
57	ISLTNOT01	Library was constructed using RNA isolated from a pooled collection of pancreatic islet cells.
58	COLNNOT11	Library was constructed using RNA isolated from colon tissue removed from a 60-year-old Caucasian male during a left hemicolectomy.
59	BONRTUT01	Library was constructed using RNA isolated from rib tumor tissue removed from a 16-year-old Caucasian male during a rib osteotomy and a wedge resection of the lung. Pathology indicated metastatic grade 3 (of 4) osteosarcoma, forming a mass involving the chest wall.
60	LUNGTUT10	Library was constructed using RNA isolated from lung tumor tissue removed from the left upper lobe of a 65-year-old Caucasian female during a segmental lung resection. Pathology indicated metastatic grade 2 myxoid liposarcoma and metastatic grade 4 liposarcoma. Patient history included soft tissue cancer, breast cancer, and secondary lung cancer.
61	OVARNOT09	Library was constructed using RNA isolated from ovarian tissue removed from a 28-year-old Caucasian female during a vaginal hysterectomy and removal of the fallopian tubes and ovaries. Pathology indicated multiple follicular cysts ranging in size from 0.4 to 1.5 cm in the right and left ovaries, chronic cervicitis and squamous metaplasia of the cervix, and endometrium in weakly proliferative phase. Family history included benign hypertension, hyperlipidemia, and atherosclerotic coronary artery disease.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
62	THP1AZS08	Library was constructed using 5.76 million clones from a 5-aza-2'-deoxycytidine (AZ) treated THP-1 promonocyte cell line library. Starting RNA was made from THP-1 promonocyte cells treated for three days with 0.8 micromolar AZ. 5.76 million clones from the AZ-treated THP-1 cell library were then subjected to two rounds of subtractive hybridization with 5 million clones from the untreated THP-1 cell library. Subtractive hybridization conditions were based on the methodologies of Swaroop et al. (1991) Nucleic Acids Res. 19:1954, and Bonaldo et al. (1996) Genome Research 6:791. THP-1 (ATCC TIB 202) is a human promonocyte cell line derived from peripheral blood of a 1-year-old Caucasian male with acute monocytic leukemia (ref: Int. J. Cancer (1980) 26:171).
63	BRSTNOT12	Library was constructed using RNA isolated from diseased breast tissue removed from a 32-year-old Caucasian female during a bilateral reduction mammoplasty. Pathology indicated nonproliferative fibrocystic disease. Family history included benign hypertension and atherosclerotic coronary artery disease.
64	PENCNOT09	Library was constructed using RNA isolated from penis right corpora cavernosa tissue.
65	PROSTUS19	Library was constructed using 2.36 million clones from a prostate tumor library which was subjected to two rounds of subtraction hybridization with 2.36 million clones from a normal prostate library. The starting library for subtraction was constructed using RNA isolated from prostate tumor tissue removed from a 59-year-old Caucasian male during a radical prostatectomy with regional lymph node excision. Pathology indicated adenocarcinoma (Gleason grade 3+3) involving the prostate peripherally with invasion of the capsule. Adenofibromatous hyperplasia was present. The patient presented with elevated prostate-specific antigen (PSA). Patient history included diverticulitis of the colon, asbestosis, and thrombophlebitis. Family history included benign hypertension, multiple myeloma, hyperlipidemia, and rheumatoid arthritis. The hybridization probe for subtraction was derived from a similarly constructed library, except that NotI-anchored oligo(dT) primer was used. Subtractive hybridization conditions were based on the methodologies of Swaroop et al. (1991) Nucleic Acids Res. 19:1954 and Bonaldo, et al. (1996) Genome Research 6:791.
66	BRABDIR01	Library was constructed using RNA isolated from diseased cerebellum tissue removed from the brain of a 57-year-old Caucasian male, who died from a cerebrovascular accident. Patient history included Huntington's disease, emphysema, and tobacco abuse.
67	LIVRDIR01	Library was constructed using RNA isolated from diseased liver tissue removed from a 63-year-old Caucasian female during a liver transplant. Patient history included primary biliary cirrhosis. Serology was positive for anti-mitochondrial antibody.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
68	COLCDIT03	Library was constructed using RNA isolated from diseased colon polyp tissue removed from the cecum of a 67-year-old female. Pathology indicated a benign cecum polyp. Pathology for the associated tumor tissue indicated invasive grade 3 adenocarcinoma that arose in tubulovillious adenoma forming a fungating mass in the cecum.
69	TBLYNOT01	Library was constructed at Stratagene (STR937214) using RNA isolated from a hybrid of T-B lymphoblasts from an untreated leukemic cell line.
70	KIDNNOT01	Library was constructed using RNA isolated from the kidney tissue of a 64-year-old Caucasian female, who died from an intracranial bleed. Patient history included rheumatoid arthritis and tobacco use.
71	LUNGAST01	Library was constructed using RNA isolated from the lung tissue of a 17-year-old Caucasian male, who died from head trauma. Patient history included asthma.
72	LPARNOT02	Library was constructed using RNA isolated from tissue obtained from the left parotid (salivary) gland of a 70-year-old male with parotid cancer.
73	OVARNOT03	Library was constructed using RNA isolated from ovarian tissue removed from a 43-year-old Caucasian female during a bilateral salpingo-oophorectomy. Pathology for the associated tumor tissue indicated grade 2 mucinous cyst adenocarcinoma. The patient presented with stress inconticnence. Patient history included mitral valve disorder, pneumonia, and viral hepatitis. Family history included atherosclerotic coronary artery disease, cerebrovascular disease, breast cancer, and uterine cancer.
74	ENDCNOT03	Library was constructed using RNA isolated from dermal microvascular endothelial cells removed from a neonatal Caucasian male.
75	LUNGNOT18	Library was constructed using RNA isolated from left upper lobe lung tissue removed from a 66-year-old Caucasian female. Pathology for the associated tumor tissue indicated a grade 2 adenocarcinoma. Patient history included cerebrovascular disease, atherosclerotic coronary artery disease, and pulmonary insufficiency. Family history included a myocardial infarction and atherosclerotic coronary artery disease.
76	NGANNOT01	Library was constructed using RNA isolated from tumorous neuroganglion tissue removed from a 9-year-old Caucasian male during a soft tissue excision of the chest wall. Pathology indicated a ganglioneuroma. Family history included asthma.
77	LUNGTUT09	Library was constructed using RNA isolated from lung tumor tissue removed from a 68-year-old Caucasian male during segmental lung resection. Pathology indicated invasive grade 3 squamous cell carcinoma and a metastatic tumor. Patient history included type II diabetes, thyroid disorder, depressive disorder, hyperlipidemia, esophageal ulcer, and tobacco use.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
78	ESOGTUT02	Library was constructed using RNA isolated from esophageal tumor tissue obtained from a 61-year-old Caucasian male during a partial esophagectomy, proximal gastrectomy, pyloromyotomy, and regional lymph node excision. Pathology indicated an invasive grade 3 adenocarcinoma in the esophagus. Family history included atherosclerotic coronary artery disease, type II diabetes, chronic liver disease, primary cardiomyopathy, benign hypertension, and cerebrovascular disease.
79	KIDNNOT19	Library was constructed using RNA isolated from kidney tissue removed a 65-year-old Caucasian male during an exploratory laparotomy and nephroureterectomy. Pathology for the associated tumor tissue indicated a grade 1 renal cell carcinoma within the upper pole of the left kidney. Patient history included malignant melanoma of the abdominal skin, benign neoplasm of colon, cerebrovascular disease, and umbilical hernia. Family history included myocardial infarction, atherosclerotic coronary artery disease, cerebrovascular disease, and prostate cancer.
80	TLYJINT01	Library was constructed using RNA isolated from a Jurkat cell line derived from the T cells of a male. Patient history included acute T-cell leukemia. This is an uninduced Jurkat cell line library from the same donor.
81	PENCNOT06	Library was constructed using RNA isolated from penis corpora cavernosa tissue removed from a 3-year-old Black male. Pathology for the associated tumor tissue indicated invasive grade 4 urothelial carcinoma forming a soft tissue scrotal mass that invaded the cavernous body of the penis and encased both testicles. Right inguinal lymph node showed metastatic grade 4 urothelial carcinoma, with extranodal invasion.
82	UTRSTUT05	Library was constructed using RNA isolated from uterine tumor tissue removed from a 41-year-old Caucasian female during a vaginal hysterectomy with dilation and curettage. Pathology indicated uterine leiomyoma. The endometrium was secretory and contained fragments of endometrial polyps. Benign endo- and ectocervical mucosa were identified in the endocervix. Patient history included a ventral hernia and a benign ovarian neoplasm.
83	LUNGNOT37	Library was constructed using polyA RNA isolated from lung tissue removed from a 15-year-old Caucasian female who died from a closed head injury. Serology was positive for cytomegalovirus.
84	LIVRTUT09	Library was constructed using RNA isolated from an untreated C3A hepatocyte cell line which is a derivative of Hep G2, a cell line derived from a hepatoblastoma removed from a 15-year-old Caucasian male.
85	MCLRUNT01	Library was constructed using RNA isolated from untreated peripheral blood mononuclear cell tissue obtained from buffy coat, removed from a 60-year-old male.
86	MCLRUNT01	Library was constructed using RNA isolated from untreated peripheral blood mononuclear cell tissue obtained from buffy coat, removed from a 60-year-old male.

Table 5

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	PE Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	PE Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	PE Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	*ESTs:* Probability value= 1.0E-8 or less *Full Length sequences*: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises as least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	*ESTs:* fasta E value=1.06E-6 *Assembled ESTs*: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less *Full Length sequences:* fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and, if applicable, Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322.	Score=10-50 bits for PFAM hits, depending on individual protein families

Table 5 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score≥GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

a) an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, and SEQ ID NO:43,

b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, and SEQ ID NO:43,

c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, and SEQ ID NO:43, and

d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID

NO:41, SEQ ID NO:42, and SEQ ID NO:43.

2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, and SEQ ID NO:43.

3. An isolated polynucleotide encoding a polypeptide of claim 1.

4. An isolated polynucleotide encoding a polypeptide of claim 2.

5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86.

6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

7. A cell transformed with a recombinant polynucleotide of claim 6.

8. A transgenic organism comprising a recombinant polynucleotide of claim 6.

9. A method for producing a polypeptide of claim 1, the method comprising:

a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

b) recovering the polypeptide so expressed.

10. An isolated antibody which specifically binds to a polypeptide of claim 1.

11. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:

a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86,

b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86,

c) a polynucleotide sequence complementary to a),

d) a polynucleotide sequence complementary to b), and

e) an RNA equivalent of a)-d).

12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.

13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and

b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and

b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

16. A pharmaceutical composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

17. A pharmaceutical composition of claim 16, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, and SEQ ID NO:43.

18. A method for treating a disease or condition associated with decreased expression of functional TPPT, comprising administering to a patient in need of such treatment the pharmaceutical composition of claim 16.

19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

a) exposing a sample comprising a polypeptide of claim 1 to a compound, and

b) detecting agonist activity in the sample.

20. A pharmaceutical composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

21. A method for treating a disease or condition associated with decreased expression of functional TPPT, comprising administering to a patient in need of such treatment a pharmaceutical composition of claim 20.

22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

a) exposing a sample comprising a polypeptide of claim 1 to a compound, and

b) detecting antagonist activity in the sample.

23. A pharmaceutical composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

24. A method for treating a disease or condition associated with overexpression of functional TPPT, comprising administering to a patient in need of such treatment a pharmaceutical composition of claim 23.

25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and

b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,

b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and

c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method

comprising:

a) exposing a sample comprising the target polynucleotide to a compound, and

b) detecting altered expression of the target polynucleotide.

28. An isolated polynucleotide comprising a polynucleotide sequence of SEQ ID NO:83.

29. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 28.

30. A cell transformed with a recombinant polynucleotide of claim 29.

31. A transgenic organism comprising a recombinant polynucleotide of claim 29.

32. A method for producing a polypeptide comprising an amino acid sequence of SEQ ID NO:40, the method comprising:

a) culturing the cell of claim 30 under conditions suitable for expression of the polypeptide, and

b) recovering the polypeptide so expressed.

33. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 28, the method comprising:

a) exposing a sample comprising the target polynucleotide to a compound, and

b) detecting altered expression of the target polynucleotide.

34 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

a) an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:11, and SEQ ID NO:37,

b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO.11, and SEQ ID NO:37,

c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:11, and SEQ ID NO:37, and

d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:11, and SEQ ID NO:37

35. An isolated polypeptide of claim 34 selected from the group consisting of SEQ ID NO 5, SEQ ID NO:11, and SEQ ID NO.37.

36. An isolated polynucleotide encoding a polypeptide of claim 34.

37. An isolated polynucleotide encoding a polypeptide of claim 35

38. An isolated polynucleotide of claim 37 selected from the group consisting of SEQ ID NO:48, SEQ ID NO:54, and SEQ ID NO:80.

39. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 36.

40. A cell transformed with a recombinant polynucleotide of claim 39.

41. A transgenic organism comprising a recombinant polynucleotide of claim 39.

42. A method for producing a polypeptide of claim 34, the method comprising:

a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 34, and

b) recovering the polypeptide so expressed.

43. An isolated antibody which specifically binds to a polypeptide of claim 34.

44. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:

a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:48, SEQ ID NO:54, and SEQ ID NO:80,

b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:48, SEQ ID NO:54, and SEQ ID NO:80,

c) a polynucleotide sequence complementary to a),

d) a polynucleotide sequence complementary to b), and

e) an RNA equivalent of a)-d).

45 An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 44.

46. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 44, the method comprising:

a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and

b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

47. A method of claim 46, wherein the probe comprises at least 60 contiguous nucleotides.

48. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 44, the method comprising:

a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and

b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof

49. A pharmaceutical composition comprising an effective amount of a polypeptide of claim 34 and a pharmaceutically acceptable excipient.

50 A pharmaceutical composition of claim 49, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:11, and SEQ ID NO.37.

51. A method for treating a disease or condition associated with decreased expression of functional human transport proteins (TPPT), comprising administering to a patient in need of such treatment the pharmaceutical composition of claim 49.

52. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 34, the method comprising:

a) exposing a sample comprising a polypeptide of claim 34 to a compound, and

b) detecting agonist activity in the sample.

53. A pharmaceutical composition comprising an agonist compound identified by a method of claim 52 and a pharmaceutically acceptable excipient.

54 A method for treating a disease or condition associated with decreased expression of functional human transport proteins (TPPT), comprising administering to a patient in need of such treatment a pharmaceutical composition of claim 53.

55. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 34, the method comprising:

a) exposing a sample comprising a polypeptide of claim 34 to a compound, and

b) detecting antagonist activity in the sample.

56. A pharmaceutical composition comprising an antagonist compound identified by a method of claim 55 and a pharmaceutically acceptable excipient.

57. A method for treating a disease or condition associated with overexpression of functional human transport proteins (TPPT), comprising administering to a patient in need of such treatment a pharmaceutical composition of claim 56.

58. A method of screening for a compound that specifically binds to the polypeptide of claim 34, said method comprising the steps of:

a) combining the polypeptide of claim 34 with at least one test compound under suitable conditions, and

b) detecting binding of the polypeptide of claim 34 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 34.

59. A method of screening for a compound that modulates the activity of the polypeptide of claim 34, said method comprising:

a) combining the polypeptide of claim 34 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 34,

b) assessing the activity of the polypeptide of claim 34 in the presence of the test compound, and

c) comparing the activity of the polypeptide of claim 34 in the presence of the test compound with the activity of the polypeptide of claim 34 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 34 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 34.

60. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 38, the method comprising:

a) exposing a sample comprising the target polynucleotide to a compound, and

b) detecting altered expression of the target polynucleotide.

61. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:1.

62. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:2

63. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO.3.

64. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:4.

65. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:6.

66. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:7.

67. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:8.

68. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:9.

69. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO.10.

70. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:12.

71. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:13.

72. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:14.

73 A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:15.

74. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:16.

75. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:17.

76. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:18

77. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:19.

78. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:20.

79. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:21.

80. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:22.

81. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:23.

82. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:24.

83. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:25.

84. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:26.

85. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:27.

86 A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO.28.

87. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO.29.

88 A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:30.

89. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:31.

90. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:33.

91. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:34.

92 A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:35.

93. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:36.

94. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:38

95 A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:39

96. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:41

97. A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:43.

98 A method of claim 42, wherein the polypeptide has the sequence of SEQ ID NO:5.

99. A method of claim 42, wherein the polypeptide has the sequence of SEQ ID NO:11.

100 A method of claim 42, wherein the polypeptide has the sequence of SEQ ID NO:37.

101. A diagnostic test for a condition or disease associated with the expression of human transport proteins (TPPT) in a biological sample comprising the steps of:

a) combining the biological sample with an antibody of claim 10, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and

b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

102. A diagnostic test for a condition or disease associated with the expression of human transport proteins (TPPT) in a biological sample comprising the steps of.

a) combining the biological sample with an antibody of claim 43, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and

b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

103. The antibody of claim 10, wherein the antibody is:

a) a chimeric antibody,

b) a single chain antibody,

c) a Fab fragment,

d) a $F(ab')_2$ fragment, or

e) a humanized antibody.

104. The antibody of claim 43, wherein the antibody is:

a) a chimeric antibody,

b) a single chain antibody,

c) a Fab fragment,

d) a $F(ab')_2$ fragment, or

e) a humanized antibody.

105. A composition comprising an antibody of claim 10 and an acceptable excipient.

106. A composition comprising an antibody of claim 43 and an acceptable excipient.

107. A method of diagnosing a condition or disease associated with the expression of human transport proteins (TPPT) in a subject, comprising administering to said subject an effective amount of the composition of claim 105.

108. A method of diagnosing a condition or disease associated with the expression of human transport proteins (TPPT) in a subject, comprising administering to said subject an effective amount of the composition of claim 106.

109. A composition of claim 105, wherein the antibody is labeled

110. A composition of claim 106, wherein the antibody is labeled

111. A method of diagnosing a condition or disease associated with the expression of human transport proteins (TPPT) in a subject, comprising administering to said subject an effective amount of the composition of claim 109.

112. A method of diagnosing a condition or disease associated with the expression of human transport proteins (TPPT) in a subject, comprising administering to said subject an effective amount of the composition of claim 110

113. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 10 comprising:

a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO.3, SEQ ID NO:4, SEQ ID NO:6,

SEQ ID NO 7. SEQ ID NO:8. SEQ ID NO:9. SEQ ID NO:10. SEQ ID NO 12. SEQ ID NO.13. SEQ ID NO 14. SEQ ID NO:15. SEQ ID NO.16. SEQ ID NO:17. SEQ ID NO.18. SEQ ID NO 19. SEQ ID NO.20. SEQ ID NO:21. SEQ ID NO 22. SEQ ID NO:23. SEQ ID NO:24. SEQ ID NO:25. SEQ ID NO.26. SEQ ID NO.27. SEQ ID NO:28. SEQ ID NO.29. SEQ ID NO:30. SEQ ID NO.31. SEQ ID NO.33. SEQ ID NO.34. SEQ ID NO:35. SEQ ID NO:36. SEQ ID NO:38. SEQ ID NO.39. SEQ ID NO.41. and SEQ ID NO:43. or an immunogenicfragment thereof. under conditions to elicit an antibody response.

b) isolating antibodies from said animal; and

c) screening the isolated antibodies with the polypeptide. thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:NO:1. SEQ ID NO.2. SEQ ID NO:3. SEQ ID NO:4. SEQ ID NO:6. SEQ ID NO:7. SEQ ID NO:8. SEQ ID NO:9. SEQ ID NO:10. SEQ ID NO:12. SEQ ID NO:13. SEQ ID NO 14. SEQ ID NO:15. SEQ ID NO:16. SEQ ID NO:17. SEQ ID NO:18. SEQ ID NO:19. SEQ ID NO.20. SEQ ID NO:21. SEQ ID NO:22. SEQ ID NO.23. SEQ ID NO:24. SEQ ID NO:25. SEQ ID NO:26. SEQ ID NO:27. SEQ ID NO:28. SEQ ID NO.29. SEQ ID NO:30. SEQ ID NO:31. SEQ ID NO.33. SEQ ID NO:34. SEQ ID NO:35. SEQ ID NO:36. SEQ ID NO:38. SEQ ID NO:39. SEQ ID NO.41. and SEQ ID NO:43.

114. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 43 comprising:

a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:5. SEQ ID NO 11. and SEQ ID NO 37. or an immunogenic fragment thereof. under conditions to elicit an antibody response.

b) isolating antibodies from said animal. and

c) screening the isolated antibodies with the polypeptide. thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:5. SEQ ID NO:11. and SEQ ID NO:37.

115. An antibody produced by a method of claim 113.

116. An antibody produced by a method of claim 114.

117. A composition comprising the antibody of claim 115 and a suitable carrier.

118 A composition comprising the antibody of claim 116 and a suitable carrier.

119. A method of making a monoclonal antibody with the specificity of the antibody of claim 10 comprising.

a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1. SEQ ID NO:2. SEQ ID NO.3. SEQ ID NO 4. SEQ ID NO:6. SEQ ID NO:7. SEQ ID NO:8. SEQ ID NO:9. SEQ ID NO:10. SEQ ID NO:12. SEQ ID NO 13. SEQ ID NO:14. SEQ ID NO:15. SEQ ID NO:16. SEQ ID NO:17. SEQ ID NO:18. SEQ ID NO:19. SEQ ID NO:20. SEQ ID NO:21. SEQ ID NO:22. SEQ ID NO:23. SEQ ID NO:24. SEQ ID NO.25. SEQ ID NO.26. SEQ ID NO:27. SEQ ID NO:28. SEQ ID NO:29. SEQ ID NO:30. SEQ ID NO.31. SEQ ID NO.33. SEQ ID NO:34. SEQ ID NO:35. SEQ ID NO:36. SEQ ID NO:38. SEQ ID NO.39. SEQ ID NO·41. and SEQ ID NO·43. or an immunogenic fragment thereof. under conditions to elicit an antibody response;

b) isolating antibody producing cells from the animal:

c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;

d) culturing the hybridoma cells; and

e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1. SEQ ID NO:2. SEQ ID NO 3. SEQ ID NO·4. SEQ ID NO:6. SEQ ID NO.7. SEQ ID NO:8. SEQ ID NO:9. SEQ ID NO:10. SEQ ID NO:12. SEQ ID NO:13. SEQ ID NO.14. SEQ ID NO:15. SEQ ID NO:16. SEQ ID NO·17. SEQ ID NO:18. SEQ ID NO:19. SEQ ID NO.20. SEQ ID NO:21. SEQ ID NO.22. SEQ ID NO.23. SEQ ID NO.24. SEQ ID NO:25. SEQ ID NO:26. SEQ ID NO.27. SEQ ID NO.28. SEQ ID NO 29. SEQ ID NO.30. SEQ ID NO:31. SEQ ID NO.33. SEQ ID NO.34. SEQ ID NO.35. SEQ ID NO 36. SEQ ID NO:38. SEQ ID NO:39. SEQ ID NO:41. and SEQ ID NO·43.

120. A method of making a monoclonal antibody with the specificity of the antibody of claim 43 comprising:

a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:5. SEQ ID NO 11. and SEQ ID NO:37. or an immunogenic fragment thereof. under conditions to elicit an antibody response;

b) isolating antibody producing cells from the animal;

c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;

d) culturing the hybridoma cells; and

e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:5. SEQ ID NO:11, and SEQ ID NO:37.

121 A monoclonal antibody produced by a method of claim 119

122. A monoclonal antibody produced by a method of claim 120

123. A composition comprising the antibody of claim 121 and a suitable carrier.

124. A composition comprising the antibody of claim 122 and a suitable carrier

125. The antibody of claim 10, wherein the antibody is produced by screening a Fab expression library.

126. The antibody of claim 43, wherein the antibody is produced by screening a Fab expression library.

127. The antibody of claim 10, wherein the antibody is produced by screening a recombinant immunoglobulin library.

128. The antibody of claim 43, wherein the antibody is produced by screening a recombinant immunoglobulin library.

129. A method for detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:41, and SEQ ID NO:43 in a sample, comprising the steps of:

a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and

b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22,

SEQ ID NO.23, SEQ ID NO.24, SEQ ID NO.25, SEQ ID NO.26, SEQ ID NO:27, SEQ ID NO 28, SEQ ID NO.29, SEQ ID NO:30, SEQ ID NO.31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO.35, SEQ ID NO:36, SEQ ID NO.38, SEQ ID NO:39, SEQ ID NO:41, and SEQ ID NO 43 in the sample

130. A method for detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:11, and SEQ ID NO:37 in a sample, comprising the steps of:

a) incubating the antibody of claim 43 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and

b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:11, and SEQ ID NO:37 in the sample.

131. A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO.20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO.23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO.26, SEQ ID NO.27, SEQ ID NO:28, SEQ ID NO.29, SEQ ID NO:30, SEQ ID NO.31, SEQ ID NO.33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO.38, SEQ ID NO 39, SEQ ID NO:41, and SEQ ID NO:43 from a sample, the method comprising:

a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and

b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO.12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO.26, SEQ ID NO:27, SEQ ID NO.28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO.33, SEQ ID NO:34, SEQ ID NO.35, SEQ ID NO:36, SEQ ID NO.38, SEQ ID NO:39, SEQ ID NO:41, and SEQ ID NO:43.

132. A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:11, and SEQ ID NO:37 from a sample, the method comprising:

a) incubating the antibody of claim 43 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and

b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO.5, SEQ ID NO:11, and SEQ ID NO.37.

133 A microarray wherein at least one element of the microarray is a polynucleotide of claim 12.

134. A microarray wherein at least one element of the microarray is a polynucleotide of claim 45.

135 A method for generating a transcript image of a sample which contains polynucleotides, the method comprising the steps of:

a) labeling the polynucleotides of the sample,

b) contacting the elements of the microarray of claim 133 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and

c) quantifying the expression of the polynucleotides in the sample.

136. A method for generating a transcript image of a sample which contains polynucleotides, the method comprising the steps of:

a) labeling the polynucleotides of the sample,

b) contacting the elements of the microarray of claim 134 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and

c) quantifying the expression of the polynucleotides in the sample

137. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, said target polynucleotide having a sequence of claim 11.

138. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, said target polynucleotide having a sequence of claim 44.

139. An array of claim 137, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide

140. An array of claim 138, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.

141. An array of claim 139, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.

142. An array of claim 140, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.

143. An array of claim 137, which is a microarray.

144. An array of claim 138, which is a microarray.

145. An array of claim 139, further comprising said target polynucleotide hybridized to said first oligonucleotide or polynucleotide.

146. An array of claim 140, further comprising said target polynucleotide hybridized to said first oligonucleotide or polynucleotide.

147. An array of claim 137, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.

148. An array of claim 138, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.

149. An array of claim 137, wherein each distinct physical location on the substrate contains multiple nucleotide molecules having the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another physical location on the substrate.

150. An array of claim 138, wherein each distinct physical location on the substrate contains multiple nucleotide molecules having the same sequence, and each distinct physical location on the

substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another physical location on the substrate.

151. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

152 A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO.2

153 A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3

154. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

155. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

156. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

157. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.

158. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.

150 A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.

160. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO.12.

161 A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.

162 A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.

163. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.

164 A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.

165 A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:17.

166 A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:18.

167 A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO 19

168. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:20

169. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:21

170. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO.22.

171. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO.23.

172. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO.24.

173. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:25.

174 A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:26.

175. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:27.

176. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:28.

177. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:29.

178 A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:30.

179. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO.31.

180. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:33.

181. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:34.

182. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:35.

183. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:36.

184. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:38.

185. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO.39

186. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO 41

187. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO.43

188. A polypeptide of claim 34, comprising the amino acid sequence of SEQ ID NO.5

189. A polypeptide of claim 34, comprising the amino acid sequence of SEQ ID NO.11

190. A polypeptide of claim 34, comprising the amino acid sequence of SEQ ID NO.37.

191. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:44.

192. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:45.

193. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:46.

194. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:47.

195. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:49.

196. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:50.

197. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:51.

198. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:52.

199. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO.53.

200. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO.55.

201. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:56

202. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:57.

203 A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:58.

204 A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:59.

205. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:60

206 A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO.61.

207 A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:62

208. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:63

209 A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:64

210 A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO 65.

211. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:66

212. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:67.

213. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:68

214. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:69.

215. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:70

216. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:71.

217. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:72

218 A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO.73.

219. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:74

220 A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:76

221. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:77.

222 A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:78.

223. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:79.

224. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:81.

225. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:82.

226. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:84.

227. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:86.

228. A polynucleotide of claim 44, comprising the polynucleotide sequence of SEQ ID NO.48.

229. A polynucleotide of claim 44, comprising the polynucleotide sequence of SEQ ID NO:54.

230. A polynucleotide of claim 44, comprising the polynucleotide sequence of SEQ ID NO:80.

(12) INTERNATIONAL AP[redacted]ATION PUBLISHED UNDER THE PATENT [redacted]ERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 December 2000 (28.12.2000)

PCT

(10) International Publication Number
WO 00/78953 A2

(51) International Patent Classification[7]: C12N 15/12, 5/10, C07K 14/47, 14/705, 16/18, 16/28, C12Q 1/68, A61K 38/17, G01N 33/50, A01K 67/027

(21) International Application Number: PCT/US00/16668

(22) International Filing Date: 16 June 2000 (16.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/139,923	17 June 1999 (17.06.1999)	US
60/148,177	10 August 1999 (10.08.1999)	US
60/149,357	18 August 1999 (18.08.1999)	US
60/162,287	28 October 1999 (28.10.1999)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	60/139,923 (CIP)
Filed on	17 June 1999 (17.06.1999)
US	60/148,177 (CIP)
Filed on	10 August 1999 (10.08.1999)
US	60/149,357 (CIP)
Filed on	18 August 1999 (18.08.1999)
US	60/162,287 (CIP)
Filed on	28 October 1999 (28.10.1999)

(71) Applicant *(for all designated States except US)*: **INCYTE GENOMICS, INC.** [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LAL, Preeti** [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). **YANG, Junming** [CN/US]; 7125 Bark Lane, San Jose, CA 95129 (US). **YUE, Henry** [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). **HILLMAN, Jennifer, L.** [US/US]; 230 Monroe Drive, #12, Mountain View, CA 94040 (US). **TANG, Y., Tom** [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). **BANDMAN, Olga** [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). **BURFORD, Neil** [GB/US]; 1308 4th Avenue, San Francisco, CA 94122 (US). **BAUGHN, Mariah, R.** [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). **AZIMZAI, Yalda** [US/US]; 2045 Rocksprings Drive, Hayward, CA 94545 (US). **LU, Dyung, Aina, M.** [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). **AU-YOUNG, Janice** [US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). **PATTERSON, Chandra** [US/US]; 490 Sherwood Way, #1, Menlo Park, CA 94025 (US).

(74) Agents: **HAMLET-COX, Diana** et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States *(national)*: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/78953 A2

(54) Title: HUMAN TRANSPORT PROTEINS

(57) Abstract: The invention provides human transport proteins (TPPT) and polynucleotides which identify and encode TPPT. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of TPPT.

Docket No.: PF-0709 USN

DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

HUMAN TRANSPORT PROTEINS

the specification of which:

/ X / is attached hereto.

/ ___ / was filed on _____ as application Serial No. _____ and if this box contains an X / ___ /, was amended on _____.

/ X / was filed as Patent Cooperation Treaty international application No. PCT/US00/16668 on 16 June, 2000, if this box contains an X / _/, was amended on under Patent Cooperation Treaty Article 19 on _____ 2001, and if this box contains an X / _/, was amended on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under Title 35, United States Code, §119 or §365(a)-(b) of any foreign application(s) for patent or inventor's certificate indicated below and of any Patent Cooperation Treaty international applications(s) designating at least one country other than the United States indicated below and have also identified below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application for said subject matter the priority of which is claimed:

Two DECs

Docket No.: PF-0709 USN

Country	Number	Filing Date	Priority Claimed
_____	_____	_____	/_/ Yes /_/ No
_____	_____	_____	/_/ Yes /_/ No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

Application Serial No.	Filed	Status (Pending, Abandoned, Patented)
60/139,923	June 17, 1999	Expired
60/148,177	August 10, 1999	Expired
60/149,357	August 18, 1999	Expired
60/162,287	October 28, 1999	Expired

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application Serial No.	Filed	Status (Pending, Abandoned, Patented)

I hereby appoint the following:

Lucy J. Billings	Reg. No. 36,749
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Richard C. Ekstrom	Reg. No. 37,027
Barrie D. Greene	Reg. No. 46,740
Lynn E. Murry	Reg. No. 42,918
Shirley A. Recipon	Reg. No. 47,016
Susan K. Sather	Reg. No. 44,316
Michelle M. Stempien	Reg. No. 41,327
David G. Streeter	Reg. No. 43,168
Stephen Todd	Reg. No. 47,139
P. Ben Wang	Reg. No. 41,420

respectively and individually, as my patent attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

Docket No.: PF-0709 USN

LEGAL DEPARTMENT
INCYTE GENOMICS, INC.
3160 PORTER DRIVE, PALO ALTO, CA 94304

TEL: 650-855-0555 FAX: 650-849-8886 or 650-845-4166

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

First Joint Inventor: 1 - CO

Full name: Preeti Lal

Signature: Preeti Lal

Date: September 10, 2001

Citizenship: India

Residence: Santa Clara, California CA

P.O. Address: P.O. Box 5142
Santa Clara, California 95056

Second Joint Inventor: 2 - CO

Full name: Junming Yang

Signature: [signature]

Date: September 17, 2001

Citizenship: China

Residence: San Jose, California CA

P.O. Address: 7125 Bark Lane
San Jose, California 95129

(12) over

Docket No.: PF-0709 USN

Third Joint Inventor: 3 - CO

Full name: Henry Yue

Signature: Henry Yue.

Date: September 24, 2001

Citizenship: United States

Residence: Sunnyvale, California CA

P.O. Address: 826 Lois Avenue
Sunnyvale, California 94087

Fourth Joint Inventor: 4 - CO

Full name: Jennifer L. Hillman

Signature: Jennifer L Hillman

Date: September 21, 2001

Citizenship: United States

Residence: Mountain View, California CA

P.O. Address: 230 Monroe Drive, #17
Mountain View, California 94040

Fifth Joint Inventor: 5 - CO

Full name: Y. Tom Tang

Signature: Y. Tom Tang

Date: Sept. 10, 2001

Citizenship: United States

Residence: San Jose, California CA.

P.O. Address: 4230 Ranwick Court
San Jose, California 95118

Over

Docket No.: PF-0709 USN

Sixth Joint Inventor: Full name: Olga Bandman

Signature: Olga Bandman

Date: 12 September, 2001

Citizenship: United States

Residence: Mountain View, California CA.

P.O. Address: 366 Anna Avenue
Mountain View, California 94043

Seventh Joint Inventor: Full name: Neil Burford

Signature: _____

Date: _____, 2001

Citizenship: United States

Residence: Durham, Connecticut

P.O. Address: 105 Wildwood Circle
Durham, Connecticut 06422

Eighth Joint Inventor: Full name: Mariah R. Baughn

Signature: Mariah R. Baughn

Date: September 5, 2001

Citizenship: United States

Residence: San Leandro, California CA.

P.O. Address: 14244 Santiago Road
San Leandro, California 94577

over

Docket No.: PF-0709 USN

Ninth Joint Inventor: S - 09

Full name: Yalda Azimzai

Signature: 

Date: September 13, 2001

Citizenship: United States

Residence: Castro Valley, California CA.

P.O. Address: 5518 Boulder Canyon Drive
Castro Valley, California 94552

Tenth Joint Inventor: 10 - 00

Full name: Dyung Aina M. Lu

Signature: 

Date: Sept 7, 2001

Citizenship: United States

Residence: San Jose, California CA.

P.O. Address: 233 Coy Drive
San Jose, California 95123

Eleventh Joint Inventor: 11 - 00

Full name: Janice Au-Young

Signature: 

Date: September 7, 2001

Citizenship: United States

Residence: Brisbane, California CA.

P.O. Address: 233 Golden Eagle Lane
Brisbane, California 94005

Over

Docket No.: PF-0709 USN

Twelfth Joint Inventor: 12 - ∞ Full name: Chandra ~~Patterson~~ Arvizu CA 9/10/01

Signature: Chandra Arvizu

Date: September 10, 2001

Citizenship: United States

Residence: Menlo Park, California CA .

P.O. Address: 490 Sherwood Way, #1
Menlo Park, California 94025

Over to 2nd INDEX

Docket No.: PF-0709 USN

DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

HUMAN TRANSPORT PROTEINS

the specification of which:

/ X / is attached hereto.

/ ___ / was filed on _____ as application Serial No. _____ and if this box contains an X / ___ /, was amended on _____.

/ X / was filed as Patent Cooperation Treaty international application No. PCT/US00/16668 ___ on 16 June, 2000, if this box contains an X /_/, was amended on under Patent Cooperation Treaty Article 19 on _____ 2001, and if this box contains an X /_/, was amended on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under Title 35, United States Code, §119 or §365(a)-(b) of any foreign application(s) for patent or inventor's certificate indicated below and of any Patent Cooperation Treaty international applications(s) designating at least one country other than the United States indicated below and have also identified below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application for said subject matter the priority of which is claimed:

Docket No.: PF-0709 USN

Country	Number	Filing Date	Priority Claimed
			/_/ Yes /_/ No
			/_/ Yes /_/ No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

Application Serial No.	Filed	Status (Pending, Abandoned, Patented)
60/139,923	June 17, 1999	Expired
60/148,177	August 10, 1999	Expired
60/149,357	August 18, 1999	Expired
60/162,287	October 28, 1999	Expired

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application Serial No.	Filed	Status (Pending, Abandoned, Patented)

I hereby appoint the following:

Lucy J. Billings	Reg. No. 36,749
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Richard C. Ekstrom	Reg. No. 37,027
Barrie D. Greene	Reg. No. 46,740
Lynn E. Murry	Reg. No. 42,918
Shirley A. Recipon	Reg. No. 47,016
Susan K. Sather	Reg. No. 44,316
Michelle M. Stempien	Reg. No. 41,327
David G. Streeter	Reg. No. 43,168
Stephen Todd	Reg. No. 47,139
P. Ben Wang	Reg. No. 41,420

respectively and individually, as my patent attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

Docket No.: PF-0709 USN

LEGAL DEPARTMENT
INCYTE GENOMICS, INC.
3160 PORTER DRIVE, PALO ALTO, CA 94304

TEL: 650-855-0555 FAX: 650-849-8886 or 650-845-4166

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

First Joint Inventor:	Full name:	Preeti Lal
	Signature:	
	Date:	, 2001
	Citizenship:	India
	Residence:	Santa Clara, California
	P.O. Address:	P.O. Box 5142 Santa Clara, California 95056
Second Joint Inventor:	Full name:	Junming Yang
	Signature:	
	Date:	, 2001
	Citizenship:	China
	Residence:	San Jose, California
	P.O. Address:	7125 Bark Lane San Jose, California 95129

Docket No.: PF-0709 USN

Third Joint Inventor:

Full name: Henry Yue

Signature: _____

Date: _____, 2001

Citizenship: United States

Residence: Sunnyvale, California

P.O. Address: 826 Lois Avenue
Sunnyvale, California 94087

Fourth Joint Inventor:

Full name: Jennifer L. Hillman

Signature: _____

Date: _____, 2001

Citizenship: United States

Residence: Mountain View, California

P.O. Address: 230 Monroe Drive, #17
Mountain View, California 94040

Fifth Joint Inventor:

Full name: Y. Tom Tang

Signature: _____

Date: _____, 2001

Citizenship: United States

Residence: San Jose, California

P.O. Address: 4230 Ranwick Court
San Jose, California 95118

Docket No.: PF-0709 USN

Sixth Joint Inventor:

Full name: Olga Bandman

Signature: _____

Date: _____, 2001

Citizenship: United States

Residence: Mountain View, California

P.O. Address: 366 Anna Avenue
Mountain View, California 94043

Seventh Joint Inventor: G - 00

Full name: Neil Burford

Signature: Neil Burford

Date: 9/21, 2001

Citizenship: 9/21/01 ~~United States~~ UNITED KINGDOM

Residence: Durham, Connecticut CT

P.O. Address: 105 Wildwood Circle
Durham, Connecticut 06422

Eighth Joint Inventor:

Full name: Mariah R. Baughn

Signature: _____

Date: _____, 2001

Citizenship: United States

Residence: San Leandro, California

P.O. Address: 14244 Santiago Road
San Leandro, California 94577

Ninth Joint Inventor:

Full name: Yalda Azimzai

Signature: _____

Date: _____, 2001

Citizenship: United States

Residence: Castro Valley, California

P.O. Address: 5518 Boulder Canyon Drive
Castro Valley, California 94552

Tenth Joint Inventor:

Full name: Dyung Aina M. Lu

Signature: _____

Date: _____, 2001

Citizenship: United States

Residence: San Jose, California

P.O. Address: 233 Coy Drive
San Jose, California 95123

Eleventh Joint Inventor:

Full name: Janice Au-Young

Signature: _____

Date: _____, 2001

Citizenship: United States

Residence: Brisbane, California

P.O. Address: 233 Golden Eagle Lane
Brisbane, California 94005

[redacted]

Docket No.: PF-0709 USN

Twelfth Joint Inventor:	Full name:	Chandra Patterson
	Signature:	
	Date:	, 2001
	Citizenship:	United States
	Residence:	Menlo Park, California
	P.O. Address:	490 Sherwood Way, #1 Menlo Park, California 94025

SEQUENCE LISTING

<110> INCYTE GENOMICS, INC.
LAL, Preeti
YANG, Junming
YUE, Henry
HILLMAN, Jennifer L.
TANG, Y. Tom
BANDMAN, Olga
BURFORD, Neil
BAUGHN, Mariah R.
AZIMZAI, Yalda
LU, Dyung Aina M.
AU-YOUNG, Janice
PATTERSON, Chandra

<120> HUMAN TRANSPORT PROTEINS

<130> PF-0709 PCT

<140> To Be Assigned
<141> Herewith

<150> 60/139,923; 60/148,177; 60/149,357; 60/162,287
<151> 1999-06-17; 1999-08-10; 1999-08-18; 1999-10-28

<160> 86
<170> PERL Program

<210> 1
<211> 623
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 264114CD1

<400> 1
Met Ser Thr Gln Asp Glu Arg Gln Ile Asn Thr Glu Tyr Ala Val
1 5 10 15
Ser Leu Leu Glu Gln Leu Lys Leu Phe Tyr Glu Gln Gln Leu Phe
20 25 30
Thr Asp Ile Val Leu Ile Val Glu Gly Thr Glu Phe Pro Cys His
35 40 45
Lys Met Val Leu Ala Thr Cys Ser Ser Tyr Phe Arg Ala Met Phe
50 55 60
Met Ser Gly Leu Ser Glu Ser Lys Gln Thr His Val His Leu Arg
65 70 75
Asn Val Asp Ala Ala Thr Leu Gln Ile Ile Ile Thr Tyr Ala Tyr
80 85 90
Thr Gly Asn Leu Ala Met Asn Asp Ser Thr Val Glu Gln Leu Tyr
95 100 105
Glu Thr Ala Cys Phe Leu Gln Val Glu Asp Val Leu Gln Arg Cys
110 115 120
Arg Glu Tyr Leu Ile Lys Lys Ile Asn Ala Glu Asn Cys Val Arg
125 130 135
Leu Leu Ser Phe Ala Asp Leu Phe Ser Cys Glu Glu Leu Lys Gln
140 145 150
Ser Ala Lys Arg Met Val Glu His Lys Phe Thr Ala Val Tyr His
155 160 165
Gln Asp Ala Phe Met Gln Leu Ser His Asp Leu Leu Ile Asp Ile
170 175 180
Leu Ser Ser Asp Asn Leu Asn Val Glu Lys Glu Glu Thr Val Arg
185 190 195
Glu Ala Ala Met Leu Trp Leu Glu Tyr Asn Thr Glu Ser Arg Ser

200 205 210
Gln Tyr Leu Ser Ser Val Leu Ser Gln Ile Arg Ile Asp Ala Leu
215 220 225
Ser Glu Val Thr Gln Arg Ala Trp Phe Gln Gly Leu Pro Pro Asn
230 235 240
Asp Lys Ser Val Val Val Gln Gly Leu Tyr Lys Ser Met Pro Lys
245 250 255
Phe Phe Lys Pro Arg Leu Gly Met Thr Lys Glu Glu Met Met Ile
260 265 270
Phe Ile Glu Ala Ser Ser Glu Asn Pro Cys Ser Leu Tyr Ser Ser
275 280 285
Val Cys Tyr Ser Pro Gln Ala Glu Lys Val Tyr Lys Leu Cys Ser
290 295 300
Pro Pro Ala Asp Leu His Lys Val Gly Thr Val Val Thr Pro Asp
305 310 315
Asn Asp Ile Tyr Ile Ala Gly Gly Gln Val Pro Leu Lys Asn Thr
320 325 330
Lys Thr Asn His Ser Lys Thr Ser Lys Leu Gln Thr Ala Phe Arg
335 340 345
Thr Val Asn Cys Phe Tyr Trp Phe Asp Ala Gln Gln Asn Thr Trp
350 355 360
Phe Pro Lys Thr Pro Met Leu Phe Val Arg Ile Lys Pro Ser Leu
365 370 375
Val Cys Cys Glu Gly Tyr Ile Tyr Ala Ile Gly Gly Asp Ser Val
380 385 390
Gly Gly Glu Leu Asn Arg Arg Thr Val Glu Arg Tyr Asp Thr Glu
395 400 405
Lys Asp Glu Trp Thr Met Val Ser Pro Leu Pro Cys Ala Trp Gln
410 415 420
Trp Ser Ala Ala Val Val Val His Asp Cys Ile Tyr Val Met Thr
425 430 435
Leu Asn Leu Met Tyr Cys Tyr Phe Pro Arg Ser Asp Ser Trp Val
440 445 450
Glu Met Ala Met Arg Gln Thr Ser Arg Ser Phe Ala Ser Ala Ala
455 460 465
Ala Phe Gly Asp Lys Ile Phe Tyr Ile Gly Gly Leu His Ile Ala
470 475 480
Thr Asn Ser Gly Ile Arg Leu Pro Ser Gly Thr Val Asp Gly Ser
485 490 495
Ser Val Thr Val Glu Ile Tyr Asp Val Asn Lys Asn Glu Trp Lys
500 505 510
Met Ala Ala Asn Ile Pro Ala Lys Arg Tyr Ser Asp Pro Cys Val
515 520 525
Arg Ala Val Val Ile Ser Asn Ser Leu Cys Val Phe Met Arg Glu
530 535 540
Thr His Leu Asn Glu Arg Ala Lys Tyr Val Thr Tyr Gln Tyr Asp
545 550 555
Leu Glu Leu Asp Arg Trp Ser Leu Arg Gln His Ile Ser Glu Arg
560 565 570
Val Leu Trp Asp Leu Gly Arg Asp Phe Arg Cys Thr Val Gly Lys
575 580 585
Leu Tyr Pro Ser Cys Leu Glu Glu Ser Pro Trp Lys Pro Pro Thr
590 595 600
Tyr Leu Phe Ser Thr Asp Gly Thr Glu Glu Phe Glu Leu Asp Gly
605 610 615
Glu Met Val Ala Leu Pro Pro Val
620

<210> 2
<211> 99
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1455669CD1

<400> 2
Met Ala Ala Pro Ala Glu Pro Cys Ala Gly Gln Gly Val Trp Asn

```
  1               5                  10                  15
Gln Thr Glu Pro Glu Pro Ala Ala Thr Ser Leu Leu Ser Leu Cys
             20                  25                  30
Phe Leu Arg Thr Ala Gly Val Trp Val Pro Pro Met Tyr Leu Trp
         35                  40                  45
Val Leu Gly Pro Ile Tyr Leu Leu Phe Ile His His His Gly Arg
     50                  55                  60
Gly Tyr Leu Arg Met Ser Pro Leu Phe Lys Ala Lys Met Val Ala
 65                  70                  75
Ala Ile Pro Gly Ser Leu Glu Pro Gly Asn Val Arg Gly Arg Gln
             80                  85                  90
Gly Thr Gly Trp Asn Leu Val Lys Ser
         95
<210> 3
<211> 374
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2084989CD1

<400> 3
Met Glu Ser Lys Met Gly Glu Leu Pro Leu Asp Ile Asn Ile Gln
  1               5                  10                  15
Glu Pro Arg Trp Asp Gln Ser Thr Phe Leu Gly Arg Ala Arg His
             20                  25                  30
Phe Phe Thr Val Thr Asp Pro Arg Asn Leu Leu Leu Ser Gly Ala
         35                  40                  45
Gln Leu Glu Ala Ser Arg Asn Ile Val Gln Asn Tyr Arg Ala Gly
     50                  55                  60
Val Val Thr Pro Gly Ile Thr Glu Asp Gln Leu Trp Arg Ala Lys
 65                  70                  75
Tyr Val Tyr Asp Ser Ala Phe His Pro Asp Thr Gly Glu Lys Val
             80                  85                  90
Val Leu Ile Gly Arg Met Ser Ala Gln Val Pro Met Asn Met Thr
         95                 100                 105
Ile Thr Gly Cys Met Leu Thr Phe Tyr Arg Lys Thr Pro Thr Val
    110                 115                 120
Val Phe Trp Gln Trp Val Asn Gln Ser Phe Asn Ala Ile Val Asn
125                 130                 135
Tyr Ser Asn Arg Ser Gly Asp Thr Pro Ile Thr Val Arg Gln Leu
            140                 145                 150
Gly Thr Ala Tyr Val Ser Ala Thr Thr Gly Ala Val Ala Thr Ala
        155                 160                 165
Leu Gly Leu Lys Ser Leu Thr Lys His Leu Pro Pro Leu Val Gly
    170                 175                 180
Arg Phe Val Pro Phe Ala Ala Val Ala Ala Ala Asn Cys Ile Asn
185                 190                 195
Ile Pro Leu Met Arg Gln Arg Glu Leu Gln Val Gly Ile Pro Val
            200                 205                 210
Ala Asp Glu Ala Gly Gln Arg Leu Gly Tyr Ser Val Thr Ala Ala
        215                 220                 225
Lys Gln Gly Ile Phe Gln Val Val Ile Ser Arg Ile Cys Met Ala
    230                 235                 240
Ile Pro Ala Met Ala Ile Pro Pro Leu Ile Met Asp Thr Leu Glu
245                 250                 255
Lys Lys Asp Phe Leu Lys Val Gly Asp Cys Thr Ser Leu Val Leu
            260                 265                 270
Glu Trp Ala Met Ala Gly Arg Ser Asp Gln Ala Pro Thr Leu Ser
        275                 280                 285
Pro Ala Ser Pro Asp Ser Leu Arg Leu Ala Ser Pro Ser Pro Asp
    290                 295                 300
Pro Cys Thr Ala Ser Ser Thr Phe Val His Ser Ala Arg Met Asn
305                 310                 315
Trp Ala Gly Val Lys Glu Leu Cys Arg Gly Arg Arg Arg Gly Gln
            320                 325                 330
Arg Lys Glu Thr Asn Phe Ile Ser Val Thr Pro Val Ala Ser Asp
```

335 340 345
Thr Gln Lys Gly Thr Val Ile Val Met Leu Asp Leu Met Leu Ile
350 355 360
Leu Leu Pro Pro Ser Ala Ser Ile Leu Arg Gly Thr His Gly
365 370

<210> 4
<211> 271
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2501034CD1

<400> 4
Met Gly Asn Gly Gly Arg Ser Gly Leu Gln Gln Gly Lys Gly Asn
1 5 10 15
Val Asp Gly Val Ala Ala Thr Pro Thr Ala Ala Ser Ala Ser Cys
20 25 30
Gln Tyr Arg Cys Ile Glu Cys Asn Gln Glu Ala Lys Glu Leu Tyr
35 40 45
Arg Asp Tyr Asn His Gly Val Leu Lys Ile Thr Ile Cys Lys Ser
50 55 60
Cys Gln Lys Pro Val Asp Lys Tyr Ile Glu Tyr Asp Pro Val Ile
65 70 75
Ile Leu Ile Asn Ala Ile Leu Cys Lys Ala Gln Ala Tyr Arg His
80 85 90
Ile Leu Phe Asn Thr Gln Ile Asn Ile His Gly Lys Leu Cys Ile
95 100 105
Phe Cys Leu Leu Cys Glu Ala Tyr Leu Arg Trp Trp Gln Leu Gln
110 115 120
Asp Ser Asn Gln Asn Thr Ala Pro Asp Asp Leu Ile Arg Tyr Ala
125 130 135
Lys Glu Trp Asp Phe Tyr Arg Met Phe Ala Ile Ala Ala Leu Glu
140 145 150
Gln Thr Ala Tyr Phe Ile Gly Ile Phe Thr Phe Leu Trp Val Glu
155 160 165
Arg Pro Met Thr Ala Lys Lys Lys Pro Asn Phe Ile Leu Leu Leu
170 175 180
Lys Ala Leu Leu Leu Ser Ser Tyr Gly Lys Leu Leu Leu Ile Pro
185 190 195
Ala Val Ile Trp Glu His Asp Tyr Thr Ser Val Cys Leu Lys Leu
200 205 210
Ile Lys Val Phe Val Leu Thr Ser Asn Phe Gln Ala Ile Arg Val
215 220 225
Thr Leu Asn Ile Asn Arg Lys Leu Ser Phe Leu Ala Val Leu Ser
230 235 240
Gly Leu Leu Leu Glu Ser Ile Met Val Tyr Phe Phe Gln Ser Met
245 250 255
Glu Trp Asp Val Gly Ser Asp Tyr Ala Ile Phe Lys Ser Gln Asp
260 265 270
Phe

<210> 5
<211> 323
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2745212CD1

<400> 5
Met Ala Pro Lys Gln Asp Pro Lys Pro Lys Phe Gln Glu Gly Glu
1 5 10 15
Arg Val Leu Cys Phe His Gly Pro Leu Leu Tyr Glu Ala Lys Cys
20 25 30
Val Lys Val Ala Ile Lys Asp Lys Gln Val Lys Tyr Phe Ile His

```
                    35                  40                  45
Tyr Ser Gly Trp Asn Lys Asn Trp Asp Glu Trp Val Pro Glu Ser
                50                  55                  60
Arg Val Leu Lys Tyr Val Asp Thr Asn Leu Gln Lys Gln Arg Glu
            65                  70                  75
Leu Gln Lys Ala Asn Gln Glu Gln Tyr Ala Glu Gly Lys Met Arg
                80                  85                  90
Gly Ala Ala Pro Gly Lys Lys Thr Ser Gly Leu Gln Gln Lys Asn
                95                 100                 105
Val Glu Val Lys Thr Lys Lys Asn Lys Gln Lys Thr Pro Gly Asn
               110                 115                 120
Gly Asp Gly Gly Ser Thr Ser Glu Thr Pro Gln Pro Pro Arg Lys
               125                 130                 135
Lys Arg Ala Arg Val Asp Pro Thr Val Glu Asn Glu Glu Thr Phe
               140                 145                 150
Met Asn Arg Val Glu Val Lys Val Lys Ile Pro Glu Glu Leu Lys
               155                 160                 165
Pro Trp Leu Val Asp Asp Trp Asp Leu Ile Thr Arg Gln Lys Gln
               170                 175                 180
Leu Phe Tyr Leu Pro Ala Lys Lys Asn Val Asp Ser Ile Leu Glu
               185                 190                 195
Asp Tyr Ala Asn Tyr Lys Lys Ser Arg Gly Asn Thr Asp Asn Lys
               200                 205                 210
Glu Tyr Ala Val Asn Glu Val Val Ala Gly Ile Lys Glu Tyr Phe
               215                 220                 225
Asn Val Met Leu Gly Thr Gln Leu Leu Tyr Lys Phe Glu Arg Pro
               230                 235                 240
Gln Tyr Ala Glu Ile Leu Ala Asp His Pro Asp Ala Pro Met Ser
               245                 250                 255
Gln Val Tyr Gly Ala Pro His Leu Leu Arg Leu Phe Val Arg Ile
               260                 265                 270
Gly Ala Met Leu Ala Tyr Thr Pro Leu Asp Glu Lys Ser Leu Ala
               275                 280                 285
Leu Leu Leu Asn Tyr Leu His Asp Phe Leu Lys Tyr Leu Ala Lys
               290                 295                 300
Asn Ser Ala Thr Leu Phe Ser Ala Ser Asp Tyr Glu Val Ala Pro
               305                 310                 315
Pro Glu Tyr His Arg Lys Ala Val
               320
```

<210> 6
<211> 274
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4833111CD1

<400> 6

```
Met Asp Arg Pro Gly Phe Val Ala Ala Leu Val Ala Gly Gly Val
  1               5                  10                  15
Ala Gly Val Ser Val Asp Leu Ile Leu Phe Pro Leu Asp Thr Ile
            20                  25                  30
Lys Thr Arg Leu Gln Ser Pro Gln Gly Phe Ser Lys Ala Gly Gly
            35                  40                  45
Phe His Gly Ile Tyr Ala Gly Val Pro Ser Ala Ala Ile Gly Ser
            50                  55                  60
Phe Pro Asn Ala Ala Ala Phe Phe Ile Thr Tyr Glu Tyr Val Lys
            65                  70                  75
Trp Phe Leu His Ala Asp Ser Ser Ser Tyr Leu Thr Pro Met Lys
                80                  85                  90
His Met Leu Ala Ala Ser Ala Gly Glu Val Val Ala Cys Leu Ile
                95                 100                 105
Arg Val Pro Ser Glu Val Val Lys Gln Arg Ala Gln Val Ser Ala
               110                 115                 120
Ser Thr Arg Thr Phe Gln Ile Phe Ser Asn Ile Leu Tyr Glu Glu
               125                 130                 135
Gly Ile Gln Gly Leu Tyr Arg Gly Tyr Lys Ser Thr Val Leu Arg
```

```
                  140                 145                 150
Glu Ile Pro Phe Ser Leu Val Gln Phe Pro Leu Trp Glu Ser Leu
                  155                 160                 165
Lys Ala Leu Trp Ser Trp Arg Gln Asp His Val Val Asp Ser Trp
                  170                 175                 180
Gln Ser Ala Val Cys Gly Ala Phe Ala Gly Gly Phe Ala Ala Ala
                  185                 190                 195
Val Thr Thr Pro Leu Asp Val Ala Lys Thr Arg Ile Thr Leu Ala
                  200                 205                 210
Lys Ala Gly Ser Ser Thr Ala Asp Gly Asn Val Leu Ser Val Leu
                  215                 220                 225
His Gly Val Trp Arg Ser Gln Gly Leu Ala Gly Leu Phe Ala Gly
                  230                 235                 240
Val Phe Pro Arg Met Ala Ala Ile Ser Leu Gly Gly Phe Ile Phe
                  245                 250                 255
Leu Gly Ala Tyr Asp Arg Thr His Ser Leu Leu Leu Glu Val Gly
                  260                 265                 270
Arg Lys Ser Pro
```

<210> 7
<211> 291
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 876677CD1

```
<400> 7
Met Asp Ser Arg Val Ser Ser Pro Glu Lys Gln Asp Lys Glu Asn
  1               5                  10                  15
Phe Val Gly Val Asn Asn Lys Arg Leu Gly Val Cys Gly Trp Ile
             20                  25                  30
Leu Phe Ser Leu Ser Phe Leu Leu Val Ile Ile Thr Phe Pro Ile
             35                  40                  45
Ser Ile Trp Met Cys Leu Lys Ile Ile Lys Glu Tyr Glu Arg Ala
             50                  55                  60
Val Val Phe Arg Leu Gly Arg Ile Gln Ala Asp Lys Ala Lys Gly
             65                  70                  75
Pro Gly Leu Ile Leu Val Leu Pro Cys Ile Asp Val Phe Val Lys
             80                  85                  90
Val Asp Leu Arg Thr Val Thr Cys Asn Ile Pro Pro Gln Glu Ile
             95                 100                 105
Leu Thr Arg Asp Ser Val Thr Thr Gln Val Asp Gly Val Val Tyr
            110                 115                 120
Tyr Arg Ile Tyr Ser Ala Val Ser Ala Val Ala Asn Val Asn Asp
            125                 130                 135
Val His Gln Ala Thr Phe Leu Leu Ala Gln Thr Thr Leu Arg Asn
            140                 145                 150
Val Leu Gly Thr Gln Thr Leu Ser Gln Ile Leu Ala Gly Arg Glu
            155                 160                 165
Glu Ile Ala His Ser Ile Gln Thr Leu Leu Asp Asp Ala Thr Glu
            170                 175                 180
Leu Trp Gly Ile Arg Val Ala Arg Val Glu Ile Lys Asp Val Arg
            185                 190                 195
Ile Pro Val Gln Leu Gln Arg Ser Met Ala Ala Glu Ala Glu Ala
            200                 205                 210
Thr Arg Glu Ala Arg Ala Lys Val Leu Ala Ala Glu Gly Glu Met
            215                 220                 225
Asn Ala Ser Lys Ser Leu Lys Ser Ala Ser Met Val Leu Ala Glu
            230                 235                 240
Ser Pro Ile Ala Leu Gln Leu Arg Tyr Leu Gln Thr Leu Ser Thr
            245                 250                 255
Val Ala Thr Glu Lys Asn Ser Thr Ile Val Phe Pro Leu Pro Met
            260                 265                 270
Asn Ile Leu Glu Gly Ile Gly Gly Val Ser Tyr Asp Asn His Lys
            275                 280                 285
Lys Leu Pro Asn Lys Ala
```

290

<210> 8
<211> 381
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2326143CD1

<400> 8
Met Ser Arg His Glu Gly Val Ser Cys Asp Ala Cys Leu Lys Gly
1 5 10 15
Asn Phe Arg Gly Arg Arg Tyr Lys Cys Leu Ile Cys Tyr Asp Tyr
20 25 30
Asp Leu Cys Ala Ser Cys Tyr Glu Ser Gly Ala Thr Thr Thr Arg
35 40 45
His Thr Thr Asp His Pro Met Gln Cys Ile Leu Thr Arg Val Asp
50 55 60
Phe Asp Leu Tyr Tyr Gly Gly Glu Ala Phe Ser Val Glu Gln Pro
65 70 75
Gln Ser Phe Thr Cys Pro Tyr Cys Gly Lys Met Gly Tyr Thr Glu
80 85 90
Thr Ser Leu Gln Glu His Val Thr Ser Glu His Ala Glu Thr Ser
95 100 105
Thr Glu Val Ile Cys Pro Ile Cys Ala Ala Leu Pro Gly Gly Asp
110 115 120
Pro Asn His Val Thr Asp Asp Phe Ala Ala His Leu Thr Leu Glu
125 130 135
His Arg Ala Pro Arg Asp Leu Asp Glu Ser Ser Gly Val Arg His
140 145 150
Val Arg Arg Met Phe His Pro Gly Arg Gly Leu Gly Gly Pro Arg
155 160 165
Ala Arg Arg Ser Asn Met His Phe Thr Ser Ser Ser Thr Gly Gly
170 175 180
Leu Ser Ser Ser Gln Ser Ser Tyr Ser Pro Ser Asn Arg Glu Ala
185 190 195
Met Asp Pro Ile Ala Glu Leu Leu Ser Gln Leu Ser Gly Val Arg
200 205 210
Arg Ser Ala Gly Gly Gln Leu Asn Ser Ser Gly Pro Ser Ala Ser
215 220 225
Gln Leu Gln Gln Leu Gln Met Gln Leu Gln Leu Glu Arg Gln His
230 235 240
Ala Gln Ala Ala Arg Gln Gln Leu Glu Thr Ala Arg Asn Ala Thr
245 250 255
Arg Arg Thr Asn Thr Ser Ser Val Thr Thr Thr Ile Thr Gln Ser
260 265 270
Thr Ala Thr Thr Asn Ile Ala Asn Thr Glu Ser Ser Gln Gln Thr
275 280 285
Leu Gln Asn Ser Gln Phe Leu Leu Thr Arg Leu Asn Asp Pro Lys
290 295 300
Met Ser Glu Thr Glu Arg Gln Ser Met Glu Ser Glu Arg Ala Asp
305 310 315
Arg Ser Leu Phe Val Gln Glu Leu Leu Leu Ser Thr Leu Val Arg
320 325 330
Glu Glu Ser Ser Ser Ser Asp Glu Asp Asp Arg Gly Glu Met Ala
335 340 345
Asp Phe Gly Ala Met Gly Cys Val Asp Ile Met Pro Leu Asp Val
350 355 360
Ala Leu Glu Asn Leu Asn Leu Lys Glu Ser Asn Lys Gly Asn Glu
365 370 375
Pro Pro Pro Pro Pro Leu
380

<210> 9
<211> 190
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2786302CD1

<400> 9
Met Lys Tyr Gly Asn Glu Ile Met Asn Lys Asp Pro Val Phe Arg
1 5 10 15
Ile Ser Pro Arg Ser Arg Glu Thr His Pro Asn Pro Glu Glu Pro
20 25 30
Glu Glu Glu Asp Glu Asp Val Gln Ala Glu Arg Val Gln Ala Ala
35 40 45
Asn Ala Leu Thr Ala Pro Asn Leu Glu Glu Glu Pro Val Ile Thr
50 55 60
Ala Ser Cys Leu His Lys Glu Tyr Tyr Glu Thr Lys Lys Ser Cys
65 70 75
Phe Ser Thr Arg Lys Lys Lys Ile Ala Ile Arg Asn Val Ser Phe
80 85 90
Cys Val Lys Lys Gly Glu Val Leu Gly Leu Leu Gly His Asn Gly
95 100 105
Ala Gly Lys Ser Thr Ser Ile Lys Met Ile Thr Gly Cys Thr Lys
110 115 120
Pro Thr Ala Gly Val Val Val Leu Gln Gly Ser Arg Ala Ser Val
125 130 135
Arg Gln Gln His Asp Asn Ser Leu Lys Phe Leu Gly Tyr Cys Pro
140 145 150
Gln Glu Asn Ser Leu Trp Pro Lys Leu Thr Met Lys Glu His Leu
155 160 165
Glu Leu Tyr Ala Ala Val Glu Arg Leu Gly Gln Lys Arg Cys Cys
170 175 180
Ser Gln Tyr Phe Thr Ile Gly Gly Arg Ser
185 190

<210> 10
<211> 297
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3735780CD1

<400> 10
Met Met Asp Ser Glu Ala His Glu Lys Arg Pro Pro Ile Leu Thr
1 5 10 15
Ser Ser Lys Gln Asp Ile Ser Pro His Ile Thr Asn Val Gly Glu
20 25 30
Met Lys His Tyr Leu Cys Gly Cys Cys Ala Ala Phe Asn Asn Val
35 40 45
Ala Ile Thr Phe Pro Ile Gln Lys Val Leu Phe Arg Gln Gln Leu
50 55 60
Tyr Gly Ile Lys Thr Arg Asp Ala Ile Leu Gln Leu Arg Arg Asp
65 70 75
Gly Phe Arg Asn Leu Tyr Arg Gly Ile Leu Pro Pro Leu Met Gln
80 85 90
Lys Thr Thr Thr Leu Ala Leu Met Phe Gly Leu Tyr Glu Asp Leu
95 100 105
Ser Cys Leu Leu His Lys His Val Ser Ala Pro Glu Phe Ala Thr
110 115 120
Ser Gly Val Ala Ala Val Leu Ala Gly Thr Thr Glu Ala Ile Phe
125 130 135
Thr Pro Leu Glu Arg Val Gln Thr Leu Leu Gln Asp His Lys His
140 145 150
His Asp Lys Phe Thr Asn Thr Tyr Gln Ala Phe Lys Ala Leu Lys
155 160 165
Cys His Gly Ile Gly Glu Tyr Tyr Arg Gly Leu Val Pro Ile Leu
170 175 180
Phe Arg Asn Gly Leu Ser Asn Val Leu Phe Phe Gly Leu Arg Gly
185 190 195
Pro Ile Lys Glu His Leu Pro Thr Ala Thr Thr His Ser Ala His

200 205 210
Leu Val Asn Asp Phe Ile Cys Gly Gly Leu Leu Gly Ala Met Leu
215 220 225
Gly Phe Leu Phe Phe Pro Ile Asn Val Val Lys Thr Arg Ile Gln
230 235 240
Ser Gln Ile Gly Gly Glu Phe Gln Ser Phe Pro Lys Val Phe Gln
245 250 255
Lys Ile Trp Leu Glu Arg Asp Arg Lys Leu Ile Asn Leu Phe Arg
260 265 270
Gly Ala His Leu Asn Tyr His Arg Ser Leu Ile Ser Trp Gly Ile
275 280 285
Ile Asn Ala Thr Tyr Glu Phe Leu Leu Lys Val Ile
290 295

<210> 11
<211> 89
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 039026CD1

<400> 11
Met Ala Ala Gln Ile Pro Glu Ser Asp Gln Ile Lys Gln Phe Lys
1 5 10 15
Glu Phe Leu Gly Thr Tyr Asn Lys Leu Thr Glu Thr Cys Phe Leu
20 25 30
Asp Cys Val Lys Asp Phe Thr Thr Arg Glu Val Lys Pro Glu Glu
35 40 45
Thr Thr Cys Ser Glu His Cys Leu Gln Lys Tyr Leu Lys Met Thr
50 55 60
Gln Arg Ile Ser Met Arg Phe Gln Glu Tyr His Ile Gln Gln Asn
65 70 75
Glu Ala Leu Ala Ala Lys Ala Gly Leu Leu Gly Gln Pro Arg
80 85

<210> 12
<211> 115
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 260607CD1

<400> 12
Met Ala Leu Ile Pro Ser Arg Val Trp Leu Pro Phe Ala Val Trp
1 5 10 15
Val Val Asp Ser Ala Pro Val Arg Gly Leu Val Arg Arg Glu Pro
20 25 30
Phe Leu Arg Thr Gly Ser Phe Ile Ala Leu Phe Tyr Phe Pro Pro
35 40 45
Leu Leu Pro Val Leu Ile Asn Leu Phe Ser Phe Phe Leu Thr Pro
50 55 60
Ser Phe Trp Arg Gln Leu Gly Ala Ile Leu Val Tyr Ala Ser Leu
65 70 75
Leu Ala Glu Lys Thr Pro Phe Lys Thr Gln Arg Thr Leu Glu Gly
80 85 90
Asp Ala Leu Val Gly Ser Val Ser Ile Phe Leu Cys Ala Lys Asp
95 100 105
Arg Gln Thr Glu Ala Glu Arg Gly Cys Ser
110 115

<210> 13
<211> 675
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature

<223> Incyte ID No: 1429651CD1

<400> 13

```
Met Glu Ser Gly Thr Ser Ser Pro Gln Pro Pro Gln Leu Asp Pro
  1               5                  10                  15
Leu Asp Ala Phe Pro Gln Lys Gly Leu Glu Pro Gly Asp Ile Ala
             20                  25                  30
Val Leu Val Leu Tyr Phe Leu Phe Val Leu Ala Val Gly Leu Trp
         35                  40                  45
Ser Thr Val Lys Thr Lys Arg Asp Thr Val Lys Gly Tyr Phe Leu
     50                  55                  60
Ala Gly Gly Asp Met Val Trp Trp Pro Val Gly Ala Ser Leu Phe
 65                  70                  75
Ala Ser Asn Val Gly Ser Gly His Phe Ile Gly Leu Ala Gly Ser
             80                  85                  90
Gly Ala Ala Thr Gly Ile Ser Val Ser Ala Tyr Glu Leu Asn Gly
         95                 100                 105
Leu Phe Ser Val Leu Met Leu Ala Trp Ile Phe Leu Pro Ile Tyr
    110                 115                 120
Ile Ala Gly Gln Val Thr Thr Met Pro Glu Tyr Leu Arg Lys Arg
125                 130                 135
Phe Gly Gly Ile Arg Ile Pro Ile Ile Leu Ala Val Leu Tyr Leu
            140                 145                 150
Phe Ile Tyr Ile Phe Thr Lys Ile Ser Val Asp Met Tyr Ala Gly
        155                 160                 165
Ala Ile Phe Ile Gln Gln Ser Leu His Leu Asp Leu Tyr Leu Ala
    170                 175                 180
Ile Val Gly Leu Leu Ala Ile Thr Ala Val Tyr Thr Val Ala Gly
185                 190                 195
Gly Leu Ala Ala Val Ile Tyr Thr Asp Ala Leu Gln Thr Leu Ile
            200                 205                 210
Met Leu Ile Gly Ala Leu Thr Leu Met Gly Tyr Ser Phe Ala Ala
        215                 220                 225
Val Gly Gly Met Glu Gly Leu Lys Glu Lys Tyr Phe Leu Ala Leu
    230                 235                 240
Ala Ser Asn Arg Ser Glu Asn Ser Ser Cys Gly Leu Pro Arg Glu
245                 250                 255
Asp Ala Phe His Ile Phe Arg Asp Pro Leu Thr Ser Asp Leu Pro
            260                 265                 270
Trp Pro Gly Val Leu Phe Gly Met Ser Ile Pro Ser Leu Trp Tyr
        275                 280                 285
Trp Cys Thr Asp Gln Val Ile Val Gln Arg Thr Leu Ala Ala Lys
    290                 295                 300
Asn Leu Ser His Ala Lys Gly Gly Ala Leu Met Ala Ala Tyr Leu
305                 310                 315
Lys Val Leu Pro Leu Phe Ile Met Val Phe Pro Gly Met Val Ser
            320                 325                 330
Arg Ile Leu Phe Pro Asp Gln Val Ala Cys Ala Asp Pro Glu Ile
        335                 340                 345
Cys Gln Lys Ile Cys Ser Asn Pro Ser Gly Cys Ser Asp Ile Ala
    350                 355                 360
Tyr Pro Lys Leu Val Leu Glu Leu Leu Pro Thr Gly Leu Arg Gly
365                 370                 375
Leu Met Met Ala Val Met Val Ala Ala Leu Met Ser Ser Leu Thr
            380                 385                 390
Ser Ile Phe Asn Ser Ala Ser Thr Ile Phe Thr Met Asp Leu Trp
        395                 400                 405
Asn His Leu Arg Pro Arg Ala Ser Glu Lys Glu Leu Met Ile Val
    410                 415                 420
Gly Arg Val Phe Val Leu Leu Leu Val Leu Val Ser Ile Leu Trp
425                 430                 435
Ile Pro Val Val Gln Ala Ser Gln Gly Gly Gln Leu Phe Ile Tyr
            440                 445                 450
Ile Gln Ser Ile Ser Ser Tyr Leu Gln Pro Pro Val Ala Val Val
        455                 460                 465
Phe Ile Met Gly Cys Phe Trp Lys Arg Thr Asn Glu Lys Gly Ala
    470                 475                 480
Phe Trp Gly Leu Ile Ser Gly Leu Leu Leu Gly Leu Val Arg Leu
```

```
                    485                 490                 495
Val Leu Asp Phe Ile Tyr Val Gln Pro Arg Cys Asp Gln Pro Asp
                    500                 505                 510
Glu Arg Pro Val Leu Val Lys Ser Ile His Tyr Leu Tyr Phe Ser
                    515                 520                 525
Met Ile Leu Ser Thr Val Thr Leu Ile Thr Val Ser Thr Val Ser
                    530                 535                 540
Trp Phe Thr Glu Pro Pro Ser Lys Glu Met Val Ser His Leu Thr
                    545                 550                 555
Trp Phe Thr Arg His Asp Pro Val Val Gln Lys Glu Gln Ala Pro
                    560                 565                 570
Pro Ala Ala Pro Leu Ser Leu Thr Leu Ser Gln Asn Gly Met Pro
                    575                 580                 585
Glu Ala Ser Ser Ser Ser Ser Val Gln Phe Glu Met Val Gln Glu
                    590                 595                 600
Asn Thr Ser Lys Thr His Ser Cys Asp Met Thr Pro Lys Gln Ser
                    605                 610                 615
Lys Val Val Lys Ala Ile Leu Trp Leu Cys Gly Ile Gln Glu Lys
                    620                 625                 630
Gly Lys Glu Glu Leu Pro Ala Arg Ala Glu Ala Ile Ile Val Ser
                    635                 640                 645
Leu Glu Glu Asn Pro Leu Val Lys Thr Leu Leu Asp Val Asn Leu
                    650                 655                 660
Ile Phe Cys Val Ser Cys Ala Ile Phe Ile Trp Gly Tyr Phe Ala
                    665                 670                 675

<210> 14
<211> 320
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2069971CD1

<400> 14
Met Tyr His Cys His Ser Gly Ser Lys Pro Thr Glu Lys Gly Ala
  1                 5                  10                  15
Asn Glu Tyr Ala Tyr Ala Lys Trp Lys Leu Cys Ser Ala Ser Ala
                 20                  25                  30
Ile Cys Phe Ile Phe Met Ile Ala Glu Val Val Gly Gly His Ile
                 35                  40                  45
Ala Gly Ser Leu Ala Val Val Thr Asp Ala Ala His Leu Leu Ile
                 50                  55                  60
Asp Leu Thr Ser Phe Leu Leu Ser Leu Phe Ser Leu Trp Leu Ser
                 65                  70                  75
Ser Lys Pro Pro Ser Lys Arg Leu Thr Phe Gly Trp His Arg Ala
                 80                  85                  90
Glu Ile Leu Gly Ala Leu Leu Ser Ile Leu Cys Ile Trp Val Val
                 95                 100                 105
Thr Gly Val Leu Val Tyr Leu Ala Cys Glu Arg Leu Leu Tyr Pro
                110                 115                 120
Asp Tyr Gln Ile Gln Ala Thr Val Met Ile Ile Val Ser Ser Cys
                125                 130                 135
Ala Val Ala Ala Asn Ile Val Leu Thr Val Val Leu His Gln Arg
                140                 145                 150
Cys Leu Gly His Asn His Lys Glu Val Gln Ala Asn Ala Ser Val
                155                 160                 165
Arg Ala Ala Phe Val His Ala Leu Gly Asp Leu Phe Gln Ser Ile
                170                 175                 180
Ser Val Leu Ile Ser Ala Leu Ile Ile Tyr Phe Lys Pro Glu Tyr
                185                 190                 195
Lys Ile Ala Asp Pro Ile Cys Thr Phe Ile Phe Ser Ile Leu Val
                200                 205                 210
Leu Ala Ser Thr Ile Thr Ile Leu Lys Asp Phe Ser Ile Leu Leu
                215                 220                 225
Met Glu Gly Val Pro Lys Ser Leu Asn Tyr Ser Gly Val Lys Glu
                230                 235                 240
```

Leu Ile Leu Ala Val Asp Gly Val Leu Ser Val His Ser Leu His
245 250 255
Ile Trp Ser Leu Thr Met Asn Gln Val Ile Leu Ser Ala His Val
260 265 270
Ala Thr Ala Ala Ser Arg Asp Ser Gln Val Val Arg Arg Glu Ile
275 280 285
Ala Lys Ala Leu Ser Lys Ser Phe Thr Met His Ser Leu Thr Ile
290 295 300
Gln Met Glu Ser Pro Val Asp Gln Asp Pro Asp Cys Leu Phe Cys
305 310 315
Glu Asp Pro Cys Asp
320

<210> 15
<211> 462
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2329339CD1

<400> 15
Met Ala Glu Glu Gln Glu Phe Thr Gln Leu Cys Lys Leu Pro Ala
1 5 10 15
Gln Pro Ser His Pro His Cys Val Asn Asn Thr Tyr Arg Ser Ala
20 25 30
Gln His Ser Gln Ala Leu Leu Arg Gly Leu Leu Ala Leu Arg Asp
35 40 45
Ser Gly Ile Leu Phe Asp Val Val Leu Val Val Glu Gly Arg His
50 55 60
Ile Glu Ala His Arg Ile Leu Leu Ala Ala Ser Cys Asp Tyr Phe
65 70 75
Arg Gly Met Phe Ala Gly Gly Leu Lys Glu Met Glu Gln Glu Glu
80 85 90
Val Leu Ile His Gly Val Ser Tyr Asn Ala Met Cys Gln Ile Leu
95 100 105
His Phe Ile Tyr Thr Ser Glu Leu Glu Leu Ser Leu Ser Asn Val
110 115 120
Gln Glu Thr Leu Val Ala Ala Cys Gln Leu Gln Ile Pro Glu Ile
125 130 135
Ile His Phe Cys Cys Asp Phe Leu Met Ser Trp Val Asp Glu Glu
140 145 150
Asn Ile Leu Asp Val Tyr Arg Leu Ala Glu Leu Phe Asp Leu Ser
155 160 165
Arg Leu Thr Glu Gln Leu Asp Thr Tyr Ile Leu Lys Asn Phe Val
170 175 180
Ala Phe Ser Arg Thr Asp Lys Tyr Arg Gln Leu Pro Leu Glu Lys
185 190 195
Val Tyr Ser Leu Leu Ser Ser Asn Arg Leu Glu Val Ser Cys Glu
200 205 210
Thr Glu Val Tyr Glu Gly Ala Leu Leu Tyr His Tyr Ser Leu Glu
215 220 225
Gln Val Gln Ala Asp Gln Ile Ser Leu His Glu Pro Pro Lys Leu
230 235 240
Leu Glu Thr Val Arg Phe Pro Leu Met Glu Ala Glu Val Leu Gln
245 250 255
Arg Leu His Asp Lys Leu Asp Pro Ser Pro Leu Arg Asp Thr Val
260 265 270
Ala Ser Gly Leu Met Tyr His Arg Asn Glu Ser Leu Gln Pro Ser
275 280 285
Leu Gln Ser Pro Gln Thr Glu Leu Arg Ser Asp Phe Gln Cys Val
290 295 300
Val Gly Phe Gly Gly Ile His Ser Thr Pro Ser Thr Val Leu Ser
305 310 315
Asp Gln Ala Lys Tyr Leu Asn Pro Leu Leu Gly Glu Trp Lys His
320 325 330
Phe Thr Ala Ser Leu Ala Pro Arg Met Ser Asn Gln Gly Ile Ala
335 340 345

```
Val Leu Asn Asn Phe Val Tyr Leu Ile Gly Gly Asp Asn Asn Val
                350                 355                 360
Gln Gly Phe Arg Ala Glu Ser Arg Cys Trp Arg Tyr Asp Pro Arg
                365                 370                 375
His Asn Arg Trp Phe Gln Ile Gln Ser Leu Gln Gln Glu His Ala
                380                 385                 390
Asp Leu Ser Val Cys Val Val Gly Arg Tyr Ile Tyr Ala Val Ala
                395                 400                 405
Gly Arg Asp Tyr His Asn Asp Leu Asn Ala Val Glu Arg Tyr Asp
                410                 415                 420
Pro Ala Thr Asn Ser Trp Ala Tyr Val Ala Pro Leu Lys Arg Glu
                425                 430                 435
Val Tyr Ala His Ala Gly Ala Thr Leu Glu Gly Lys Met Tyr Ile
                440                 445                 450
Thr Cys Gly Arg Lys Leu Ile Pro Phe Ser Glu Gly
                455                 460
<210> 16
<211> 98
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2540219CD1

<400> 16
Met Arg Ala Cys Ala Val Trp Leu Ala Gly Gly Met Ala Gly Ala
  1                 5                  10                  15
Ile Ser Trp Gly Thr Ala Thr Pro Met Asp Val Val Lys Ser Arg
                 20                  25                  30
Leu Gln Ala Asp Gly Val Tyr Leu Asn Lys Tyr Lys Gly Val Leu
                 35                  40                  45
Asp Cys Ile Ser Gln Ser Tyr Gln Lys Glu Gly Leu Lys Val Phe
                 50                  55                  60
Phe Arg Gly Ile Thr Val Asn Ala Val Arg Gly Phe Pro Met Ser
                 65                  70                  75
Ala Ala Met Phe Leu Gly Tyr Glu Leu Ser Leu Gln Ala Ile Arg
                 80                  85                  90
Gly Asp His Ala Val Thr Ser Pro
                 95
<210> 17
<211> 748
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2722462CD1

<400> 17
Met Asn Tyr Gln Glu Ala Ala Ile Tyr Leu Gln Glu Gly Glu Asn
  1                 5                  10                  15
Asn Asp Lys Phe Phe Thr His Pro Lys Asp Ala Lys Ala Leu Ala
                 20                  25                  30
Ala Tyr Leu Phe Ala His Asn His Leu Phe Tyr Leu Met Glu Leu
                 35                  40                  45
Ala Thr Ala Leu Leu Leu Leu Leu Leu Ser Leu Cys Glu Ala Pro
                 50                  55                  60
Ala Val Pro Ala Leu Arg Leu Gly Ile Tyr Val His Ala Thr Leu
                 65                  70                  75
Glu Leu Phe Ala Leu Met Val Val Val Phe Glu Leu Cys Met Lys
                 80                  85                  90
Leu Arg Trp Leu Gly Leu His Thr Phe Ile Arg His Lys Arg Thr
                 95                 100                 105
Met Val Lys Thr Ser Val Leu Val Val Gln Phe Val Glu Ala Ile
                110                 115                 120
Val Val Leu Val Arg Gln Met Ser His Val Arg Val Thr Arg Ala
                125                 130                 135
```

```
Leu Arg Cys Ile Phe Leu Val Asp Cys Arg Tyr Cys Gly Gly Val
                140                 145                 150
Arg Arg Asn Leu Arg Gln Ile Phe Gln Ser Leu Pro Pro Phe Met
            155                 160                 165
Asp Ile Leu Leu Leu Leu Leu Phe Phe Met Ile Ile Phe Ala Ile
        170                 175                 180
Leu Gly Phe Tyr Leu Phe Ser Pro Asn Pro Ser Asp Pro Tyr Phe
    185                 190                 195
Ser Thr Leu Glu Asn Ser Ile Val Ser Leu Phe Val Leu Leu Thr
200                 205                 210
Thr Ala Asn Phe Pro Asp Val Met Met Pro Ser Tyr Ser Arg Asn
215                 220                 225
Pro Trp Ser Cys Val Phe Phe Ile Val Tyr Leu Ser Ile Glu Leu
230                 235                 240
Tyr Phe Ile Met Asn Leu Leu Leu Ala Val Val Phe Asp Thr Phe
245                 250                 255
Asn Asp Ile Glu Lys Arg Lys Phe Lys Ser Leu Leu Leu His Lys
260                 265                 270
Arg Thr Ala Ile Gln His Ala Tyr Arg Leu Leu Ile Ser Gln Arg
275                 280                 285
Arg Pro Ala Gly Ile Ser Tyr Arg Gln Phe Glu Gly Leu Met Arg
290                 295                 300
Phe Tyr Lys Pro Arg Met Ser Ala Arg Glu Arg Tyr Leu Thr Phe
305                 310                 315
Lys Ala Leu Asn Gln Asn Asn Thr Pro Leu Leu Ser Leu Lys Asp
320                 325                 330
Phe Tyr Asp Ile Tyr Glu Val Ala Ala Leu Lys Trp Lys Ala Lys
335                 340                 345
Lys Asn Arg Glu His Trp Phe Asp Glu Leu Pro Arg Thr Ala Leu
350                 355                 360
Leu Ile Phe Lys Gly Ile Asn Ile Leu Val Lys Ser Lys Ala Phe
365                 370                 375
Gln Tyr Phe Met Tyr Leu Val Val Ala Val Asn Gly Val Trp Ile
380                 385                 390
Leu Val Glu Thr Phe Met Leu Lys Gly Gly Asn Phe Phe Ser Lys
395                 400                 405
His Val Pro Trp Ser Tyr Leu Val Phe Leu Thr Ile Tyr Gly Val
410                 415                 420
Glu Leu Phe Leu Lys Val Ala Gly Leu Gly Pro Val Glu Tyr Leu
425                 430                 435
Ser Ser Gly Trp Asn Leu Phe Asp Phe Ser Val Thr Val Phe Ala
440                 445                 450
Phe Leu Gly Leu Leu Ala Leu Ala Leu Asn Met Glu Pro Phe Tyr
455                 460                 465
Phe Ile Val Val Leu Arg Pro Leu Gln Leu Leu Arg Leu Phe Lys
470                 475                 480
Leu Lys Glu Arg Tyr Arg Asn Val Leu Asp Thr Met Phe Glu Leu
485                 490                 495
Leu Pro Arg Met Ala Ser Leu Gly Leu Thr Leu Leu Ile Phe Tyr
500                 505                 510
Tyr Ser Phe Ala Ile Val Gly Met Glu Phe Phe Cys Gly Ile Val
515                 520                 525
Phe Pro Asn Cys Cys Asn Thr Ser Thr Val Ala Asp Ala Tyr Arg
530                 535                 540
Trp Arg Asn His Thr Val Gly Asn Arg Thr Val Val Glu Glu Gly
545                 550                 555
Tyr Tyr Tyr Leu Asn Asn Phe Asp Asn Ile Leu Asn Ser Phe Val
560                 565                 570
Thr Leu Phe Glu Leu Thr Val Val Asn Asn Trp Tyr Ile Ile Met
575                 580                 585
Glu Gly Val Thr Ser Gln Thr Ser His Trp Ser Arg Leu Tyr Phe
590                 595                 600
Met Thr Phe Tyr Ile Val Thr Met Val Val Met Thr Ile Ile Val
605                 610                 615
Ala Phe Ile Leu Glu Ala Phe Val Phe Arg Met Asn Tyr Ser Arg
620                 625                 630
Lys Asn Gln Asp Ser Glu Val Asp Gly Gly Ile Thr Leu Glu Lys
635                 640                 645
```

Glu Ile Ser Lys Glu Glu Leu Val Ala Val Leu Glu Leu Tyr Arg
650 655 660
Glu Ala Arg Gly Ala Ser Ser Asp Val Thr Arg Leu Leu Glu Thr
665 670 675
Leu Ser Gln Met Glu Arg Tyr Gln Gln His Ser Met Val Phe Leu
680 685 690
Gly Arg Arg Ser Arg Thr Lys Ser Asp Leu Ser Leu Lys Met Tyr
695 700 705
Gln Glu Glu Ile Gln Glu Trp Tyr Glu Glu His Ala Arg Glu Gln
710 715 720
Glu Gln Gln Arg Gln Leu Ser Ser Ser Ala Ala Pro Ala Ala Gln
725 730 735
Gln Pro Pro Gly Ser Arg Gln Arg Ser Gln Thr Val Thr
740 745

<210> 18
<211> 507
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2739264CD1

<400> 18
Met Ala Phe Asn Phe Gly Ala Pro Ser Gly Thr Ser Gly Thr Ala
1 5 10 15
Ala Ala Thr Ala Ala Pro Ala Gly Gly Phe Gly Gly Phe Gly Thr
20 25 30
Thr Ser Thr Thr Ala Gly Ser Ala Phe Ser Phe Ser Ala Pro Thr
35 40 45
Asn Thr Gly Thr Thr Gly Leu Phe Gly Gly Thr Gln Asn Lys Gly
50 55 60
Phe Gly Phe Gly Thr Gly Phe Gly Thr Thr Thr Gly Thr Ser Thr
65 70 75
Gly Leu Gly Thr Gly Leu Gly Thr Gly Leu Gly Phe Gly Gly Phe
80 85 90
Asn Thr Gln Gln Gln Gln Gln Thr Thr Leu Gly Gly Leu Phe Ser
95 100 105
Gln Pro Thr Gln Ala Pro Thr Gln Ser Asn Gln Leu Ile Asn Thr
110 115 120
Ala Ser Ala Leu Ser Ala Pro Thr Leu Leu Gly Asp Glu Arg Asp
125 130 135
Ala Ile Leu Ala Lys Trp Asn Gln Leu Gln Ala Phe Trp Gly Thr
140 145 150
Gly Lys Gly Tyr Phe Asn Asn Asn Ile Pro Pro Val Glu Phe Thr
155 160 165
Gln Glu Asn Pro Phe Cys Arg Phe Lys Ala Val Gly Tyr Ser Cys
170 175 180
Met Pro Ser Asn Lys Asp Glu Asp Gly Leu Val Val Leu Val Phe
185 190 195
Asn Lys Lys Glu Thr Glu Ile Arg Ser Gln Gln Gln Gln Leu Val
200 205 210
Glu Ser Leu His Lys Val Leu Gly Gly Asn Gln Thr Leu Thr Val
215 220 225
Asn Val Glu Gly Thr Lys Thr Leu Pro Asp Asp Gln Thr Glu Val
230 235 240
Val Ile Tyr Val Val Glu Arg Ser Pro Asn Gly Thr Ser Arg Arg
245 250 255
Val Pro Ala Thr Thr Leu Tyr Ala His Phe Glu Gln Ala Asn Ile
260 265 270
Lys Thr Gln Leu Gln Gln Leu Gly Val Thr Leu Ser Met Thr Arg
275 280 285
Thr Glu Leu Ser Pro Ala Gln Ile Lys Gln Leu Leu Gln Asn Pro
290 295 300
Pro Ala Gly Val Asp Pro Ile Ile Trp Glu Gln Ala Lys Val Asp
305 310 315
Asn Pro Asp Ser Glu Lys Leu Ile Pro Val Pro Met Val Gly Phe
320 325 330

```
Lys Glu Leu Leu Arg Arg Leu Lys Val Gln Asp Gln Met Thr Lys
                335                 340                 345
Gln His Gln Thr Arg Leu Asp Ile Ile Ser Glu Asp Ile Ser Glu
                350                 355                 360
Leu Gln Lys Asn Gln Thr Thr Ser Val Ala Lys Ile Ala Gln Tyr
                365                 370                 375
Lys Arg Lys Leu Met Asp Leu Ser His Arg Thr Leu Gln Val Leu
                380                 385                 390
Ile Lys Gln Glu Ile Gln Arg Lys Ser Gly Tyr Ala Ile Gln Ala
                395                 400                 405
Asp Glu Glu Gln Leu Arg Val Gln Leu Asp Thr Ile Gln Gly Glu
                410                 415                 420
Leu Asn Ala Pro Thr Gln Phe Lys Gly Arg Leu Asn Glu Leu Met
                425                 430                 435
Ser Gln Ile Arg Met Gln Asn His Phe Gly Ala Val Arg Ser Glu
                440                 445                 450
Glu Arg Tyr Tyr Ile Asp Ala Asp Leu Leu Arg Glu Ile Lys Gln
                455                 460                 465
His Leu Lys Gln Gln Gln Glu Gly Leu Ser His Leu Ile Ser Ile
                470                 475                 480
Ile Lys Asp Asp Leu Glu Asp Ile Lys Leu Val Glu His Gly Leu
                485                 490                 495
Asn Glu Thr Ile His Ile Arg Gly Gly Val Phe Ser
                500                 505
<210> 19
<211> 592
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2758310CD1

<400> 19
Met Trp Phe Cys Gly Gln Ser Thr Pro Phe Gly Cys Glu Leu His
  1               5                  10                  15
Asp Thr Cys Val Gln Leu Cys His Phe His Ser Ala Leu Leu His
             20                  25                  30
Arg Arg Gln Lys Pro Trp Pro Ser Pro Ala Val Phe Phe Arg Arg
             35                  40                  45
Asn Val Arg Gly Leu Pro Pro Arg Phe Ser Ser Pro Thr Pro Leu
             50                  55                  60
Trp Arg Lys Val Leu Ser Thr Ala Val Val Gly Ala Pro Leu Leu
             65                  70                  75
Leu Gly Ala Arg Tyr Val Met Ala Glu Ala Arg Glu Lys Arg Arg
             80                  85                  90
Met Arg Leu Val Val Asp Gly Met Gly Arg Phe Gly Arg Ser Leu
             95                 100                 105
Lys Val Gly Leu Gln Ile Ser Leu Asp Tyr Trp Trp Cys Thr Asn
            110                 115                 120
Val Val Leu Arg Gly Trp Lys Ser Pro Gly Tyr Leu Glu Val Met
            125                 130                 135
Ser Ala Cys His Gln Arg Ala Ala Asp Ala Leu Val Ala Gly Ala
            140                 145                 150
Ile Ser Asn Gly Gly Leu Tyr Val Lys Leu Gly Gln Gly Leu Cys
            155                 160                 165
Ser Phe Asn His Leu Leu Pro Pro Glu Tyr Thr Arg Thr Leu Arg
            170                 175                 180
Val Leu Glu Asp Arg Ala Leu Lys Arg Gly Phe Gln Glu Val Asp
            185                 190                 195
Glu Leu Phe Leu Glu Asp Phe Gln Ala Leu Pro His Glu Leu Phe
            200                 205                 210
Gln Glu Phe Asp Tyr Gln Pro Ile Ala Ala Ala Ser Leu Ala Gln
            215                 220                 225
Val His Arg Ala Lys Leu His Asp Gly Thr Ser Val Ala Val Lys
            230                 235                 240
Val Gln Tyr Ile Asp Leu Arg Asp Arg Phe Asp Gly Asp Ile His
            245                 250                 255
```

```
Thr Leu Glu Leu Leu Leu Arg Leu Val Glu Val Met His Pro Ser
                260                 265                 270
Phe Gly Phe Ser Trp Val Leu Gln Asp Leu Lys Gly Thr Leu Ala
                275                 280                 285
Gln Glu Leu Asp Phe Glu Asn Glu Gly Arg Asn Ala Glu Arg Cys
                290                 295                 300
Ala Arg Glu Leu Ala His Phe Pro Tyr Val Val Val Pro Arg Val
                305                 310                 315
His Trp Asp Lys Ser Ser Lys Arg Val Leu Thr Ala Asp Phe Cys
                320                 325                 330
Ala Gly Cys Lys Val Asn Asp Val Glu Ala Ile Arg Ser Gln Gly
                335                 340                 345
Leu Ala Val His Asp Ile Ala Glu Lys Leu Ile Lys Ala Phe Ala
                350                 355                 360
Glu Gln Ile Phe Tyr Thr Gly Phe Ile His Ser Asp Pro His Pro
                365                 370                 375
Gly Asn Val Leu Val Arg Lys Gly Pro Asp Gly Lys Ala Glu Leu
                380                 385                 390
Val Leu Leu Asp His Gly Leu Tyr Gln Phe Leu Glu Glu Lys Asp
                395                 400                 405
Arg Ala Ala Leu Cys Gln Leu Trp Arg Ala Ile Ile Leu Arg Asp
                410                 415                 420
Asp Ala Ala Met Arg Ala His Ala Ala Ala Leu Gly Val Gln Asp
                425                 430                 435
Tyr Leu Leu Phe Ala Glu Met Leu Met Gln Arg Pro Val Arg Leu
                440                 445                 450
Gly Gln Leu Trp Gly Ser His Leu Leu Ser Arg Glu Glu Ala Ala
                455                 460                 465
Tyr Met Val Asp Met Ala Arg Glu Arg Phe Glu Ala Val Met Ala
                470                 475                 480
Val Leu Arg Glu Leu Pro Arg Pro Met Leu Leu Val Leu Arg Asn
                485                 490                 495
Ile Asn Thr Val Arg Ala Ile Asn Val Ala Leu Gly Ala Pro Val
                500                 505                 510
Asp Arg Tyr Phe Leu Met Ala Lys Arg Ala Val Arg Gly Trp Ser
                515                 520                 525
Arg Leu Ala Gly Ala Thr Tyr Arg Gly Val Tyr Gly Thr Ser Leu
                530                 535                 540
Leu Arg His Ala Lys Val Val Trp Glu Met Leu Lys Phe Glu Val
                545                 550                 555
Ala Leu Arg Leu Glu Thr Leu Ala Met Arg Leu Thr Ala Leu Leu
                560                 565                 570
Ala Arg Ala Leu Val His Leu Ser Leu Val Pro Pro Ala Glu Glu
                575                 580                 585
Leu Tyr Gln Tyr Leu Glu Thr
                590
<210> 20
<211> 841
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2762348CD1

<400> 20
Met Ala Ser Val Phe Arg Ser Glu Glu Met Cys Leu Ser Gln Leu
  1               5                  10                  15
Phe Leu Gln Val Glu Ala Ala Tyr Cys Cys Val Ala Glu Leu Gly
             20                  25                  30
Glu Leu Gly Leu Val Gln Phe Lys Asp Leu Asn Met Asn Val Asn
             35                  40                  45
Ser Phe Gln Arg Lys Phe Val Asn Glu Val Arg Arg Cys Glu Ser
             50                  55                  60
Leu Glu Arg Ile Leu Arg Phe Leu Glu Asp Glu Met Gln Asn Glu
             65                  70                  75
Ile Val Val Gln Leu Leu Glu Lys Ser Pro Leu Thr Pro Leu Pro
             80                  85                  90
```

```
Arg Glu Met Ile Thr Leu Glu Thr Val Leu Glu Lys Leu Glu Gly
                 95                 100                 105
Glu Leu Gln Glu Ala Asn Gln Asn Gln Gln Ala Leu Lys Gln Ser
                110                 115                 120
Phe Leu Glu Leu Thr Glu Leu Lys Tyr Leu Leu Lys Lys Thr Gln
                125                 130                 135
Asp Phe Phe Glu Thr Glu Thr Asn Leu Ala Asp Asp Phe Phe Thr
                140                 145                 150
Glu Asp Thr Ser Gly Leu Leu Glu Leu Lys Ala Val Pro Ala Tyr
                155                 160                 165
Met Thr Gly Lys Leu Gly Phe Ile Ala Gly Cys Asp Pro Thr Gly
                170                 175                 180
Lys Arg Met Ala Ser Phe Glu Arg Leu Leu Trp Arg Val Cys Arg
                185                 190                 195
Gly Asn Val Tyr Leu Lys Phe Ser Glu Met Asp Ala Pro Leu Glu
                200                 205                 210
Asp Pro Val Thr Lys Glu Glu Ile Gln Lys His Ile Phe Ile Ile
                215                 220                 225
Phe Tyr Gln Gly Glu Gln Leu Arg Gln Lys Ile Lys Lys Ile Cys
                230                 235                 240
Asp Gly Phe Arg Ala Thr Val Tyr Pro Cys Pro Glu Pro Ala Val
                245                 250                 255
Glu Arg Arg Glu Met Leu Glu Ser Val Asn Val Arg Leu Glu Asp
                260                 265                 270
Leu Ile Thr Val Ile Thr Gln Thr Glu Ser His Arg Gln Arg Leu
                275                 280                 285
Leu Gln Glu Ala Ala Ala Asn Trp His Ser Trp Leu Ile Lys Val
                290                 295                 300
Gln Lys Met Lys Ala Val Tyr His Ile Leu Asn Met Cys Asn Ile
                305                 310                 315
Asp Val Thr Gln Gln Cys Val Ile Ala Glu Ile Trp Phe Pro Val
                320                 325                 330
Ala Asp Ala Thr Arg Ile Lys Arg Ala Leu Glu Gln Gly Met Glu
                335                 340                 345
Leu Ser Gly Ser Ser Met Ala Pro Ile Met Thr Thr Val Gln Ser
                350                 355                 360
Lys Thr Ala Pro Pro Thr Phe Asn Arg Thr Asn Lys Phe Thr Ala
                365                 370                 375
Gly Phe Gln Asn Ile Val Asp Ala Tyr Gly Val Gly Ser Tyr Arg
                380                 385                 390
Glu Ile Asn Pro Ala Pro Tyr Thr Ile Ile Thr Phe Pro Phe Leu
                395                 400                 405
Phe Ala Val Met Phe Gly Asp Cys Gly His Gly Thr Val Met Leu
                410                 415                 420
Leu Ala Ala Leu Trp Met Ile Leu Asn Glu Arg Arg Leu Leu Ser
                425                 430                 435
Gln Lys Thr Asp Asn Glu Ile Trp Asn Thr Phe Phe His Gly Arg
                440                 445                 450
Tyr Leu Ile Leu Leu Met Gly Ile Phe Ser Ile Tyr Thr Gly Leu
                455                 460                 465
Ile Tyr Asn Asp Cys Phe Ser Lys Ser Leu Asn Ile Phe Gly Ser
                470                 475                 480
Ser Trp Ser Val Gln Pro Met Phe Arg Asn Gly Thr Trp Asn Thr
                485                 490                 495
His Val Met Glu Glu Ser Leu Tyr Leu Gln Leu Asp Pro Ala Ile
                500                 505                 510
Pro Gly Val Tyr Phe Gly Asn Pro Tyr Pro Phe Gly Ile Asp Pro
                515                 520                 525
Ile Trp Asn Leu Ala Ser Asn Lys Leu Thr Phe Leu Asn Ser Tyr
                530                 535                 540
Lys Met Lys Met Ser Val Ile Leu Gly Ile Val Gln Met Val Phe
                545                 550                 555
Gly Val Ile Leu Ser Leu Phe Asn His Ile Tyr Phe Arg Arg Thr
                560                 565                 570
Leu Asn Ile Ile Leu Gln Phe Ile Pro Glu Met Ile Phe Ile Leu
                575                 580                 585
Cys Leu Phe Gly Tyr Leu Val Phe Met Ile Ile Phe Lys Trp Cys
                590                 595                 600
```

```
Cys Phe Asp Val His Val Ser Gln His Ala Pro Ser Ile Leu Ile
                605                 610                 615
His Phe Ile Asn Met Phe Leu Phe Asn Tyr Ser Asp Ser Ser Asn
                620                 625                 630
Ala Pro Leu Tyr Lys His Gln Gln Glu Val Gln Ser Phe Phe Val
                635                 640                 645
Val Met Ala Leu Ile Ser Val Pro Trp Met Leu Leu Ile Lys Pro
                650                 655                 660
Phe Ile Leu Arg Ala Ser His Arg Lys Ser Gln Leu Gln Ala Ser
                665                 670                 675
Arg Ile Gln Glu Asp Ala Thr Glu Asn Ile Glu Gly Asp Ser Ser
                680                 685                 690
Ser Pro Ser Ser Arg Ser Gly Gln Arg Thr Ser Ala Asp Thr His
                695                 700                 705
Gly Ala Leu Asp Asp His Gly Glu Glu Phe Asn Phe Gly Asp Val
                710                 715                 720
Phe Val His Gln Ala Ile His Thr Ile Glu Tyr Cys Leu Gly Cys
                725                 730                 735
Ile Ser Asn Thr Ala Ser Tyr Leu Arg Leu Trp Ala Leu Ser Leu
                740                 745                 750
Ala His Ala Gln Leu Ser Glu Val Leu Trp Thr Met Val Met Asn
                755                 760                 765
Ser Gly Leu Gln Thr Arg Gly Trp Gly Gly Ile Val Gly Val Phe
                770                 775                 780
Ile Ile Phe Ala Val Phe Ala Val Leu Thr Val Ala Ile Leu Leu
                785                 790                 795
Ile Met Glu Gly Leu Ser Ala Phe Leu His Ala Leu Arg Leu His
                800                 805                 810
Trp Val Glu Phe Gln Asn Lys Phe Tyr Val Gly Asp Gly Tyr Lys
                815                 820                 825
Phe Ser Pro Phe Ser Phe Lys His Ile Leu Asp Gly Thr Ala Glu
                830                 835                 840
Glu
```

<210> 21
<211> 253
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3715961CD1

```
<400> 21
Met Ser Glu Cys Pro Leu Ile Leu Tyr Ile His Lys His Ile Asp
  1                 5                  10                  15
Thr Tyr Ser Gln Ser Tyr Leu Phe Asn Asp Leu Phe Tyr Pro Val
                 20                  25                  30
Tyr Ser Gly Gly Arg Met Val Thr Tyr Glu His Leu Arg Glu Val
                 35                  40                  45
Val Phe Gly Lys Ser Glu Asp Glu His Tyr Pro Leu Trp Lys Ser
                 50                  55                  60
Val Ile Gly Gly Met Met Ala Gly Val Ile Gly Gln Phe Leu Ala
                 65                  70                  75
Asn Pro Thr Asp Leu Val Lys Val Gln Met Gln Met Glu Gly Lys
                 80                  85                  90
Arg Lys Leu Glu Gly Lys Pro Leu Arg Phe Arg Gly Val His His
                 95                 100                 105
Ala Phe Ala Lys Ile Leu Ala Glu Gly Gly Ile Arg Gly Leu Trp
                110                 115                 120
Ala Gly Trp Val Pro Asn Ile Gln Arg Ala Ala Leu Val Asn Met
                125                 130                 135
Gly Asp Leu Thr Thr Tyr Asp Thr Val Lys His Tyr Leu Val Leu
                140                 145                 150
Asn Thr Pro Leu Glu Asp Asn Ile Met Thr His Gly Leu Ser Ser
                155                 160                 165
Leu Cys Ser Gly Leu Val Ala Ser Ile Leu Gly Thr Pro Ala Asp
                170                 175                 180
```

Val Ile Lys Ser Arg Ile Met Asn Gln Pro Arg Asp Lys Gln Gly
185 190 195
Arg Gly Leu Leu Tyr Lys Ser Ser Thr Asp Cys Leu Ile Gln Ala
200 205 210
Val Gln Gly Glu Gly Phe Met Ser Leu Tyr Lys Gly Phe Leu Pro
215 220 225
Ser Trp Leu Arg Met Thr Pro Trp Ser Met Val Phe Trp Leu Thr
230 235 240
Tyr Glu Lys Ile Arg Glu Met Ser Gly Val Ser Pro Phe
245 250

<210> 22
<211> 229
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5108194CD1

<400> 22
Met Gly Asn Gly Val Lys Glu Gly Pro Val Arg Leu His Glu Asp
1 5 10 15
Ala Glu Ala Val Leu Ser Ser Ser Val Ser Ser Lys Arg Asp His
20 25 30
Arg Gln Val Leu Ser Ser Leu Leu Ser Gly Ala Leu Ala Gly Ala
35 40 45
Leu Ala Lys Thr Ala Val Ala Pro Leu Asp Arg Thr Lys Ile Ile
50 55 60
Phe Gln Val Ser Ser Lys Arg Phe Ser Ala Lys Glu Ala Phe Arg
65 70 75
Val Leu Tyr Tyr Thr Tyr Leu Asn Glu Gly Phe Leu Ser Leu Trp
80 85 90
Arg Gly Asn Ser Ala Thr Met Val Arg Val Val Pro Tyr Ala Ala
95 100 105
Ile Gln Phe Ser Ala His Glu Glu Tyr Lys Arg Ile Leu Gly Ser
110 115 120
Tyr Tyr Gly Phe Arg Gly Glu Ala Leu Pro Pro Trp Pro Arg Leu
125 130 135
Phe Ala Gly Ala Leu Ala Gly Thr Thr Ala Ala Ser Leu Thr Tyr
140 145 150
Pro Leu Asp Leu Val Arg Ala Arg Met Ala Val Thr Pro Lys Glu
155 160 165
Met Tyr Ser Asn Ile Phe His Val Phe Ile Arg Ile Ser Arg Glu
170 175 180
Glu Gly Leu Lys Thr Leu Tyr His Gly Phe Met Pro Thr Val Leu
185 190 195
Gly Val Ile Pro Tyr Ala Gly Leu Ser Phe Phe Thr Tyr Glu Thr
200 205 210
Leu Lys Ser Leu His Arg Glu Tyr Ser Gly Arg Lys Leu Ile Pro
215 220 225
Phe Ser Glu Gly

<210> 23
<211> 170
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5503122CD1

<400> 23
Met Tyr Asp Asn Leu Tyr Leu His Gly Ile Glu Asp Ser Glu Ala
1 5 10 15
Gly Ser Ala Asp Ser Tyr Thr Ser Arg Pro Ser Asp Ser Asp Val
20 25 30
Ser Leu Glu Glu Asp Arg Glu Ala Ile Arg Gln Glu Arg Glu Gln
35 40 45

```
Gln Ala Ala Ile Gln Leu Glu Arg Ala Lys Ser Lys Pro Val Ala
                50                  55                  60
Phe Ala Val Lys Thr Asn Val Ser Tyr Cys Gly Ala Leu Asp Glu
                65                  70                  75
Asp Val Pro Val Pro Ser Thr Ala Ile Ser Phe Asp Ala Lys Asp
                80                  85                  90
Phe Leu His Ile Lys Glu Lys Tyr Asn Asn Asp Trp Trp Ile Gly
                95                 100                 105
Arg Leu Val Lys Glu Gly Cys Glu Ile Gly Phe Ile Pro Ser Pro
               110                 115                 120
Leu Arg Leu Glu Asn Ile Arg Ile Gln Gln Glu Gln Lys Arg Gly
               125                 130                 135
Arg Phe His Gly Gly Lys Ser Ser Gly Asn Ser Ser Ser Ser Leu
               140                 145                 150
Gly Glu Met Val Ser Gly Thr Phe Arg Ala Thr Pro Thr Ser Thr
               155                 160                 165
Gly Glu Gly Cys Ser
               170
```

<210> 24
<211> 655
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5517972CD1

```
<400> 24
Met Ser Ser Ser Asn Val Glu Val Phe Ile Pro Val Ser Gln Gly
  1               5                  10                  15
Asn Thr Asn Gly Phe Pro Ala Thr Ala Ser Asn Asp Leu Lys Ala
             20                  25                  30
Phe Thr Glu Gly Ala Val Leu Ser Phe His Asn Ile Cys Tyr Arg
             35                  40                  45
Val Lys Leu Lys Ser Gly Phe Leu Pro Cys Arg Lys Pro Val Glu
             50                  55                  60
Lys Glu Ile Leu Ser Asn Ile Asn Gly Ile Met Lys Pro Gly Leu
             65                  70                  75
Asn Ala Ile Leu Gly Pro Thr Gly Gly Gly Lys Ser Ser Leu Leu
             80                  85                  90
Asp Val Leu Ala Ala Arg Lys Asp Pro Ser Gly Leu Ser Gly Asp
             95                 100                 105
Val Leu Ile Asn Gly Ala Pro Arg Pro Ala Asn Phe Lys Cys Asn
            110                 115                 120
Ser Gly Tyr Val Val Gln Asp Asp Val Val Met Gly Thr Leu Thr
            125                 130                 135
Val Arg Glu Asn Leu Gln Phe Ser Ala Ala Leu Arg Leu Ala Thr
            140                 145                 150
Thr Met Thr Asn His Glu Lys Asn Glu Arg Ile Asn Arg Val Ile
            155                 160                 165
Gln Glu Leu Gly Leu Asp Lys Val Ala Asp Ser Lys Val Gly Thr
            170                 175                 180
Gln Phe Ile Arg Gly Val Ser Gly Gly Glu Arg Lys Arg Thr Ser
            185                 190                 195
Ile Gly Met Glu Leu Ile Thr Asp Pro Ser Ile Leu Phe Leu Asp
            200                 205                 210
Glu Pro Thr Thr Gly Leu Asp Ser Ser Thr Ala Asn Ala Val Leu
            215                 220                 225
Leu Leu Leu Lys Arg Met Ser Lys Gln Gly Arg Thr Ile Ile Phe
            230                 235                 240
Ser Ile His Gln Pro Arg Tyr Ser Ile Phe Lys Leu Phe Asp Ser
            245                 250                 255
Leu Thr Leu Leu Ala Ser Gly Arg Leu Met Phe His Gly Pro Ala
            260                 265                 270
Gln Glu Ala Leu Gly Tyr Phe Glu Ser Ala Gly Tyr His Cys Glu
            275                 280                 285
Ala Tyr Asn Asn Pro Ala Asp Phe Phe Leu Asp Ile Ile Asn Gly
            290                 295                 300
```

```
Asp Ser Thr Ala Val Ala Leu Asn Arg Glu Glu Asp Phe Lys Ala
                305                 310                 315
Thr Glu Ile Ile Glu Pro Ser Lys Gln Asp Lys Pro Leu Ile Glu
                320                 325                 330
Lys Leu Ala Glu Ile Tyr Val Asn Ser Ser Phe Tyr Lys Glu Thr
                335                 340                 345
Lys Ala Glu Leu His Gln Leu Ser Gly Gly Glu Lys Lys Lys Lys
                350                 355                 360
Ile Thr Val Phe Lys Glu Ile Ser Tyr Thr Thr Ser Phe Cys His
                365                 370                 375
Gln Leu Arg Trp Val Ser Lys Arg Ser Phe Lys Asn Leu Leu Gly
                380                 385                 390
Asn Pro Gln Ala Ser Ile Ala Gln Ile Ile Val Thr Val Val Leu
                395                 400                 405
Gly Leu Val Ile Gly Ala Ile Tyr Phe Gly Leu Lys Asn Asp Ser
                410                 415                 420
Thr Gly Ile Gln Asn Arg Ala Gly Val Leu Phe Phe Leu Thr Thr
                425                 430                 435
Asn Gln Cys Phe Ser Ser Val Ser Ala Val Glu Leu Phe Val Val
                440                 445                 450
Glu Lys Lys Leu Phe Ile His Glu Tyr Ile Ser Gly Tyr Tyr Arg
                455                 460                 465
Val Ser Ser Tyr Phe Leu Gly Lys Leu Leu Ser Asp Leu Leu Pro
                470                 475                 480
Met Arg Met Leu Pro Ser Ile Ile Phe Thr Cys Ile Val Tyr Phe
                485                 490                 495
Met Leu Gly Leu Lys Pro Lys Ala Asp Ala Phe Phe Val Met Met
                500                 505                 510
Phe Thr Leu Met Met Val Ala Tyr Ser Ala Ser Ser Met Ala Leu
                515                 520                 525
Ala Ile Ala Ala Gly Gln Ser Val Val Ser Val Ala Thr Leu Leu
                530                 535                 540
Met Thr Ile Cys Phe Val Phe Met Met Ile Phe Ser Gly Leu Leu
                545                 550                 555
Val Asn Leu Thr Thr Ile Ala Ser Trp Leu Ser Trp Leu Gln Tyr
                560                 565                 570
Phe Ser Ile Pro Arg Tyr Gly Phe Thr Ala Leu Gln His Asn Glu
                575                 580                 585
Phe Leu Gly Gln Asn Phe Cys Pro Gly Leu Asn Ala Thr Gly Asn
                590                 595                 600
Asn Pro Cys Asn Tyr Ala Thr Cys Thr Gly Glu Glu Tyr Leu Val
                605                 610                 615
Lys Gln Gly Ile Asp Leu Ser Pro Trp Gly Leu Trp Lys Asn His
                620                 625                 630
Val Ala Leu Ala Cys Met Ile Val Ile Phe Leu Thr Ile Ala Tyr
                635                 640                 645
Leu Lys Leu Leu Phe Leu Lys Lys Tyr Ser
                650                 655
<210> 25
<211> 184
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5593114CD1

<400> 25
Met Trp Val Phe Gly Tyr Gly Ser Leu Ile Trp Lys Val Asp Phe
  1               5                  10                  15
Pro Tyr Gln Asp Lys Leu Val Gly Tyr Ile Thr Asn Tyr Ser Arg
                20                  25                  30
Arg Phe Trp Gln Gly Ser Thr Asp His Arg Gly Val Pro Gly Lys
                35                  40                  45
Pro Gly Arg Val Val Thr Leu Val Glu Asp Pro Ala Gly Cys Val
                50                  55                  60
Trp Gly Val Ala Tyr Arg Leu Pro Val Gly Lys Glu Glu Glu Val
                65                  70                  75
```

```
Lys Ala Tyr Leu Asp Phe Arg Glu Lys Gly Gly Tyr Arg Thr Thr
                80                  85                  90
Thr Val Ile Phe Tyr Pro Lys Asp Pro Thr Thr Lys Pro Phe Ser
                95                 100                 105
Val Leu Leu Tyr Ile Gly Thr Cys Asp Asn Pro Asp Tyr Leu Gly
               110                 115                 120
Pro Ala Pro Leu Glu Asp Ile Ala Glu Gln Ile Phe Asn Ala Ala
               125                 130                 135
Gly Pro Ser Gly Arg Asn Thr Glu Tyr Leu Phe Glu Leu Ala Asn
               140                 145                 150
Ser Ile Arg Asn Leu Val Pro Glu Glu Ala Asp Glu His Leu Phe
               155                 160                 165
Ala Leu Glu Lys Leu Val Lys Glu Arg Leu Glu Gly Lys Gln Asn
               170                 175                 180
Leu Asn Cys Ile
```

<210> 26
<211> 154
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 044775CD1

```
<400> 26
Met Gly Ala Phe Glu Cys Val Arg Lys Val Tyr Gln Thr Asp Gly
  1                5                  10                  15
Leu Lys Gly Phe Tyr Arg Gly Met Ser Ala Ser Tyr Ala Gly Ile
             20                  25                  30
Ser Glu Thr Val Ile His Phe Val Ile Tyr Glu Ser Ile Lys Gln
             35                  40                  45
Lys Leu Leu Glu Tyr Lys Thr Ala Ser Thr Met Glu Asn Asp Glu
             50                  55                  60
Glu Ser Val Lys Glu Ala Ser Asp Phe Val Gly Met Met Leu Ala
             65                  70                  75
Ala Ala Thr Ser Lys Thr Cys Ala Thr Thr Ile Ala Tyr Pro His
             80                  85                  90
Glu Val Val Arg Thr Arg Leu Arg Glu Glu Gly Thr Lys Tyr Arg
             95                 100                 105
Ser Phe Phe Gln Thr Leu Ser Leu Leu Val Gln Glu Glu Gly Tyr
            110                 115                 120
Gly Ser Leu Tyr Arg Gly Leu Thr Thr His Leu Val Arg Gln Ile
            125                 130                 135
Pro Asn Thr Ala Ile Met Met Ala Thr Tyr Glu Leu Val Val Tyr
            140                 145                 150
Leu Leu Asn Gly
```

<210> 27
<211> 438
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 116588CD1

```
<400> 27
Met Leu Leu Val Thr Pro Arg Pro Glu Arg Gly Gly Arg Gly Thr
  1                5                  10                  15
Glu Leu Gly Glu Phe Cys Gly Thr Pro Leu Leu Phe Ser Ser Tyr
             20                  25                  30
Phe Cys Tyr Asp Asn Pro Ala Ala Leu Gln Thr Gln Val Lys Arg
             35                  40                  45
Asp Met Gln Val Asn Thr Thr Lys Phe Met Leu Leu Tyr Ala Trp
             50                  55                  60
Tyr Ser Trp Pro Asn Val Val Leu Cys Phe Phe Gly Gly Phe Leu
             65                  70                  75
```

```
Ile Asp Arg Val Phe Gly Ile Arg Trp Gly Thr Ile Ile Phe Ser
                80                  85                  90
Cys Phe Val Cys Ile Gly Gln Val Val Phe Ala Leu Gly Gly Ile
                95                 100                 105
Phe Asn Ala Phe Trp Leu Met Glu Phe Gly Arg Phe Val Phe Gly
               110                 115                 120
Ile Gly Gly Glu Ser Leu Ala Val Ala Gln Asn Thr Tyr Ala Val
               125                 130                 135
Ser Trp Phe Lys Gly Lys Glu Leu Asn Leu Val Phe Gly Leu Gln
               140                 145                 150
Leu Ser Met Ala Arg Ile Gly Ser Thr Val Asn Met Asn Leu Met
               155                 160                 165
Gly Trp Leu Tyr Ser Lys Ile Glu Ala Leu Leu Gly Ser Ala Gly
               170                 175                 180
His Thr Thr Leu Gly Ile Thr Leu Met Ile Gly Gly Val Thr Cys
               185                 190                 195
Ile Leu Ser Leu Ile Cys Ala Leu Ala Leu Ala Tyr Leu Asp Gln
               200                 205                 210
Arg Ala Glu Arg Ile Leu His Lys Glu Gln Gly Lys Thr Gly Glu
               215                 220                 225
Val Ile Lys Leu Thr Asp Val Lys Asp Phe Ser Leu Pro Leu Trp
               230                 235                 240
Leu Ile Phe Ile Ile Cys Val Cys Tyr Tyr Val Ala Val Phe Pro
               245                 250                 255
Phe Ile Gly Leu Gly Lys Val Phe Phe Thr Glu Lys Phe Gly Phe
               260                 265                 270
Ser Ser Gln Ala Ala Ser Ala Ile Asn Ser Val Val Tyr Val Ile
               275                 280                 285
Ser Ala Pro Met Ser Pro Val Phe Gly Leu Leu Val Asp Lys Thr
               290                 295                 300
Gly Lys Asn Ile Ile Trp Val Leu Cys Ala Val Ala Ala Thr Leu
               305                 310                 315
Val Ser His Met Met Leu Ala Phe Thr Met Trp Asn Pro Trp Ile
               320                 325                 330
Ala Met Cys Leu Leu Gly Leu Ser Tyr Ser Leu Leu Ala Cys Ala
               335                 340                 345
Leu Trp Pro Met Val Ala Phe Val Val Pro Glu His Gln Leu Gly
               350                 355                 360
Thr Ala Tyr Gly Phe Met Gln Ser Ile Gln Asn Leu Gly Leu Ala
               365                 370                 375
Ile Ile Ser Ile Ile Ala Gly Met Ile Leu Asp Ser Arg Gly Tyr
               380                 385                 390
Leu Phe Leu Glu Val Phe Phe Ile Ala Cys Val Ser Leu Ser Leu
               395                 400                 405
Leu Ser Val Val Leu Leu Tyr Leu Val Asn Arg Ala Gln Gly Gly
               410                 415                 420
Asn Leu Asn Tyr Ser Ala Arg Gln Arg Glu Glu Ile Lys Phe Ser
               425                 430                 435
His Thr Glu
```

<210> 28
<211> 237
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 875369CD1

<400> 28

```
Met Ala His Val Gly Ser Arg Lys Arg Ser Arg Ser Arg Ser Arg
  1               5                  10                  15
Ser Arg Gly Arg Gly Ser Glu Lys Arg Lys Lys Lys Ser Arg Lys
             20                  25                  30
Asp Thr Ser Arg Asn Cys Ser Ala Ser Thr Ser Gln Gly Arg Lys
         35                  40                  45
Ala Ser Thr Ala Pro Gly Ala Glu Ala Ser Pro Ser Pro Cys Ile
     50                  55                  60
```

```
Thr Glu Arg Ser Lys Gln Lys Ala Arg Arg Arg Thr Arg Ser Ser
                65                  70                  75
Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser
                80                  85                  90
Ser Ser Ser Ser Ser Ser Ser Ser Asp Gly Arg Lys Lys Arg Gly
                95                 100                 105
Lys Tyr Lys Asp Lys Arg Arg Lys Lys Lys Lys Arg Lys Lys Lys
               110                 115                 120
Leu Lys Lys Lys Gly Lys Glu Lys Ala Glu Ala Gln Gln Val Glu
               125                 130                 135
Ala Leu Pro Gly Pro Ser Leu Asp Gln Trp His Arg Ser Ala Gly
               140                 145                 150
Glu Glu Glu Asp Gly Pro Val Leu Thr Asp Glu Gln Lys Ser Arg
               155                 160                 165
Ile Gln Ala Met Lys Pro Met Thr Lys Glu Glu Trp Asp Ala Arg
               170                 175                 180
Gln Ser Ile Ile Arg Lys Val Val Asp Pro Glu Thr Gly Arg Thr
               185                 190                 195
Arg Leu Ile Lys Gly Asp Gly Glu Val Leu Glu Glu Ile Val Thr
               200                 205                 210
Lys Glu Arg His Arg Glu Ile Asn Lys Gln Ala Thr Arg Gly Asp
               215                 220                 225
Cys Leu Ala Phe Gln Met Arg Ala Gly Leu Leu Pro
               230                 235
<210> 29
<211> 219
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1325518CD1

<400> 29
Met Lys Leu Leu Leu Trp Ala Cys Ile Val Cys Val Ala Phe Ala
  1               5                  10                  15
Arg Lys Arg Arg Phe Pro Phe Ile Gly Glu Asp Asp Asn Asp Asp
             20                  25                  30
Gly His Pro Leu His Pro Ser Leu Asn Ile Pro Tyr Gly Ile Arg
             35                  40                  45
Asn Leu Pro Pro Pro Leu Tyr Tyr Arg Pro Val Asn Thr Val Pro
             50                  55                  60
Ser Tyr Pro Gly Asn Thr Tyr Thr Asp Thr Gly Leu Pro Ser Tyr
             65                  70                  75
Pro Trp Ile Leu Thr Ser Pro Gly Phe Pro Tyr Val Tyr His Ile
             80                  85                  90
Arg Gly Phe Pro Leu Ala Thr Gln Leu Asn Val Pro Pro Leu Pro
             95                 100                 105
Pro Arg Gly Phe Pro Phe Val Pro Pro Ser Arg Phe Phe Ser Ala
            110                 115                 120
Ala Ala Ala Pro Ala Ala Pro Pro Ile Ala Ala Glu Pro Ala Ala
            125                 130                 135
Ala Ala Pro Leu Thr Ala Thr Pro Val Ala Ala Glu Pro Ala Ala
            140                 145                 150
Gly Ala Pro Val Ala Ala Glu Pro Ala Ala Glu Ala Pro Val Gly
            155                 160                 165
Ala Glu Pro Ala Ala Glu Ala Pro Val Ala Ala Glu Pro Ala Ala
            170                 175                 180
Glu Ala Pro Val Gly Val Glu Pro Ala Ala Glu Glu Pro Ser Pro
            185                 190                 195
Ala Glu Pro Ala Thr Ala Lys Pro Ala Ala Pro Glu Pro His Pro
            200                 205                 210
Ser Pro Ser Leu Glu Gln Ala Asn Gln
            215
<210> 30
<211> 707
<212> PRT
<213> Homo sapiens
```

<220>
<221> misc_feature
<223> Incyte ID No: 2060987CD1

<400> 30
Met Ala Ala Ala Ala Thr Ala Ala Glu Gly Val Pro Ser Arg Gly
1 5 10 15
Pro Pro Gly Glu Val Ile His Leu Asn Val Gly Gly Lys Arg Phe
20 25 30
Ser Thr Ser Arg Gln Thr Leu Thr Trp Ile Pro Asp Ser Phe Phe
35 40 45
Ser Ser Leu Leu Ser Gly Arg Ile Ser Thr Leu Lys Asp Glu Thr
50 55 60
Gly Ala Ile Phe Ile Asp Arg Asp Pro Thr Val Phe Ala Pro Ile
65 70 75
Leu Asn Phe Leu Arg Thr Lys Glu Leu Asp Pro Arg Gly Val His
80 85 90
Gly Ser Ser Leu Leu His Glu Ala Gln Phe Tyr Gly Leu Thr Pro
95 100 105
Leu Val Arg Arg Leu Gln Leu Arg Glu Glu Leu Asp Arg Ser Ser
110 115 120
Cys Gly Asn Val Leu Phe Asn Gly Tyr Leu Pro Pro Pro Val Phe
125 130 135
Pro Val Lys Arg Arg Asn Arg His Ser Leu Val Gly Pro Gln Gln
140 145 150
Leu Gly Gly Arg Pro Ala Pro Val Arg Arg Ser Asn Thr Met Pro
155 160 165
Pro Asn Leu Gly Asn Ala Gly Leu Leu Gly Arg Met Leu Asp Glu
170 175 180
Lys Thr Pro Pro Ser Pro Ser Gly Gln Pro Glu Glu Pro Gly Met
185 190 195
Val Arg Leu Val Cys Gly His His Asn Trp Ile Ala Val Ala Tyr
200 205 210
Thr Gln Phe Leu Val Cys Tyr Arg Leu Lys Glu Ala Ser Gly Trp
215 220 225
Gln Leu Val Phe Ser Ser Pro Arg Leu Asp Trp Pro Ile Glu Arg
230 235 240
Leu Ala Leu Thr Ala Arg Val His Gly Gly Gly Ala Leu Gly Glu His
245 250 255
Asp Lys Met Val Ala Ala Ala Thr Gly Ser Glu Ile Leu Leu Trp
260 265 270
Ala Leu Gln Ala Glu Gly Gly Gly Ser Glu Ile Gly Val Phe His
275 280 285
Leu Gly Val Pro Val Glu Ala Leu Phe Phe Val Gly Asn Gln Leu
290 295 300
Ile Ala Thr Ser His Thr Gly Arg Ile Gly Val Trp Asn Ala Val
305 310 315
Thr Lys His Trp Gln Val Gln Glu Val Gln Pro Ile Thr Ser Tyr
320 325 330
Asp Ala Ala Gly Ser Phe Leu Leu Leu Gly Cys Asn Asn Gly Ser
335 340 345
Ile Tyr Tyr Val Asp Val Gln Lys Phe Pro Leu Arg Met Lys Asp
350 355 360
Asn Asp Leu Leu Val Ser Glu Leu Tyr Arg Asp Pro Ala Glu Asp
365 370 375
Gly Val Thr Ala Leu Ser Val Tyr Leu Thr Pro Lys Thr Ser Asp
380 385 390
Ser Gly Asn Trp Ile Glu Ile Ala Tyr Gly Thr Ser Ser Gly Gly
395 400 405
Val Arg Val Ile Val Gln His Pro Glu Thr Val Gly Ser Gly Pro
410 415 420
Gln Leu Phe Gln Thr Phe Thr Val His Arg Ser Pro Val Thr Lys
425 430 435
Ile Met Leu Ser Glu Lys His Leu Ile Ser Val Cys Ala Asp Asn
440 445 450
Asn His Val Arg Thr Trp Ser Val Thr Arg Phe Arg Gly Met Ile
455 460 465
Ser Thr Gln Pro Gly Ser Thr Pro Leu Ala Ser Phe Lys Ile Leu

```
                  470                 475                 480
Ala Leu Glu Ser Ala Asp Gly His Gly Gly Cys Ser Ala Gly Asn
                  485                 490                 495
Asp Ile Gly Pro Tyr Gly Glu Arg Asp Asp Gln Gln Val Phe Ile
                  500                 505                 510
Gln Lys Val Val Pro Ser Ala Ser Gln Leu Phe Val Arg Leu Ser
                  515                 520                 525
Ser Thr Gly Gln Arg Val Cys Ser Val Arg Ser Val Asp Gly Ser
                  530                 535                 540
Pro Thr Thr Ala Phe Thr Val Leu Glu Cys Glu Gly Ser Arg Arg
                  545                 550                 555
Leu Gly Ser Arg Pro Arg Arg Tyr Leu Leu Thr Gly Gln Ala Asn
                  560                 565                 570
Gly Ser Leu Ala Met Trp Asp Leu Thr Thr Ala Met Asp Gly Leu
                  575                 580                 585
Gly Gln Ala Pro Ala Gly Gly Leu Thr Glu Gln Glu Leu Met Glu
                  590                 595                 600
Gln Leu Glu His Cys Glu Leu Ala Pro Pro Ala Pro Ser Ala Pro
                  605                 610                 615
Ser Trp Gly Cys Leu Pro Ser Pro Ser Pro Arg Ile Ser Leu Thr
                  620                 625                 630
Ser Leu His Ser Ala Ser Ser Asn Thr Ser Leu Ser Gly His Arg
                  635                 640                 645
Gly Ser Pro Ser Pro Pro Gln Ala Glu Ala Arg Arg Arg Gly Gly
                  650                 655                 660
Gly Ser Phe Val Glu Arg Cys Gln Glu Leu Val Arg Ser Gly Pro
                  665                 670                 675
Asp Leu Arg Arg Pro Pro Thr Pro Ala Pro Trp Pro Ser Ser Gly
                  680                 685                 690
Leu Gly Thr Pro Leu Thr Pro Pro Lys Met Lys Leu Asn Glu Thr
                  695                 700                 705
Ser Phe
```

<210> 31
<211> 279
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2172064CD1

<400> 31

```
Met Cys Gly Arg Phe Leu Arg Arg Leu Leu Ala Glu Glu Ser Arg
  1                 5                  10                  15
Arg Ser Thr Pro Val Gly Arg Leu Leu Leu Pro Val Leu Leu Gly
                 20                  25                  30
Phe Arg Leu Val Leu Leu Ala Ala Ser Gly Pro Gly Val Tyr Gly
                 35                  40                  45
Asp Glu Gln Ser Glu Phe Val Cys His Thr Gln Gln Pro Gly Cys
                 50                  55                  60
Lys Ala Ala Cys Phe Asp Ala Phe His Pro Leu Ser Pro Leu Arg
                 65                  70                  75
Ser Trp Val Phe Gln Val Ile Leu Val Ala Val Pro Ser Ala Leu
                 80                  85                  90
Tyr Met Gly Phe Thr Leu Tyr His Val Ile Trp His Trp Glu Leu
                 95                 100                 105
Ser Gly Lys Gly Lys Glu Glu Glu Thr Leu Ile Gln Gly Arg Glu
                110                 115                 120
Gly Asn Thr Asp Val Pro Gly Ala Gly Ser Leu Arg Leu Leu Trp
                125                 130                 135
Ala Tyr Val Ala Gln Leu Gly Ala Arg Leu Val Leu Glu Gly Ala
                140                 145                 150
Ala Leu Gly Leu Gln Tyr His Leu Tyr Gly Phe Gln Met Pro Ser
                155                 160                 165
Ser Phe Ala Cys Arg Arg Glu Pro Cys Leu Gly Ser Ile Thr Cys
                170                 175                 180
Asn Leu Ser Arg Pro Ser Glu Lys Thr Ile Phe Leu Lys Thr Met
```

```
                185                 190                 195
Phe Gly Val Ser Gly Phe Cys Leu Leu Phe Thr Phe Leu Glu Leu
                200                 205                 210
Val Leu Leu Gly Leu Gly Arg Trp Trp Arg Thr Trp Lys His Lys
                215                 220                 225
Ser Ser Ser Ser Lys Tyr Phe Leu Thr Ser Glu Ser Thr Arg Arg
                230                 235                 240
His Lys Lys Ala Thr Asp Ser Leu Pro Val Val Glu Thr Lys Glu
                245                 250                 255
Gln Phe Gln Glu Ala Val Pro Gly Arg Ser Leu Ala Gln Glu Lys
                260                 265                 270
Gln Arg Pro Val Gly Pro Arg Asp Ala
                275
```

<210> 32
<211> 154
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2219267CD1

```
<400> 32
Met Val Thr Gly Leu Ala Ser Leu Leu Leu Leu Ala Gly Ala Gln
  1               5                  10                  15
Tyr Leu Pro Gly Trp Thr Val Leu Phe Leu Ser Val Leu Gly Leu
             20                  25                  30
Leu Ala Ser Arg Ala Val Ser Ala Leu Ser Ser Leu Phe Ala Ala
             35                  40                  45
Glu Val Phe Pro Thr Val Ile Arg Gly Ala Gly Leu Gly Leu Val
             50                  55                  60
Leu Gly Ala Gly Phe Leu Gly Gln Ala Ala Gly Pro Leu Asp Thr
             65                  70                  75
Leu His Gly Arg Gln Gly Phe Phe Leu Gln Gln Val Val Phe Ala
             80                  85                  90
Ser Leu Ala Val Leu Ala Leu Leu Cys Val Leu Leu Leu Pro Glu
             95                 100                 105
Ser Arg Ser Arg Gly Leu Pro Gln Ser Leu Gln Asp Ala Asp Arg
            110                 115                 120
Leu Arg Arg Ser Pro Leu Leu Arg Gly Arg Pro Arg Gln Asp His
            125                 130                 135
Leu Pro Leu Leu Pro Pro Ser Asn Ser Tyr Trp Ala Gly His Thr
            140                 145                 150
Pro Glu Gln His
```

<210> 33
<211> 289
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2308629CD1

```
<400> 33
Met Val Ala Gly Ala Val Ala Gly Ile Leu Glu His Cys Val Met
  1               5                  10                  15
Tyr Pro Ile Asp Cys Val Lys Thr Arg Met Gln Ser Leu Gln Pro
             20                  25                  30
Asp Pro Ala Ala Arg Tyr Arg Asn Val Leu Glu Ala Leu Trp Arg
             35                  40                  45
Ile Ile Arg Thr Glu Gly Leu Trp Arg Pro Met Arg Gly Leu Asn
             50                  55                  60
Val Thr Ala Thr Gly Ala Gly Pro Ala His Ala Leu Tyr Phe Ala
             65                  70                  75
Cys Tyr Glu Lys Leu Lys Lys Thr Leu Ser Asp Val Ile His Pro
             80                  85                  90
Gly Gly Asn Ser His Ile Ala Asn Gly Ala Ala Gly Cys Val Ala
```

```
                    95                  100                 105
Thr Leu Leu His Asp Ala Ala Met Asn Pro Ala Glu Val Val Lys
                   110                 115                 120
Gln Arg Met Gln Met Tyr Asn Ser Pro Tyr His Arg Val Thr Asp
                   125                 130                 135
Cys Val Arg Ala Val Trp Gln Asn Glu Gly Ala Gly Ala Phe Tyr
                   140                 145                 150
Arg Ser Tyr Thr Thr Gln Leu Thr Met Asn Val Pro Phe Gln Ala
                   155                 160                 165
Ile His Phe Met Thr Tyr Glu Phe Leu Gln Glu His Phe Asn Pro
                   170                 175                 180
Gln Arg Arg Tyr Asn Pro Ser Ser His Val Leu Ser Gly Ala Cys
                   185                 190                 195
Ala Gly Ala Val Ala Ala Ala Ala Thr Thr Pro Leu Asp Val Cys
                   200                 205                 210
Lys Thr Leu Leu Asn Thr Gln Glu Ser Leu Ala Leu Asn Ser His
                   215                 220                 225
Ile Thr Gly His Ile Thr Gly Met Ala Ser Ala Phe Arg Thr Val
                   230                 235                 240
Tyr Gln Val Gly Gly Val Thr Ala Tyr Phe Arg Gly Val Gln Ala
                   245                 250                 255
Arg Val Ile Tyr Gln Ile Pro Ser Thr Ala Ile Ala Trp Ser Val
                   260                 265                 270
Tyr Glu Phe Phe Lys Tyr Leu Ile Thr Lys Arg Gln Glu Glu Trp
                   275                 280                 285
Arg Ala Gly Lys
```

<210> 34
<211> 300
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2660038CD1

<400> 34

```
Met Asp Phe Leu Met Ser Gly Leu Ala Ala Cys Gly Ala Cys Val
  1                 5                  10                  15
Phe Thr Asn Pro Leu Glu Val Val Lys Thr Arg Met Gln Leu Gln
                  20                  25                  30
Gly Glu Leu Gln Ala Pro Gly Thr Tyr Gln Arg His Tyr Arg Asn
                  35                  40                  45
Val Phe His Ala Phe Ile Thr Ile Gly Lys Val Asp Gly Leu Ala
                  50                  55                  60
Ala Leu Gln Lys Gly Leu Ala Pro Ala Leu Leu Tyr Gln Phe Leu
                  65                  70                  75
Met Asn Gly Ile Arg Leu Gly Thr Tyr Gly Leu Ala Glu Ala Gly
                  80                  85                  90
Gly Tyr Leu His Thr Ala Glu Ala Thr His Ser Pro Ala Arg Ser
                  95                 100                 105
Ala Ala Ala Gly Ala Met Ala Gly Val Met Gly Ala Tyr Leu Gly
                 110                 115                 120
Ser Pro Ile Tyr Met Val Lys Thr His Leu Gln Ala Gln Ala Ala
                 125                 130                 135
Ser Glu Ile Ala Val Gly His Gln Tyr Lys His Gln Gly Met Phe
                 140                 145                 150
Gln Ala Leu Thr Glu Ile Gly Gln Lys His Gly Leu Val Gly Leu
                 155                 160                 165
Trp Arg Gly Ala Leu Gly Gly Leu Pro Arg Val Ile Val Gly Ser
                 170                 175                 180
Ser Thr Gln Leu Cys Thr Phe Ser Ser Thr Lys Asp Leu Leu Ser
                 185                 190                 195
Gln Trp Glu Ile Phe Pro Pro Gln Ser Trp Lys Leu Ala Leu Val
                 200                 205                 210
Ala Ala Met Met Ser Gly Ile Ala Val Val Leu Ala Met Ala Pro
                 215                 220                 225
Phe Asp Val Ala Cys Thr Arg Leu Tyr Asn Gln Pro Thr Asp Ala
```

```
                    230                 235                 240
Gln Gly Lys Gly Leu Met Tyr Arg Gly Ile Leu Asp Ala Leu Leu
                    245                 250                 255
Gln Thr Ala Arg Thr Glu Gly Ile Phe Gly Met Tyr Lys Gly Ile
                    260                 265                 270
Gly Ala Ser Tyr Phe Arg Leu Gly Pro His Thr Ile Leu Ser Leu
                    275                 280                 285
Phe Phe Trp Asp Gln Leu Arg Ser Leu Tyr Tyr Thr Asp Thr Lys
                    290                 295                 300

<210> 35
<211> 382
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2670745CD1

<400> 35
Met Leu Arg Trp Thr Val His Leu Glu Gly Gly Pro Arg Arg Val
  1                 5                  10                  15
Asn His Ala Ala Val Ala Val Gly His Arg Val Tyr Ser Phe Gly
                   20                  25                  30
Gly Tyr Cys Ser Gly Glu Asp Tyr Glu Thr Leu Arg Gln Ile Asp
                   35                  40                  45
Val His Ile Phe Asn Ala Val Ser Leu Arg Trp Thr Lys Leu Pro
                   50                  55                  60
Pro Val Lys Ser Ala Ile Arg Gly Gln Ala Pro Val Val Pro Tyr
                   65                  70                  75
Met Arg Tyr Gly His Ser Thr Val Leu Ile Asp Asp Thr Val Leu
                   80                  85                  90
Leu Trp Gly Gly Arg Asn Asp Thr Glu Gly Ala Cys Asn Val Leu
                   95                 100                 105
Tyr Ala Phe Asp Val Asn Thr His Lys Trp Phe Thr Pro Arg Val
                  110                 115                 120
Ser Gly Thr Val Pro Gly Ala Arg Asp Gly His Ser Ala Cys Val
                  125                 130                 135
Leu Gly Lys Ile Met Tyr Ile Phe Gly Gly Tyr Glu Gln Gln Ala
                  140                 145                 150
Asp Cys Phe Ser Asn Asp Ile His Lys Leu Asp Thr Ser Thr Met
                  155                 160                 165
Thr Trp Thr Leu Ile Cys Thr Lys Gly Ser Pro Ala Arg Trp Arg
                  170                 175                 180
Asp Phe His Ser Ala Thr Met Leu Gly Ser His Met Tyr Val Phe
                  185                 190                 195
Gly Gly Arg Ala Asp Arg Phe Gly Pro Phe His Ser Asn Asn Glu
                  200                 205                 210
Ile Tyr Cys Asn Arg Ile Arg Val Phe Asp Thr Arg Thr Glu Ala
                  215                 220                 225
Trp Leu Asp Cys Pro Pro Thr Pro Val Leu Pro Glu Gly Arg Arg
                  230                 235                 240
Ser His Ser Ala Phe Gly Tyr Asn Gly Glu Leu Tyr Ile Phe Gly
                  245                 250                 255
Gly Tyr Asn Ala Arg Leu Asn Arg His Phe His Asp Leu Trp Lys
                  260                 265                 270
Phe Asn Pro Val Ser Phe Thr Trp Lys Lys Ile Glu Pro Lys Gly
                  275                 280                 285
Lys Gly Pro Cys Pro Arg Arg Arg Gln Cys Cys Cys Ile Val Gly
                  290                 295                 300
Asp Lys Ile Val Leu Phe Gly Gly Thr Ser Pro Ser Pro Glu Glu
                  305                 310                 315
Gly Leu Gly Asp Glu Phe Asp Leu Ile Asp His Ser Asp Leu His
                  320                 325                 330
Ile Leu Asp Phe Ser Pro Ser Leu Lys Thr Leu Cys Lys Leu Ala
                  335                 340                 345
Val Ile Gln Tyr Asn Leu Asp Gln Ser Cys Leu Pro His Asp Ile
                  350                 355                 360
```

Arg Trp Glu Leu Asn Ala Met Thr Thr Asn Ser Asn Ile Ser Arg
365 370 375
Pro Ile Val Ser Ser His Gly
380

<210> 36
<211> 287
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2676443CD1

<400> 36
Met Ala Ala Glu Ala Arg Val Ser Arg Trp Tyr Phe Gly Gly Leu
1 5 10 15
Ala Ser Cys Gly Ala Ala Cys Cys Thr His Pro Leu Asp Leu Leu
20 25 30
Lys Val His Leu Gln Thr Gln Gln Glu Val Lys Leu Arg Met Thr
35 40 45
Gly Met Ala Leu Arg Val Val Arg Thr Asp Gly Ile Leu Ala Leu
50 55 60
Tyr Ser Gly Leu Ser Ala Ser Leu Cys Arg Gln Met Thr Tyr Ser
65 70 75
Leu Thr Arg Phe Ala Ile Tyr Glu Thr Val Arg Asp Arg Val Ala
80 85 90
Lys Gly Ser Gln Gly Pro Leu Pro Phe His Glu Lys Val Leu Leu
95 100 105
Gly Ser Val Ser Gly Leu Ala Gly Gly Phe Val Gly Thr Pro Ala
110 115 120
Asp Leu Val Asn Val Arg Met Gln Asn Asp Val Lys Leu Pro Gln
125 130 135
Gly Gln Arg Arg Asn Tyr Ala His Ala Leu Asp Gly Leu Tyr Arg
140 145 150
Val Ala Arg Glu Glu Gly Leu Arg Arg Leu Phe Ser Gly Ala Thr
155 160 165
Met Ala Ser Ser Arg Gly Ala Leu Val Thr Val Gly Gln Leu Ser
170 175 180
Cys Tyr Asp Gln Ala Lys Gln Leu Val Leu Ser Thr Gly Tyr Leu
185 190 195
Ser Asp Asn Ile Phe Thr His Phe Val Ala Ser Phe Ile Ala Gly
200 205 210
Gly Cys Ala Thr Phe Leu Cys Gln Pro Leu Asp Val Leu Lys Thr
215 220 225
Arg Leu Met Asn Ser Lys Gly Glu Tyr Gln Gly Val Phe His Cys
230 235 240
Ala Val Glu Thr Ala Lys Leu Gly Pro Leu Ala Phe Tyr Lys Gly
245 250 255
Leu Val Pro Ala Gly Ile Arg Leu Ile Pro His Thr Val Leu Thr
260 265 270
Phe Val Phe Leu Glu Gln Leu Arg Lys Asn Phe Gly Ile Lys Val
275 280 285
Pro Ser

<210> 37
<211> 497
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3295764CD1

<400> 37
Met Asp Val Pro Gly Pro Val Ser Arg Arg Ala Ala Ala Ala Ala
1 5 10 15
Ala Thr Val Leu Leu Arg Thr Ala Arg Val Arg Arg Glu Cys Trp
20 25 30

```
Phe Leu Pro Thr Ala Leu Leu Cys Ala Tyr Gly Phe Phe Ala Ser
                35                  40                  45
Leu Arg Pro Ser Glu Pro Phe Leu Thr Pro Tyr Leu Leu Gly Pro
            50                  55                  60
Asp Lys Asn Leu Thr Glu Arg Glu Val Phe Asn Glu Ile Tyr Pro
        65                  70                  75
Val Trp Thr Tyr Ser Tyr Leu Val Leu Leu Phe Pro Val Phe Leu
                80                  85                  90
Ala Thr Asp Tyr Leu Arg Tyr Lys Pro Val Val Leu Leu Gln Gly
            95                  100                 105
Leu Ser Leu Ile Val Thr Trp Phe Met Leu Leu Tyr Ala Gln Gly
        110                 115                 120
Leu Leu Ala Ile Gln Phe Leu Glu Phe Phe Tyr Gly Ile Ala Thr
    125                 130                 135
Ala Thr Glu Ile Ala Tyr Tyr Ser Tyr Ile Tyr Ser Val Val Asp
    140                 145                 150
Leu Gly Met Tyr Gln Lys Val Thr Ser Tyr Cys Arg Ser Ala Thr
    155                 160                 165
Leu Val Gly Phe Thr Val Gly Ser Val Leu Gly Gln Ile Leu Val
    170                 175                 180
Ser Val Ala Gly Trp Ser Leu Phe Ser Leu Asn Val Ile Ser Leu
    185                 190                 195
Thr Cys Val Ser Val Ala Phe Ala Val Ala Trp Phe Leu Pro Met
    200                 205                 210
Pro Gln Lys Ser Leu Phe Phe His His Ile Pro Ser Thr Cys Gln
    215                 220                 225
Arg Val Asn Gly Ile Lys Val Gln Asn Gly Gly Ile Val Thr Asp
    230                 235                 240
Thr Pro Ala Ser Asn His Leu Pro Gly Trp Glu Asp Ile Glu Ser
    245                 250                 255
Lys Ile Pro Leu Asn Met Glu Glu Pro Pro Val Glu Glu Pro Glu
    260                 265                 270
Pro Lys Pro Asp Arg Leu Leu Val Leu Lys Val Leu Trp Asn Asp
    275                 280                 285
Phe Leu Met Cys Tyr Ser Ser Arg Pro Leu Leu Cys Trp Ser Val
    290                 295                 300
Trp Trp Ala Leu Ser Thr Cys Gly Tyr Phe Gln Val Val Asn Tyr
    305                 310                 315
Thr Gln Gly Leu Trp Glu Lys Val Met Pro Ser Arg Tyr Ala Ala
    320                 325                 330
Ile Tyr Asn Gly Gly Val Glu Ala Val Ser Thr Leu Leu Gly Ala
    335                 340                 345
Val Ala Val Phe Ala Val Gly Tyr Ile Lys Ile Ser Trp Ser Thr
    350                 355                 360
Trp Gly Glu Met Thr Leu Ser Leu Phe Ser Leu Leu Ile Ala Ala
    365                 370                 375
Ala Val Tyr Ile Met Asp Thr Val Gly Asn Ile Trp Val Cys Tyr
    380                 385                 390
Ala Ser Tyr Val Val Phe Arg Ile Ile Tyr Met Leu Leu Ile Thr
    395                 400                 405
Ile Ala Thr Phe Gln Ile Ala Ala Asn Leu Ser Met Glu Arg Tyr
    410                 415                 420
Ala Leu Val Phe Gly Val Asn Thr Phe Ile Ala Leu Ala Leu Gln
    425                 430                 435
Thr Leu Leu Thr Leu Ile Val Val Asp Ala Ser Gly Leu Gly Leu
    440                 445                 450
Glu Ile Thr Thr Gln Phe Leu Ile Tyr Ala Ser Tyr Phe Ala Leu
    455                 460                 465
Ile Ala Val Val Phe Leu Ala Ser Gly Ala Val Ser Val Met Lys
    470                 475                 480
Lys Cys Arg Lys Leu Glu Asp Pro Gln Ser Ser Ser Gln Val Thr
    485                 490                 495
Thr Ser
```

<210> 38
<211> 228
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3438320CD1

<400> 38
Met Pro Arg Arg Gly Leu Val Ala Gly Pro Asp Leu Glu Tyr Phe
1 5 10 15
Gln Arg Arg Tyr Phe Thr Pro Ala Glu Val Ala Gln His Asn Arg
20 25 30
Pro Glu Asp Leu Trp Val Ser Tyr Leu Gly Arg Val Tyr Asp Leu
35 40 45
Thr Ser Leu Ala Gln Glu Tyr Lys Gly Asn Leu Leu Leu Lys Pro
50 55 60
Ile Val Glu Val Ala Gly Gln Asp Ile Ser His Trp Phe Asp Pro
65 70 75
Lys Thr Arg Asp Ile Arg Lys His Ile Asp Pro Leu Thr Gly Cys
80 85 90
Leu Arg Tyr Cys Thr Pro Arg Gly Arg Phe Val His Val Pro Pro
95 100 105
Gln Leu Pro Cys Ser Asp Trp Ala Asn Asp Phe Gly Lys Pro Trp
110 115 120
Trp Gln Gly Ser Tyr Tyr Glu Val Gly Arg Leu Ser Ala Lys Thr
125 130 135
Arg Ser Ile Arg Ile Ile Asn Thr Leu Thr Ser Gln Glu His Thr
140 145 150
Leu Glu Val Gly Val Leu Glu Ser Ile Trp Glu Ile Leu His Arg
155 160 165
Tyr Leu Pro Tyr Asn Ser His Ala Ala Ser Tyr Thr Trp Lys Tyr
170 175 180
Glu Gly Lys Asn Leu Asn Met Asp Phe Thr Leu Glu Glu Asn Gly
185 190 195
Ile Arg Asp Glu Glu Glu Glu Phe Asp Tyr Leu Ser Met Asp Gly
200 205 210
Thr Leu His Thr Pro Ala Ile Leu Leu Tyr Phe Asn Asp Asp Leu
215 220 225
Thr Glu Leu

<210> 39
<211> 273
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3986488CD1

<400> 39
Met Ala Ala Thr Ile Met Ile Leu Tyr Val Ser Lys Leu Asn Lys
1 5 10 15
Ile Ile His Phe Pro Asp Phe Asp Lys Lys Ile Pro Val Lys Leu
20 25 30
Phe Pro Leu Pro Leu Leu Tyr Val Gly Asn His Ile Ser Gly Leu
35 40 45
Ser Ser Thr Ser Lys Leu Ser Leu Pro Met Phe Thr Val Leu Arg
50 55 60
Lys Phe Thr Ile Pro Leu Thr Leu Leu Leu Glu Thr Ile Ile Leu
65 70 75
Gly Lys Gln Tyr Ser Leu Asn Ile Ile Leu Ser Val Phe Ala Ile
80 85 90
Ile Leu Gly Ala Phe Ile Ala Ala Gly Ser Asp Leu Ala Phe Asn
95 100 105
Leu Glu Gly Tyr Ile Phe Val Phe Leu Asn Asp Ile Phe Thr Ala
110 115 120
Ala Asn Gly Val Tyr Thr Lys Gln Lys Met Asp Pro Lys Glu Leu
125 130 135
Gly Lys Tyr Gly Val Leu Phe Tyr Asn Ala Cys Phe Met Ile Ile
140 145 150
Pro Thr Leu Ile Ile Ser Val Ser Thr Gly Asp Leu Gln Gln Ala

```
                155                 160                 165
Thr Glu Phe Asn Gln Trp Lys Asn Val Val Phe Ile Leu Gln Phe
                170                 175                 180
Leu Leu Ser Cys Phe Leu Gly Phe Leu Leu Met Tyr Ser Thr Val
                185                 190                 195
Leu Cys Ser Tyr Tyr Asn Ser Ala Leu Thr Thr Ala Val Val Gly
                200                 205                 210
Ala Ile Lys Asn Val Ser Val Ala Tyr Ile Gly Ile Leu Ile Gly
                215                 220                 225
Gly Asp Tyr Ile Phe Ser Leu Leu Asn Phe Val Gly Leu Asn Ile
                230                 235                 240
Cys Met Ala Gly Gly Leu Arg Tyr Ser Phe Leu Thr Leu Ser Ser
                245                 250                 255
Gln Leu Lys Pro Lys Pro Val Gly Glu Glu Asn Ile Cys Leu Asp
                260                 265                 270
Leu Lys Ser
```

<210> 40
<211> 206
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4378816CD1

<400> 40

```
Met Gly Ala Glu Trp Glu Leu Gly Ala Glu Ala Gly Gly Ser Leu
  1               5                  10                  15
Leu Leu Cys Ala Ala Leu Leu Ala Ala Gly Cys Ala Leu Gly Leu
             20                  25                  30
Arg Leu Gly Arg Gly Gln Gly Ala Ala Asp Arg Gly Ala Leu Ile
             35                  40                  45
Trp Leu Cys Tyr Asp Ala Leu Val His Phe Ala Leu Glu Gly Pro
             50                  55                  60
Phe Val Tyr Leu Ser Leu Val Gly Asn Val Ala Asn Ser Asp Gly
             65                  70                  75
Leu Ile Ala Ser Leu Trp Lys Glu Tyr Gly Lys Ala Asp Ala Arg
             80                  85                  90
Trp Val Tyr Phe Asp Pro Thr Ile Val Ser Val Glu Ile Leu Thr
             95                 100                 105
Val Ala Leu Asp Gly Ser Leu Ala Leu Phe Leu Ile Tyr Ala Ile
            110                 115                 120
Val Lys Glu Lys Tyr Tyr Arg His Phe Leu Gln Ile Thr Leu Cys
            125                 130                 135
Val Cys Glu Leu Tyr Gly Cys Trp Met Thr Phe Leu Pro Glu Trp
            140                 145                 150
Leu Thr Arg Ser Pro Asn Leu Asn Thr Ser Asn Trp Leu Tyr Cys
            155                 160                 165
Trp Leu Tyr Leu Phe Phe Phe Asn Gly Val Trp Val Leu Ile Pro
            170                 175                 180
Gly Leu Leu Leu Trp Gln Ser Trp Leu Glu Leu Lys Lys Met His
            185                 190                 195
Gln Lys Glu Thr Ser Ser Val Lys Lys Phe Gln
            200                 205
```

<210> 41
<211> 235
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4797137CD1

<400> 41

```
Met Gln Gln Arg Gly Ala Ala Gly Ser Arg Gly Cys Ala Leu Phe
  1               5                  10                  15
Pro Leu Leu Gly Val Leu Phe Phe Gln Gly Val Tyr Ile Val Phe
```

```
                    20                  25                  30
Ser Leu Glu Ile Arg Ala Asp Ala His Val Arg Gly Tyr Val Gly
                    35                  40                  45
Glu Lys Ile Lys Leu Lys Cys Thr Phe Lys Ser Thr Ser Asp Val
                    50                  55                  60
Thr Asp Lys Leu Thr Ile Asp Trp Thr Tyr Arg Pro Pro Ser Ser
                    65                  70                  75
Ser His Thr Val Ser Ile Phe His Tyr Gln Ser Phe Gln Tyr Pro
                    80                  85                  90
Thr Thr Ala Gly Thr Phe Arg Asp Arg Ile Ser Trp Val Gly Asn
                    95                 100                 105
Val Tyr Lys Gly Asp Ala Ser Ile Ser Ile Ser Asn Pro Thr Ile
                   110                 115                 120
Lys Asp Asn Gly Thr Phe Ser Cys Ala Val Lys Asn Pro Pro Asp
                   125                 130                 135
Val His His Asn Ile Pro Met Thr Glu Leu Thr Val Thr Glu Arg
                   140                 145                 150
Gly Phe Gly Thr Met Leu Ser Ser Val Ala Leu Leu Ser Ile Leu
                   155                 160                 165
Val Phe Val Pro Ser Ala Val Val Val Ala Leu Leu Leu Val Arg
                   170                 175                 180
Met Gly Arg Lys Ala Ala Gly Leu Lys Lys Arg Ser Arg Ser Gly
                   185                 190                 195
Tyr Lys Lys Ser Ser Ile Glu Val Ser Asp Asp Thr Asp Gln Glu
                   200                 205                 210
Glu Glu Glu Ala Cys Met Ala Arg Leu Cys Val Arg Cys Ala Glu
                   215                 220                 225
Cys Leu Asp Ser Asp Tyr Glu Glu Thr Tyr
                   230                 235
```

<210> 42
<211> 147
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5470806CD1

```
<400> 42
Met Ala Ser Leu Arg Leu Phe Leu Leu Cys Leu Ala Val Leu Ile
  1                 5                  10                  15
Phe Ala Ser Glu Ala Gly Pro Gly Gly Ala Gly Glu Ser Lys Cys
                   20                  25                  30
Pro Leu Met Val Lys Val Leu Asp Ala Val Arg Gly Ser Pro Ala
                   35                  40                  45
Val Asp Val Ala Val Lys Val Phe Lys Lys Thr Ala Asp Gly Ser
                   50                  55                  60
Trp Glu Pro Phe Ala Ser Gly Lys Thr Ala Glu Ser Gly Glu Leu
                   65                  70                  75
His Gly Leu Thr Thr Asp Glu Lys Phe Thr Glu Gly Val Tyr Arg
                   80                  85                  90
Val Glu Leu Asp Thr Lys Ser Tyr Trp Lys Ala Leu Gly Ile Ser
                   95                 100                 105
Pro Phe His Glu Tyr Ala Glu Val Val Phe Thr Ala Asn Asp Ser
                  110                 115                 120
Gly His Arg His Tyr Thr Ile Ala Ala Leu Leu Ser Pro Tyr Ser
                  125                 130                 135
Tyr Ser Thr Thr Ala Val Val Ser Asn Pro Gln Asn
                  140                 145
```

<210> 43
<211> 147
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5473242CD1

<400> 43
Met Val His Leu Thr Asp Ala Glu Lys Ala Thr Val Asn Gly Leu
1 5 10 15
Trp Gly Lys Val Asn Pro Val Glu Ile Gly Ala Glu Ser Leu Ala
20 25 30
Ser Leu Leu Ile Val Tyr Pro Trp Thr Gln Arg Tyr Phe Ser Lys
35 40 45
Phe Gly Asp Leu Ser Ser Val Ser Ala Ile Met Gly Asn Pro Gln
50 55 60
Val Lys Ala His Gly Glu Lys Val Ile Asn Ala Phe Asp Asp Gly
65 70 75
Leu Lys His Leu Asp Asn Leu Lys Gly Thr Phe Ala Ser Leu Ser
80 85 90
Glu Leu His Cys Asp Lys Leu His Val Asp Pro Glu Asn Phe Arg
95 100 105
Leu Leu Gly Asn Met Ile Val Ile Met Met Gly His His Leu Gly
110 115 120
Lys Glu Phe Thr Pro Ser Ala Gln Ala Ala Phe Gln Lys Val Val
125 130 135
Ala Gly Val Ala Ser Ala Leu Ala His Lys Tyr His
140 145

<210> 44
<211> 2701
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 264114CB1

<400> 44
gcggcggcgc cagcttcctc ggccggaggg gaggcgagac cccaggcgag gccgcggcgg 60
gagggccacg cccccgacgc cgcgccggag gggcccagtg tggacggggc caccggctgg 120
agcggatccc acacctccgg accgagggac gcggttactc cacaggatcc gctgaactta 180
ggatgttgcc acaaaatcta cctcgtgtat ttttctcttt cactcatgag ctgcacaatt 240
gcagatttga gcacaatgtc tgcagactgt gttgaaaaac tctgaagaac ctaattaaca 300
caggatgacc taggagtgat tctaagtctg tgtaacaaga tattactcat tagtgaatgt 360
gtcagtcttg gtactgaatg ctgcagataa cagcaagtag gttctccttt atttctgaag 420
tattcacttg accttccatc agtaagacgg actttctaa tctgttcctg gagatattaa 480
tggaatacag tcatgtccac tcaagacgag aggcagatca atactgaata tgctgtgtca 540
ttgttggaac agttgaaact gttttatgaa cagcagttgt ttactgacat agtgttaatt 600
gttgagggca ctgaattccc ttgtcataag atggttcttg caacatgtag ctcttattc 660
agggccatgt ttatgagtgg actaagtgaa agcaaacaaa cccatgtaca cctgaggaat 720
gtcgatgctg ccaccttaca gataataata acttatgcat acacgggtaa cttggcaatg 780
aatgacagca ctgtagaaca gctttatgaa acagcttgct tcctacaggt agaagatgtg 840
ttacaacgtt gtcgagaata tttaattaaa aaaataaatg cagagaattg tgtacgattg 900
ttgagttttg ctgatctctt cagttgtgag gaattaaaac agagtgctaa aagaatggtg 960
gagcacaagt tcactgctgt gtatcatcag gacgcgttca tgcagctgtc acatgaccta 1020
ctgatagata ttctcagtag tgacaattta aatgtagaaa aggaagaaac cgttcgagaa 1080
gctgctatgc tgtggctaga gtataacaca gaatcacgat cccagtattt gtcttctgtt 1140
cttagccaaa tcagaattga tgcactttca gaagtaacac agagagcttg gtttcaaggt 1200
ctgccaccca atgataagtc agtggtggtt caaggtctgt ataagtccat gcccaagttt 1260
ttcaaaccaa gacttgggat gactaaagag gaaatgatga ttttcattga agcatcttca 1320
gaaaatcctt gtagtcttta ctctttctgtc tgttacagcc cccaagcaga aaaagtttac 1380
aagttatgta gcccaccagc tgatttgcat aaggttggga ccgttgtaac tcctgataat 1440
gatatctaca tagcagggag tcaagttcct ctgaaaaaca caaaaacaaa tcacagtaaa 1500
acaagcaaac ttcagactgc cttcagaact gtgaattgct tttattggtt tgatgcacag 1560
caaaatacct ggtttccaaa gacccaatg ctttttgtcc gcataaagcc atctttggtt 1620
tgctgtgaag gctatatcta tgcaattgga ggagatagcg taggtggaga acttaatcgg 1680
aggaccgtag aaagatacga cactgagaga gatgagtgga cgatggtaag ccctttacct 1740
tgtgcttggc aatggagtgc agcagttgtg gttcatgact gcatttatgt gatgacactg 1800
aacctcatgt actgttattt tccaaggtct gactcatggg tagaaatggc catgagacag 1860
actagtaggt cctttgcttc agctgcagct tttggtgata aaatttctta tattggaggg 1920
ttgcatattg ctaccaattc cggcataaga ctcccctctg gcactgtaga tgggtcttca 1980
gtaactgtgg aaatttatga tgtgaataaa aatgagtgga aaatggcagc caacatccct 2040
gctaagaggt actctgaccc ctgtgttaga gctgttgtga tctcaaattc tctatgtgtg 2100
tttatgcgag aaacccactt aaatgagcga gctaaatacg tcacctacca atatgacctg 2160
gaacttgacc ggtggtctct gcggcagcat atatctgaac gtgtactgtg ggacttgggg 2220

```
agagattttc gatgcactgt ggggaaactc tatccatcct gccttgaaga gtctccatgg 2280
aaaccaccaa cttatctttt ttcaacggat gggacagaag agtttgaact ggatggagaa 2340
atggttgcac taccacctgt atagtgggga agttcaggga gtgcacgcct gagttatgtg 2400
ctttgtcatt ttctttgcta aacaaaagag gctatgaaag aactaaatat gagtacataa 2460
aattctatct ttgataaatt ttatttttat gccctactta atatttgcat cagtataata 2520
tatatcagtg agtcttacag aaagatatgc ttccataata tgaaatagat tattcaataa 2580
ttgagaaact ttatgttaga tcatgagagt ataagaatct ggattatcta acattgttag 2640
ccctgtgtat gtacagttca aaaagttcat ttataaaagt agtttcctgt tcctagttga 2700
t                                                                  2701

<210> 45
<211> 736
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1455669CB1

<400> 45
gagacttagc gacagacaga cgctgggacc cacgacgaca gaaggcgccg atggccgcgc 60
ctgctgagcc ctgcgcgggg cagggggtct ggaaccagac agagcctgaa cctgccgcca 120
ccagcctgct gagcctgtgc ttcctgagaa cagcaggggt ctgggtaccc cccatgtacc 180
tctgggtcct tggtcccatc tacctcctct tcatccacca ccatggccgg ggctacctcc 240
ggatgtcccc actcttcaaa gccaagatgg tagctgccat ccctgggagc ctggaaccag 300
gcaatgttcg ggggaggcag gggacaggct ggaacctggt gaagtcttaa agtagactcc 360
tcctatcggg gtgtagaagg gaatctgtta atcaaacaga gcaatattag aaaggctaca 420
gaggtcaact cagtggaaca cggttctccc aaacagattt tgtaattccg aaaatccacg 480
catgcgcaaa catacgcata cactcccatg ttcctggaca gtttatagct accataacct 540
ggcatttttcc aaaacatacc atgtagactc ttggatacac aaggtaattt tagagccaca 600
ttaggatgaa ccttttaaaa agttatgcat ttatttttat gttcccccac tggctgtatt 660
ataggacaat ttttatatgt gatatgtatt taccttagtg tgttaaataa acactggcat 720
tccaagtgtg aaaaaa                                                  736

<210> 46
<211> 1826
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2084989CB1

<400> 46
ccttaggcgc cagggacagc cgagcgttac ctggtcccgg gcagcggagt tctttaccca 60
ccccagttct ggttctgacg ccctagctca ttccgcaaat ttagggcttg ggtctggctt 120
gttcccctcc ggctcgaacc acctctttctc tgagccgagc cagctaccgg ggctcctgga 180
attgccaccc ctccctgggc accettgagg cctccgtgga gggacgtcac ggggcagagc 240
gggacgtgag cctgagtttg ctgcaggcgt gctctgtgtg gtggctgggt tctgccaatc 300
cccgtgccca ccgggtgggc gcggccggga agctcctgcc cctccctgct ggtcggcgtc 360
acgcgtgacg tcccgcgtga tggctgggag ggcccggcgg cgacagcgga ggcagagagg 420
aaggcggttc tgagagcttc agagagcgat ggaaagcaaa atgggtgaat tgcctttaga 480
catcaacatc caggaacctc gctgggacca aagtactttc ctgggcagag cccggcactt 540
tttcactgtt actgatcctc gaaatctgct gctgtccggg gcacagctgg aagcttctcg 600
gaacatcgtg cagaactaca gggccggcgt ggtgacccca gggatcaccg aggaccagct 660
gtggagggcc aagtatgtgt atgactccgc cttccatccg gacacagggg agaaggtggt 720
cctgattggc cgcatgtcag cccaggtgcc catgaacatg accatcactg gctgcatgct 780
cacattctac aggaagaccc caaccgtggt gttctggcag tgggtgaatc agtccttcaa 840
tgccattgtt aactactcca accgcagtgg tgacactccc atcactgtga ggcagctggg 900
gacagcctat gtgagtgcca ccactggagc tgtggccacg gccctgggac tcaaatccct 960
caccaagcac ctgccccccct tggtcggcag atttgtgccc tttgcagcag tggcagctgc 1020
caactgcatc aacatccccc tgatgaggca gagagagctg caggtgggca tcccggtggc 1080
tgatgaggca ggtcagaggc ttggctactc ggtgactgca gccaagcagg gaatcttcca 1140
ggtggtgatt tcaagaatct gcatggcgat tcctgcaatg gccatcccac cactgatcat 1200
ggacactctg gagaagaaag acttcctgaa ggtaggcgac tgtacctctc ttgtcctgga 1260
atgggcgatg gctgggagaa gtgaccaggc cccaactctc tctccagcct cgcctgattc 1320
tctaagactt gccagccctt ctcctgaccc ctgcaccgcc tcctccacct tcgttcattc 1380
agcaagaatg aactgggctg gggtgaagga actctgcagg ggcaggagga gaggacaaag 1440
```

```
gaaggaaacc aacttcatca gtgttactcc agtggcttct gacacacaga aggggactgt 1500
catagtcatg cttgatctca tgctcattct tttacccctt agtgcctcca tactgagagg 1560
tacacacggg tgaacacgca cacacagaca tgaacaggac acgaaagcaa agcacaggaa 1620
caagctctgg ctcattcaca gaatcattta ttcacaaatg tattgagtgc catgcaccag 1680
gcatgtttta gggctgagga gatggcactg aacacaatgg ttatggcccc tgtcctcatg 1740
aagtttatag tctgatgcag aaaccaataa acaaggaggc acccacataa atacattctt 1800
agaaagtgta aaaataaaaa aaaaaa                                      1826

<210> 47
<211> 1325
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2501034CB1

<400> 47
ccacgggtcc ggttctggac tgcagttgag tggaaatggg caacggcggg cggagcggcc 60
tgcagcaggg gaaggggaac gtggatgggg tggcagcgac tcctactgct gcctcggcct 120
cctgccagta caggtgcatc gaatgcaacc aggaggccaa agagttgtac cgagactata 180
accacggtgt gctgaagata accatctgta aatcctgcca gaaacctgta gacaaatata 240
tcgagtatga tcctgttatc atcttgatta atgctatatt gtgcaaagct caggcctaca 300
gacatattct tttcaatact caaataaata tccatggaaa actctgcata ttttgtttgc 360
tttgtgaagc atacctgagg tggtggcagc ttcaagattc caaccagaat actgccccta 420
atgacttgat cagatatgct aaggaatggg atttctatag aatgtttgcg attgctgctt 480
tagaacaaac tgcctatttt attggcattt ttaccttcct gtgggtagaa cggccatgga 540
cggcaaaaaa aaagcccaac ttcatttgc tgctgaaagc attattatta tctagctacg 600
gaaaactctt gctgattcca gctgtcattt gggaacatga ctacacatct gtgtgcctca 660
aactcattaa agtatttgtt cttacatcaa atttcaggc aattagagtg accctaaaca 720
tcaaccgtaa gctctccttc ttggccgtgt tgagtggctt actgctggaa agcatcatgg 780
tctacttctt ccagagtatg gaatgggatg ttggaagtga ttatgccatc tttaaatctc 840
aggacttctg aagagtttta ttcttcttca ctatctgtgg catgaccagc tgtatctgaa 900
agagaaaaga catgaaatat aaaccaacct cctcatttct gttgagtaaa atgaagcaaa 960
gattggaaac actttctgaa aaagaaagca atgataatag cggtggatac ccacccccac 1020
aaatgcaccc aagagacaag ccatttacat acagatattc acagtcacac atagaaacac 1080
ccacatggac acaaggaatg ttgctgcaga gactgaatga catgcaacag gtgaaggttt 1140
atacgttata cacaaggcca ggtaagcgct cataattcac acatagtaaa acatctaggt 1200
ttcattcctt tgacatgttt atatcttttt aatttaaatg ttgttactgg cttaaaatat 1260
tttgtgttct tacaatagaa acgcttttaa taaagtcttt cagaataaac caaaaaaaaa 1320
aaaaa                                                            1325

<210> 48
<211> 1832
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2745212CB1

<400> 48
tgggctgtcg ttggctggag cagcggctgc gcgggtcgcg gtgctgtgag gtctgcgggc 60
gctggcaaat ccggcccagg atgtagagct ggcagtgcct gacggcgcgt ctgacgcgga 120
gttgggtggg gtagagagta gggggcggta gtcgggggtg gtgggagaag gaggaggcgg 180
cgaatcactt ataaatggcg ccgaagcagg acccgaagcc taaattccag gagggtgagc 240
gagtgctgtg ctttcatggg cctcttcttt atgaagcaaa gtgtgtaaag gttgccataa 300
aggacaaaca agtgaaatac ttcatacatt acagtggttg gaataaaaat tgggatgaat 360
gggttccgga gagcagagta ctcaaatacg tggacaccaa tttgcagaaa cagcgagaac 420
ttcaaaaagc caatcaggag cagtatgcag aggggaagat gagaggggct gccccaggaa 480
agaagacatc tggtctgcaa cagaaaaatg ttgaagtgaa aacgaaaaag aacaaacaga 540
aaacacctgg aaatggagat ggtggcagta ccagtgagac ccctcagcct cctcggaaga 600
aaagggcccg ggtagatcct actgttgaaa atgaggaaac attcatgaac agagttgaag 660
ttaaagtaaa gattcctgaa gagctaaaac cgtggcttgt tgatgactgg gacttaatta 720
ccaggcaaaa acagctcttt tatcttcctg ccaagaagaa tgtggattcc attcttgagg 780
attatgcaaa ttacaagaaa tctcgtggaa acacagataa taaggagtat gcggttaatg 840
aagttgtggc agggataaaa gaatacttca acgtaatgtt gggtacccag ctactctata 900
aatttgagag accacagtat gctgaaattc ttgcagatca tcccgatgca cccatgtccc 960
```

```
aggtgtatgg agcgccacat ctcctgagat tatttgtacg aattggagca atgttggctt 1020
atacacctct ggatgagaag agccttgctt tattactcaa ttatcttcac gatttcctaa 1080
agtacctggc aaagaattct gcaactttgt tcagtgccag cgattatgaa gtggctcctc 1140
ctgagtacca tcggaaagct gtgtgagagg cactctcact cacttatgtt tggatctccg 1200
taaacacatt tttgttctta gtctatctct tgtacaaacg atgtgctttg aagatgttag 1260
tgtataacaa ttgatgtttg ttttctgttt gattttaaac agagaaaaaa taaaaggggg 1320
taatagctcc ttttttcttc tttctttttt tttttgattt caaaattgct gccagtgttt 1380
tcaatgatgg acaacagagg gatatgctgt agagtgtttt attgcctagt tgacaaagct 1440
gcttttgaat gctggtggtt ctattccttt gacactacgc actttataa tacatgttaa 1500
tgctatatga caaaatgctc tgattcctag tgccaaaggt tcaattcagt gtatataact 1560
gaacacactc atccatttgt gcttttgttt ttttttatgg tgcttaaagt aaagagccca 1620
tcctttgcaa gtcatccatg ttgttactta ggcattttat cttggctcaa attgttgaag 1680
aatggtggct tgtttcatgg tttttgtatt tgtgtctaat gcacgtttta acatgataga 1740
cgcaatgcat tgtgtagcta gttttctgga aaagtcaatc ttttaggaat tgtttttcag 1800
atcttcaata aatttttttct ttaaatttca aa                              1832

<210> 49
<211> 1211
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4833111CB1

<400> 49
gacagacccg cctcaaacat ggcggcgccc agcgcgcgag gacgtgatcc gcttctgctc 60
cggcttggat tgtagccttg acgaggtctg agcgaccatg gaccggccgg ggttcgtggc 120
agcgctggtg gctggtgggg tagcaggtgt ttctgttgac ttgatattat ttcctctgga 180
taccattaaa accaggctgc agagtcccca aggatttagt aaggctggtg gttttcatgg 240
aatatatgct ggcgttcctt ctgctgctat tggatccttt cctaatgctg ctgcattttt 300
tatcacctat gaatatgtga agtggttttt gcatgctgat tcatcttcgt atttgacacc 360
tatgaaacat atgttggctg cctctgctgg agaagtggtt gcctgcctga ttcgagttcc 420
atctgaagtg gttaagcaga gggcacaggt atctgcttct acaagaacat ttcagatttt 480
ctctaacatc ttatatgaag agggtatcca agggttgtat cgaggctata aaagcacagt 540
tttaagagag attccttttt ctttggtcca gtttccctta tgggagtcct taaaagccct 600
ctggtcctgg aggcaggatc atgtggtgga ttcttggcag tcagcagtct gtggagcttt 660
tgcaggtgga tttgccgctg cagtcaccac ccctctagac gtggcaaaga caagaattac 720
gctggcaaag gctggctcca gcactgctga tgggaatgtg ctctctgtcc tgcatggggt 780
ctggcggtca caggggctgg caggattatt tgcaggtgtc ttccctcgaa tggcagccat 840
cagtctggga ggtttcatct ttctgggggc ttatgaccga acgcacagct tgctgttgga 900
agttggcaga aagagtcctt gaagcagaga caagcctcac ctccacttct gtcaagagag 960
gggcctgcag tgcaaaccct cttccgctga gcagctgtct gaactatagg ccccagtgct 1020
gaagaccagt tgtgctaaga taccggcatg gagattgtgc catccgtggt ataggctggc 1080
tggtatgaag tcattggcct gtatgccaga gagctaagag aagaaaacgg ggtctgtggc 1140
ggtactctga acaatttcct cagaacctct taataaataa gtttggtaat gctgagaaaa 1200
aaaaaaaaaa a                                                      1211

<210> 50
<211> 1046
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 876677CB1

<400> 50
cccacgcgtc cgggaatgtc tttcactctc tcatactttc tcctctcccc tctcccaagc 60
acatctgagt tgctgcctgt tcttcacact tagctccaaa cccatgaaaa attgccaagt 120
ataaaagctt ctcaagaatg agatggattc tagggtgtct tcacctgaga agcaagataa 180
agagaatttc gtgggtgtca acaataaacg gcttggtgta tgtggctgga tcctgttttc 240
cctctctttc ctgttggtga tcattacctt ccccatctcc atatggatgt gcttgaagat 300
cattaaggag tatgaacgtg ctgttgtatt ccgtctggga cgcatccaag ctgacaaagc 360
caaggggcca ggtttgatcc tggtcctgcc atgcatagat gtgtttgtca aagttgacct 420
ccgaacagtt acttgcaaca ttcctccaca agagatcctc accagagact ccgtaactac 480
tcaggtagat ggagttgtct attacagaat ctatagtgct gtctcagcag tggctaatgt 540
caacgatgtc catcaagcaa catttctgct ggctcaaacc actctgagaa atgtcttagg 600
```

```
gacacagacc ttgtcccaga tcttagctgg acgagaagag atcgcccata gcatccagac 660
tttacttgat gatgccaccg aactgtgggg gatccgggtg gcccgagtgg aaatcaaaga 720
tgttcggatt cccgtgcagt tgcagagatc catggcagcc gaggctgagg ccacccggga 780
agcgagagcc aaggtccttg cagctgaagg agaaatgaat gcttccaaat ccctgaagtc 840
agcctccatg gtgctggctg agtctcccat agctctccag ctgcgctacc tgcagacctt 900
gagcacggta gccaccgaga agaattctac gattgtgttt cctctgccca tgaatatact 960
agagggcatt ggtggcgtca gctatgataa ccacaagaag cttccaaata aagcctgagg 1020
tcctcttgcg gtagtcagct attgca                                    1046

<210> 51
<211> 1660
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2326143CB1

<400> 51
gctcccctgc ccaccccgcc cccgtggccg agcccgggag tcgagtggga gtcggccggc 60
cggcgcgggc agccgtgacc cccgcggggg acactgcagc cggagcccgg gaggggccgc 120
gccgccaccg tctgaactag gatgtcccga catgaaggtg tcagctgtga tgcatgttta 180
aaaggaaatt ttcgaggtcg cagatataag tgtttaattt gctacgatta cgatctttgt 240
gcatcttgtt atgaaagtgg tgcaacaaca acaaggcata caactgacca cccaatgcag 300
tgcatattaa caagggtaga ttttgattta tactatggtg gggaagcttt ctctgtagag 360
cagccacagt cttttacttg tccctattgt ggaaaaatgg gctatacgga gacatctctt 420
caagaacatg ttacttctga acatgcagaa acatcaacag aagtgatttg tccaatatgt 480
gcagcgttac ctggaggcga tcctaatcat gtcacggatg actttgcagc tcatcttaca 540
cttgaacaca gagcccctag agatttagat gaatcgagtg gtgttcgaca tgtacgtaga 600
atgtttcacc ctggccgggg attaggaggt cctcgtgctc gtagatcaaa catgcacttt 660
actagcagtt ctactggtgg actttcttct tctcagagtt catattctcc aagcaatagg 720
gaagccatgg atcctatagc tgagctttta tctcagttat caggagtgag acgttctgca 780
ggaggacagc ttaattcctc tggcccttcc gcttctcagt tacaacaact gcagatgcag 840
ctgcagctag aacggcagca tgcccaggca gcacggcaac aactggagac cgcacgcaac 900
gcaacccggc gtactaacac aagcagtgtc accactacaa tcacacaatc cacagcaaca 960
accaacatag ctaatacaga aagcagtcag cagactctac agaattccca gtttctttta 1020
acaaggttga atgatcctaa aatgtctgaa acggagcgcc agtccatgga aagcgagcgt 1080
gcagaccgca gcctgtttgt ccaagagctc cttctgtcca ctttagtgcg tgaagagagc 1140
tcatcctcag atgaggatga tcgggggggag atggcagatt ttggtgctat gggctgtgta 1200
gatattatgc ctttagatgt tgctttagaa aacctaaatt taaaagagag taataaagga 1260
aatgagcctc caccacctcc tctttgatga catcccaatt cgcagacaat gtcctctgtg 1320
ctgtatttgc caatgaaagt ggacaacaac tatcttgggt ttgtttggtg attgtaattt 1380
caggtctgtc actcttgtta cattgtgtac attcaaaagg aagagagaaa atatatatga 1440
taatcatttc cacttaacta atttttactt ctagcaggta aatgtaggta gcagtgcagg 1500
ggtgatcttt gcttcctgta ccttgacatg caaaaggctc tcctaatact ccacattcaa 1560
actgaagagg aaaatgaaa tctctaatga agctgctgtg tgtatttatg aatattaatg 1620
aataaaaact gcttggatgg tttaccttaa aaaaaaaaaa                      1660

<210> 52
<211> 1110
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2786302CB1

<400> 52
cctttattag agaaagagtg acctatctac ccctttacttg gggaagactc tctgcttcaa 60
cagtttcttc tgtcttctgc tcctggacat ggcatgaaaa cggaagtttg agtatttcaa 120
ggataaagaa taactctagg acaagagttg ctttggggct aaacctatct cctgtattca 180
tttagatttg gctttaaaag cccatactat tttattagct cttctatgct ttttaaaagt 240
ttttaaaaaa attaatgtgg gctttttaat tctttctcag tgggaggggtg agtttgaata 300
aacctttctt ccacatgaga agtattttac aagttgcttg tcaaatttaa aagaaaatga 360
tcaaatcttc aagaaaatga tcaaatcttc tgtgacaaaa aaatggacaa atattcacca 420
ttgagtgtga atgccatggt gatgctaatt ctgattattt ttctttttctt ttagccatac 480
cttcagagtg ttatttcct tttgtcata aggtgtctgg aaatgaagta tggaaatgaa 540
ataatgaata aagacccagt tttcagaatc tctccacgga gtagagaaac tcatcccaat 600
```

```
ccggaagagc ccgaagaaga agatgaagat gttcaagctg aaagagtcca agcagcaaat 660
gcactcactg ctccaaactt ggaggaggaa ccagtcataa ctgcaagctg tttacacaag 720
gaatattatg agacaaagaa aagttgcttt tcaacaagaa agaagaaaat agccatcaga 780
aatgtttcct tttgtgttaa aaaaggtgaa gttttgggat tactaggaca caatggagct 840
ggtaaaagta cttccattaa aatgataact gggtgcacaa agccaactgc aggagtggtg 900
gtgttacaag gcagcagagc atcagtaagg caacagcatg acaacagcct caagttcttg 960
gggtactgcc ctcaggagaa ctcactgtgg cccaagctta ccatgaaaga gcacttggag 1020
ttgtatgcag ctgtggaaag actggggcaa aaaagatgct gctctcagta tttcacgatt 1080
ggtgggaggt cttaagctcc aggaacaact                                  1110

<210> 53
<211> 1120
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3735780CB1

<400> 53
gaaatccagt tatcaaaatt gactcaagaa gagagaacct aacagaacaa taacaatgga 60
agaaattggg aacattatca caaagctatc atcctgccaa actccaggct cagatgtcac 120
aggttaaaaa aagtccttca tgaaaaagaa agatcttaag cagcatgatg gattcagaag 180
ctcatgaaaa gaggccacca atactaacat cttcaaaaca agatatatca cctcatatta 240
caaatgttgg tgagatgaag cattacttgt gtggctgctg tgcagccttc aacaatgtcg 300
caatcacatt tcccattcag aaggtcctct ttcgacaaca gctgatggc atcaaaacc 360
gggatgcaat acttcagttg agaagggatg gatttcgaaa tttgtatcgt ggaatccttc 420
ccccattgat gcagaagaca actacgcttg cacttatgtt tggtctgtat gaggatttat 480
cctgccttct ccacaagcat gtcagtgctc cagagtttgc aaccagtggc gtggcggcag 540
tgcttgcagg gacaacagaa gcaatttta ctccactgga aagagttcag acattgcttc 600
aagaccacaa acatcatgac aaatttacca acacttacca ggctttcaag gcactgaaat 660
gtcatggaat tggagagtat tatcgaggct tggtgcccat tcttttccgg aatggactca 720
gcaatgtctt gtttttcggc cttcgaggtc ccattaagga gcatctgcct accgcaacga 780
ctcacagtgc tcatctggtc aatgatttta tctgtggagg tctattgggt gccatgttgg 840
gattcttgtt ttttccaatt aatgttgtaa aaactcgcat acagtctcag attggtgggg 900
aatttcagtc tttccccaag gttttccaaa aaatctggct ggaacgggac agaaaactga 960
taaatctttt cagaggtgcc catctgaatt accatcggtc cctcatctct tggggcataa 1020
tcaatgcaac ttatgagttc ttgttaaagg ttatatgaaa aaaccatcag ttaagtgcca 1080
tttatcaact gaatagacct tctaagaaga aaaaaaaaaa                        1120

<210> 54
<211> 886
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 039026CB1

<400> 54
ggccgcggct cctgtccaga ccctgaccct ccctcccaag gctcaaccgt cccccaacaa 60
ccgccagcct tgtactgatg tcggatgcga gagcctgtgc ttaagtaaga atcaggcctt 120
attggagaca ttcaagcaaa ggttggacaa ctacttttcc agaacagaaa ggaaactcat 180
gcatcagaaa aggtgactaa taaaggtacc agaagaatat ggctgcacaa ataccagaat 240
ctgatcagat aaaacagttt aaggaatttc tggggaccta caataaactt acagagacct 300
gctttttgga ctgtgttaaa gacttcacaa caagagaagt aaaacctgaa gagaccacct 360
gttcagaaca ttgcttacag aaatatttaa aaatgacaca aagaatatcc atgagatttc 420
aggaatatca tattcagcag aatgaagccc tggcagccaa agcaggactc cttggccaac 480
cacgatagag aagtcctgat ggatgaactt ttgatgaaag attgccaaca gctgctttat 540
tggaaatgag gactcatctg atagaatccc ctgaaagcag tagccaccat gttcaaccat 600
ctgtcatgac tgtttggcaa atggaaaccg ctggagaaac aaaattgcta tttaccagga 660
ataatcacaa tagaaggtct tattgttcag tgaaataata agatgcaaca tttgttgagg 720
ccttatgatt cagcagcttg gtcacttgat tagaaaaata aaccattgtt tcttcaattg 780
tgactgttaa ttttaaagca acttatgtgt tcgatcatgt atgagataga aaaatttta 840
ttactcaaag taaaataaat ggaaatatca ctgaaaaaaa aaaaaa                886

<210> 55
<211> 2336
```

<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 260607CB1

<400> 55
taatacgctc actataggga atttggccct cgagcagtaa ttcggcacga ggaccatctc 60
tttaggatat atttttaaat tctttgaaac acataaccaa aatggtttga ttcactgact 120
gactttgaag ctgcatctgc cagttacacc ccaaatggct ttaatcccct ctcgggtctg 180
gttgcctttt gcagtttggg ttgtggactc agctcctgtg aggggtctgg ttaggagaga 240
gccatttttа aggacaggga gttttatagc ccttttctac tttcctcccc tcctcccagt 300
ccttatcaat ctttttтcct ttttcctgac cccctccttc tggaggcagt tgggagctat 360
ccttgtttat gcctcactat tggcagaaaa gaccccattt aaaacccaga gaacactgga 420
gggggatgct ctagttggtt ctgtgtccat tttcctctgt gccaaagaca gacagacaga 480
ggctgagaga ggctgttcct gaatcaaagc aatagccagc tttcgacaca tacctggctg 540
tctgaggagg aaggcctcct ggaaactggg agctaagggc gaggcccttc ccttcagagg 600
ctcctgggag attagggtgt ggtgtttgcc aagccaaggg gtagggagcc gagaaattgg 660
tctgtcggct cctggttgca ctttgggggaa ggagaggaag tttggggctc caggtagctc 720
cctgttgtgg gactgctctg tcccctgccc ctactgcaga gatagcactg ccgagttccc 780
ttcaggcctg gcagacgggc agtgaggagg ggcctcagtt agcttctcag ggtggcttcc 840
cctcctccca acccagacat accctctgcc aaactgggaa ccagcagtgc tagtaactac 900
ctcacagagc cccagagggc ctgcttgagc cttcttgctc cacaggagaa gctggtgcct 960
ctaggcaacc ccttcctccc acctctcatc aggggtgggg gttctccttt ccctccctg 1020
aagtgtttat ggggagatcc tagtggcttt gccattcaaa ccactcgact gtttgcctgt 1080
ttctttgaaaa ccagtagaag ggaaacagca cagcctgtca cagtaattgc aggaagattg 1140
aagaaaaatc ctcatcaatg ccaggggaca taaaagccat ttcccttcca aatactcgac 1200
aatttagatg cagaacattt ctctgtattc agacttagag taacaccagc tgaaaactgc 1260
agtttctttc ctttggatac ataaggcttc tctatcgggg tacgggacag ggaggaggcc 1320
tcatgtctga agggggattt aggggcgaga gccgcagccc tgaccctcgg tcctgtgcac 1380
cgctttgggg cacagtctga tggcgccttt gctggcgcct tagtatggtt gactccggat 1440
ggacaaaaga aaaaaaattt tttttcttga atgaaatagc aggaagctcc tcgggagcat 1500
gtgttttgat taaccgtagt gatggatgct acgagtataa atggattaac tacctcaatc 1560
cttacagtaa gattggaact aagggcaggg actcatgcat aaggtatga atcccagcca 1620
ggacaagtga gttgaggctt gtgccacaaa aggtttgtcc ttggggaaca ggcaggcctg 1680
ccaggatccc ccccatatcg attgggctgg gagggctggc cgtgaggtcc ccatcttctg 1740
ctttccttgc ccatgtgtca ccccttggc ctccagcttg tccctctctc actttctata 1800
gctttgttgg accagatggt gaggaaagga atggcctctt cccttctaga gggggctggc 1860
tggagtgaga cctggggctt ggcctggaac ccaccacaca gccccaaagt caggaagcct 1920
ggggaaacca gagctgagac ctcttcaaca gggttttctt gagatcctac acctccattg 1980
ggccctcttt cagtcttcaa tgggggccca gttggctcta gaaggagaag aggtgaagca 2040
ggatcctttg ccctggggga gtctgagggc gcggtccttg gactcattca ggccgtcttt 2100
gtagttgggg gagttccact gggcgatccc agccctctcc cacccaccct ctaatggacc 2160
tcctcataga agccccattt cacttttgtt ttatctacct cttagcaaaa caatagataa 2220
attaggtagt ggcagctcca cttgcttagg ttaggggggg aaaaagattt ctttttccaa 2280
aggaaaaaaa tattaccttg agaatacttt ccaaaaaata aaatttaaaa aaaaaa 2336

<210> 56
<211> 2200
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1429651CB1

<400> 56
gagaactttа cgcctggatc tcatctaact gacacagaaa ccctgtaagg atccagaggt 60
ctcgttcagg accatggaga gcggcaccag cagccctcag cctccacagt tagatccccт 120
ggatgcgttt ccccagaagg gcttggagcc tggggacatc gcggtgctag ttcgtgactt 180
cctcttttgtc ctggctgttg gactatggtc cacagtgaag accaaaagag acacagtgaa 240
aggctacttc ctggctggag gggacatggt gtggtggcca gtgggtgcat ccttgtttgc 300
cagcaatgtt ggaagtggac atttcattgg cctggcaggg tcaggtgctg ctacgggcat 360
ttctgtatca gcttatgaac ttaatggctt gttttctgtg ctgatgttgg cctggatctt 420
cctacccatc tacattgctg gtcaggtcac cacgatgcca gaatacctac ggaagcgctt 480
cggtggcatc agaatcccca tcatcctggc tgtactctac ctatttatct acatcttcac 540
caagatctcg gtagacatgt atgcaggtgc catcttcatc cagcagtctt tgcacctgga 600

```
tctgtacctg gccatagttg ggctactggc catcactgct gtatacacgg ttgctggtgg 660
cctggctgct gtgatctaca cggatgccct gcagacgctg atcatgctta taggagcgct 720
caccttgatg ggctacagtt tcgccgcggt tggtgggatg gaaggactga aggagaagta 780
cttcttggcc ctggctagca accggagtga gaacagcagc tgcgggctgc ccgggaaaga 840
tgccttccat attttccgag atccgctgac atctgatctc ccgtggccgg gggtcctatt 900
tggaatgtcc atcccatccc tctggtactg gtgcacggat caggtgatta tccagcggac 960
tctggctgcc aagaacctgt cccatgccaa aggaggtgct ctgatggctg catacctgaa 1020
ggtgctgccc ctcttcataa tggtgttccc tgggatggtc agccgcatcc tcttcccaga 1080
tcaagtggcc tgtgcagatc cagagatctg ccagaagatc tgcagcaacc cctcaggctg 1140
ttcggacatc gcgtatccca aactcgtgct ggaactcctg ccacagggc tccgtgggct 1200
gatgatggct gtgatggtgg cggctctcat gtcctccctc acctccatct ttaacagtgc 1260
cagcaccatc ttcaccatgg accttctggaa tcacctccgg cctcgggcat ctgagaagga 1320
gctcatgatt gtgggcaggg tgtttgtgct gctgctggtc ctggtctcca tcctctggat 1380
ccctgtggtc caggccagcc agggcggcca gctcttcatc tatatccagt ccatcagctc 1440
ctacctgcag ccgcctgtgg cggtggtctt catcatggga tgtttctgga agaggaccaa 1500
tgaaaagggt gccttctggg gcctgatctc gggcctgctc ctgggcttgg ttaggctggt 1560
cctggacttt atttacgtgc agcctcgatg cgaccagcca gatgagcgcc cggtcctggt 1620
gaagagcatt cactacctct acttctccat gatcctgtcc acggtcaccc tcatcactgt 1680
ctccaccgtg agtcggttca cagagccacc ctccaaggag atggtcagcc acctgacctg 1740
gtttactcgt cacgacccag tggtccagaa ggaacaagca ccaccagcag ctcccttgtc 1800
tcttaccctc tctcagaacg ggatgccaga ggccagcagc agcagcagcg tccagttcga 1860
gatggttcaa gaaaacacgt ctaaaaccca cagctgtgac atgacccaaa agcagtccaa 1920
agtggtgaag gccatcctgt ggctctgtgg aatacaggag aagggcaagg aagagctccc 1980
ggccagagca gaagccatca tagtttccct ggaagaaaac cccttggtga agacccctcct 2040
ggacgtcaac ctcattttct gcgtgagctg cgccatcttt atctggggct attttgctta 2100
gtgtggggtg aacccaggag tccaaactct gtttctcttc agtgctccat ttttttaatg 2160
aaagaaaaaa taataaagct tttgtttacc aaaaaaaaaa                      2200

<210> 57
<211> 2823
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2069971CB1

<400> 57
gaaagacata cacacttcat gtaatgctac ctgcaagtct ccctagaaaa gcagtttttg 60
taggtgaaaa caatgaagcc aggtaatatt gcaaggaggc tgtaatttta gcagacctac 120
caacaacact gatgtaggaa gctcattatt ttaatttctg gagccttttа atttttttct 180
tagaaagtgt ataaataatt gcagtgctgc tttgcttcca aaactgggca gtgagttcaa 240
caacaacgac aacaacagcc gcagctcatc ctggccgtca tggagtttct tgaaagaacg 300
tatcttgtga atgataaagc tgccaagatg tatgctttca cactagaaag aaggagctgc 360
aaatgaacac ttcatagcaa tgtggaactc caacagaaac cggtgaataa agatcagtgt 420
cccagagaga gaccagagga gctggagtca ggaggcatgt accactgcca cagtggctcc 480
aagcccacag aaaaggggc gaatgagtac gcctatgcca agtggaaact ctgttctgct 540
tcagcaatat gcttcatttt catgattgca gaggtcgtgg gtgggcacat tgctgggagt 600
cttgctgttg tcacagatgc tgcccacctc ttaattgacc tgaccagttt cctgctcagt 660
ctctttctcc tgtggttgtc atcgaagcct ccctctaagc ggctgacatt tggatggcac 720
cgagcagaga tccttggtgc cctgctctcc atcctgtgca tctgggtggt gactggcgtg 780
ctagtgtacc tggcatgtga gcgcctgctg tatcctgatt accagatcca ggcgactgtg 840
atgatcatcg tttccagctg cgcagtggcg gccaacattg tactaactgt ggttttgcac 900
cagagatgcc ttggccacaa tcacaaggaa gtacaagcca atgccagcgt cagagctgct 960
tttgtgcatg cccttggaga tctattttag agtatcagtg tgctaattag tgcacttatt 1020
atctactttа agccagagta taaaatagcc gacccaatct gcacattcat cttttccatc 1080
ctggtcttgg ccagcaccat cactatctta aaggactcct ccatcttact catggaaggt 1140
gtgccaaaga gcctgaatta cagtggtgtg aaagagctta ttttagcagt cgaccgggtg 1200
ctgtctgtgc acagccctga catctggtct ctaacaatga atcaagtaat tctctccagct 1260
catgttgcta cagcagccag ccgggacagc caagtggttc ggagagaaat tgctaaagcc 1320
cttagcaaaa gctttacgat gcactcactc accattcaga tggaatctcc agttgaccag 1380
gaccccgact gccttttctg tgaagacccc tgtgactagc tcagtcacac cgtcagtttc 1440
ccaaatttga caggccacct tcaaacatgc tgctatgcag tttctgcatc atagaaaata 1500
aggaaccaaa ggaagaaatt catgtcatgg tgcaatgcac attttatcta tttatttagt 1560
tccattcacc atgaaggaag aggcactgag atccatcaat caattggatt atatactgat 1620
cagtagctgt gttcaattgc aggaatgtgt atatagatta ttcctgagtg gagccgaagt 1680
aacagctgtt tgtaactatc ggcaatacca aattcatctc ccttccaata atgcatcttg 1740
agaacacata ggtaaatttg aactcaggaa agtcttacta gaaatcagtg gaagggacaa 1800
```

atagtcacaa aattttacca aaacattaga aacaaaaaat aaggagagcc aagtcaggaa 1860
taaaagtgac tctgtatgct aacgccacat tagaacttgg ttctctcacc aagctgtaat 1920
gtggatcttt tttctacttct gaattggaaa tatgtatgaa tatacagaga agtgcttaca 1980
actaattttt atttacttgt cacatttgg caataaatcc ctcttatttc taaattctaa 2040
cttgtttatt tcaaaacttt atataatcac tgttcaaaag gaaatatttt cacctaccag 2100
agtgcttaaa cactggcacc agccaaagaa tgtggtgtga gagacccaga agtcttcaag 2160
aacagccgac aaaaacattc gagttgaccc caccaagttg ttgccacaga taatttagat 2220
atttacctgc aggaaggaat aaagcagatg caaccaattc attcagtcca cgagcatgat 2280
gtgagcactg ctttgtgcta gacattgggc ttagcattga aactataaag aggaatcaga 2340
cgcagcaagt gcttctgtgt tctggtagca actcaacact atctgtggag agtaaactga 2400
agatgtgcag gccaacattc tggaaatcct atgtcactgg gtttggtttg gaaacctgga 2460
cttctgcatt tttaaaagtt acccagagat gctttctaaag atgagccata gtctagaaga 2520
ttgtcaacca caggagttca ttgagtggga cagctagata catacattgg cagctacaat 2580
agtatcatga attgcaatga tgtagtgggg tataaaagga aagcgatgga tattgccgga 2640
tgggcatggc cagtgatgtt tcacgtcatt gaggtgacag ctctgctgga ctttgaatta 2700
catatggagg ctctccagga agacgaagaa gagaaggaca ttctaggcaa aaagaagact 2760
aggcacaagg cacacttatg tttgtctgtt agcttttagt tgaaaaagca agatacaggg 2820
tcg 2823

<210> 58
<211> 1491
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2329339CB1

<400> 58
cgcctccctc cagctgcgag tgcggcctcg gctggcggcg gcaccaggcc acagttgtaa 60
gggatcttgt ggctgtcagg atggcagagg agcaggagtt cacccagctc tgcaagttgc 120
ctgcacagcc ctcacaccca cactgcgtga acaacaccta ccgcagcgca cagcactccc 180
aggctctgct ccgagggctg ctggctctcc gggacagcgg aatcctcttc gatgttgtgc 240
tggtggtgga gggcagacac atcgaggccc atcgcatcct gctggctgcg tcctgcgatt 300
acttcagagg aatgtttgct gggggattga aggagatgga acaggaagag gtcctgatcc 360
acggtgtgtc ctacaatgct atgtgccaaa tcctacattt catatacacc tccgagctgg 420
agctcagcct gagcaatgta caagagacac tggtggctgc ctgccagctt cagatcccag 480
aaattatcca tttctgctgt gatttcctca tgtcctgggt ggacgaagag aacattctcg 540
atgtctaccg gctggcagag ctgttgact tgagccgcct gactgagcaa ctggacaccc 600
atatcctcaa aaactttgtg gcctttcttc ggactgacaa gtaccgccag cttccattgg 660
agaaggtcta ctccctcctc agcagcaatc gcctggaggt ctcctgcgag accgaggtat 720
atgaggcggc ccttctctac cattatagcc tggagcaggt gcaggctgac cagatctcgc 780
tgcacgagcc cccaaagctc cttgagacag tgcggtttcc gctgatggaa gctgaggtcc 840
tgcagcggct gcatgacaag ctggacccca gccctttgag ggacacagtg gccagcggcc 900
tcatgtacca ccggaacgag agcctacagc ccagcctgca gagcccgcaa acggagctgc 960
ggtcggactt ccagtgcgtt gtgggcttcg ggggcattca ctccacgccg tccactgtcc 1020
tcagcgacca ggccaagtat ctaaaccccct tactgggaga gtggaagcac ttcactgcct 1080
ccctggcccc ccgcatgtcc aaccagggca tcgcggtgct caacaacttc gtatacttga 1140
ttggagggga caacaatgtc caaggatttc gagcagagtc ccgatgctgg aggtatgacc 1200
cacggcacaa ccgctggttc cagatccagt ccctgcagca ggagcacgcc gacctgtccg 1260
tgtgtgttgt aggcaggtac atctacgctg tggcgggccg tgactaccac aatgacctga 1320
atgctgtgga gcgctacgac cctgccacca actcctgggc atacgtggcc ccactcaaga 1380
gggaggtgta tgcccacgca ggcgcgacgc tggaggggaa gatgtatatc acctgcggac 1440
gcaagcttat tcccttagt gagggttaat tttagcttgc actggccgtc g 1491

<210> 59
<211> 986
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2540219CB1

<400> 59
ggacgccaac ctcggtttga agtccagggc agtggctcct gcggacagcc agcataccag 60
gggccagtgc actgcattac aaccattgtg aggaatgagg gcctgtgccg tgtggctggc 120
gggcggcatg gcaggagcaa tttcttgggg gacagcgact cctatggatg tcgtgaaaag 180

```
tcgactccaa gctgatgggg tttatttaaa caaatataaa ggtgtcctgg actgtatctc 240
ccagagttac cagaaggaag gtcttaaagt gtttttcaga ggcatcactg tgaacgcggt 300
gcgggcttcc cccatgagtg cggccatgtt ccttgggtac gagctgtcgc tgcaggctat 360
ccgcggggac cacgcagtga cgagcccata agcgccagga ggtgaacaca ggatgactac 420
agtgttcccc tgggcctcat ctctgcatgt gaagccctga gagctgcaga tgtttgcact 480
ttggacctcc aagtggacat caattagcaa gcgtgggcta ggatggtgca gacactgacg 540
tggccctttt gatgcctggg atgccctcatg agtcactgat tcaagccctc ctagggttctg 600
atccccaatg cccactctgc taggctggca tcaaagagct ttccaagaaa tgttggtctc 660
agctgagaag tcctgaccat gagcaccagg gagccagaaa ccacccagag aaacgttgct 720
tcactcctct gtctgaggat ggggaggggc cagtgagctc tgggctcagc cactccctcc 780
agtctcaagt aacacgtccc cgtgcctcca gtctcctctc agcaccgacc aggtttttcc 840
ccgctcctgc acccgtggat cctgaggaca gcggtagcgc ctttctcacc gcacgctgag 900
tccagtgcgt gctcctcact gtgcacttat tagtgtctgt tgagtgatta aatcacatcc 960
tcaggtctgc agcaaataaa tgaaag                                     986

<210> 60
<211> 4023
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2722462CB1

<400> 60
gtccggggcg gcgcgtatgg cggcactatg ccatccacga ctcccaggcc cccagtctca 60
gctctggggg tgagagttcc ccctccagcc ccgcacacaa ctgggagatg aattaccaag 120
aggcagcaat ctacctccag gaaggcgaga acaacgacaa gttcttcacc caccccaagg 180
atgccaaggc gctggcggcc tacctctttg cacacaatca cctcttctac ctgatggagc 240
tggccacggc cctgctgctg ctgctgctct ccctgtgcga ggccccccgcc gtccccgcac 300
tccggcttgg catcttatgtc cacgccaccc tggagctgtt tgccctgatg gtggtagtgt 360
ttgaactctg catgaagtta cgctggctgg gcctccacac cttcatccgg cacaagcgga 420
ccatggtcaa gacctcggtg ctggtggtgc agtttgtcga ggccatcgtg gtgttggtac 480
ggcagatgtc ccatgtgcgg gtgacccgag cactgcgctg cattttcctg gtggactgtc 540
ggtattgcgg tggcgtccgg cgcaacctgc ggcagatctt ccagtccctg ccgcccttca 600
tggacatcct cctgctgctg ctgttcttca tgatcatctt tgccatcctc ggttttctact 660
tgttctcccc taaccctaca gacccctact tcagcaccct ggagaacagc atcgtcagtc 720
tgttgtcct tctgacacca gccaatttcc cagatgtgat gatgccctcc tactcccgga 780
acccctggtc ctggctcttc ttcatcgtgt acctctccat cgagctgtat ttcatcatga 840
acctgcttct ggctgtggtg ttcgacgcct tcaatgacat tgagaaacgc aagttcaagt 900
ctttgctact gcacaagcga accgctatcc agcatgccta ccgcctgctc attaggcaga 960
ggaggcctgc cggcatctcc tacaggcagt ttgaaggcct catgcgctcc tacaagcccc 1020
ggatgagtgc cagggagcgc tatcttacct tcaaggccct gaatcagaac aacacacccc 1080
tgctcagcct aaaggacttt tacgatatct acgaagttgc tgctttgaag tggaaggcca 1140
agaaaaacag agagcactgg tttgatgagc ttcccaggac ggcgctcctc atcttcaaag 1200
gtattaatat ccttgtgaag tccaaggcct tccagtatgt catgtacttg gtggtggcag 1260
tcaacggggt ctggatcctc gtggagacat ttatgctgaa aggtgggaac ttctttctcca 1320
agcacgtgcc ctggagttac ctcgtctttc taactatcta tggggtggag ctgttcctga 1380
aggttgccgg cctgggccct gtggagtact tgtcttccgg atggaacttg tttgacttct 1440
ccgtgacagt gttcgccttc ctgggactgc tggcgctggc cctcaacatg gagccctttct 1500
atttcatcgt ggtcctgcgc cccctccagc tgctgaggtt gtttaagttg aaggagcgct 1560
accgcaacgt gctggacacc atgttcgagc tgctgccccg gatggccagc ctgggcctca 1620
ccctgctcat cttttactac tccttcgcca tcgtgggcat ggagttcttc tgcggatcg 1680
tcttcccaa ctgctgcaac acgagtacag tggcagatgc ctaccgctgg cgcaaccaca 1740
ccgtgggcaa caggaccgtg gtggaggaag gctactatta tctcaataat tttgacaaca 1800
tcctcaacag ctttgtgacc ctgtttgagc tcacagttgt caacaactgg tacatcatca 1860
tggaaggcgt caccctctcag acctccccact ggagccgcct ctacttcatg acctttttaca 1920
ttgtgaccat ggtggtgatg acgatcattg tcgcctttat cctcgaggcc ttcgtcttcc 1980
gaatgaactа cagccgcaag aaccaggact cggaagttga tggtggcatc accctgaga 2040
aggaaatctc caaagaagag ctggttgccg tcctggagct ctaccgggag gcaggggggg 2100
cctcctcgga tgtcaccagg ctgctggaga ccctctccca gatggagaga taccagcaac 2160
attccatggt gtttctggga cggcgatcaa ggacccaaga cgacctgagc ctgaagatgt 2220
accaggagga gatccaggag tggtatgagg agcatgccag ggagcaagag cagcagcgac 2280
aactcagcag cagtgcagcc cccgccgccc agcagccccc aggcagccgc cagcgctccc 2340
agaccgttac ctagcccagc gcccgaaagc cgtctcttct atgcaataac acaatagtat 2400
tactctactg cgatgtacgg aactgcggtg tgtgtacaca tactcacgta tatgcacata 2460
tttatataca ggaagaaaaa agacagacaa gatgggggctt ggtttataac caccttgccc 2520
tgtcttcctt aactccagaa gccagtttgg tgagggggtgg gggtgcggcc accaggtctg 2580
```

```
agctcttcct actgtggaag gctccagaag gcccttcaca aggagacccc tcacctggat 2640
ccagtcgact gcggggcttg cccctcatgt gggctggcct ccatcggcca cgtccaaagc 2700
tgtcactgct actgcttcag gctcacatcc ccccgacctg atggcgtgcc cgccccctct 2760
ccctgcggcc catgccacag gtttctgtgt tttgctttag ggacagaacc acttaggaaa 2820
gaaagaactc ccggtctcca gggtggtatt tcagtgtctg tgataatgtc acgcaacacc 2880
tcttcgggga ccagtgccca ggatctaatg gaagcggaat tggggcaact gggccgtgt 2940
ggccagagct cagttagcca gtgccgggcg gccacagatt acactgacca atctcctccc 3000
ttggctctgc aagcctccca cccagccttc tctggcttaa cccttgttgg cgaaaactct 3060
tccacagtgg cctcctggg gacccagaac ccggaggaag gggcatgagg caggaagtgg 3120
ggccgatgtc tgcaacccag accacttcgt ggaatgggct cttgaccaaa tccctttttt 3180
ttgcgattta cccgttcaag caaaacaacg ttttggttaa ctaaggattg tgctaaagcc 3240
gataccaggt ccttcacacg tgtgcactag gaacaggagc gaacagcaca gagagacgct 3300
ccctgtggga cgcagcagcc ccgtggcccc ggcccagttc ccagccaccc tccctggctc 3360
tgctcacacc agagatttcc atagcaggag cggttggtgc agaagtaggt tcagatgaac 3420
ctcagttaac gtcgccaccc ctcctcccac catggtaccc tgtaggagcc ctgtatgaca 3480
tctgagcgtg gtggaggtag gaggggtgcc agctgcagtg accctgccac agaggcaggg 3540
tcagtgcaga ggtcgctttg gttccgcttc cctgggccac agaacggaac acagcatagg 3600
ttctgcagca ggagccgcag tggcaggatg gagggtgcga agggcaagga gtgcactgct 3660
gggcattcct ggccagcccc ggccctctgg tgcctgcttc ctgtgacttc agaaggcagg 3720
tggacagagc ctcccctctgg ccttgtcctc ttcccagcca cagaacgggc agggtggcac 3780
ccgaccccag gggagcagta cctggtcccc cacccctcc tcccaaccac ctccaaggcc 3840
aagctgggtc ccatagccag cacggcatgg ttctcccctt ccccccttcc caggtcaggg 3900
gagttggaca agtagcaggt gtttgttttt aaagcacagc cctttgggaa agcaacacat 3960
tattgagact cactgtgatt cccccgggag tcagactggc tttgtctctt tctctctgga 4020
ggg                                                               4023
```

<210> 61
<211> 2345
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2739264CB1

<400> 61

```
gaaaggaggc ggaactcggt gatctgactg gcggtttccc ggccggactg agaaggggag 60
cgcgctgcgc gtcgcaggag taaccttactt ggtcctcctgc tttcgcgaca tggccttcaa 120
ttttggggct ccctcgggca cctccggtac cgctgcagcc accgcggccc ccgcgggtgg 180
gttttggagga tttgggacaa catctacaac tgcaggttct gcattcagct tttctgcccc 240
aactaacaca ggcactactg gactctttgg tggtactcag aacaaaggtt ttggatttgg 300
tactggtttt ggcacaacaa cgggaactag tactggttta ggtactggtt tgggaactgg 360
actgggattt ggaggattta atacacagca gcagcagcaa actacattag gtggtctctt 420
cagtcagcct acacaagctc ctacccagtc caaccagctg ataaatactg cgagtgctct 480
ttctgctcca acgctgttgg gagatgagag agatgctatt ttggcaaaat ggaatcaact 540
gcaggccttt tggggaacag gaaaagggta tttcaacaat aatattccgc cagtggaatt 600
cacacaagaa aatcccctttt gccgatttaa ggcagtaggt tatagttgca tgcccagtaa 660
taaagatgaa gatgggctag tggttttagt tttcaacaaa aaagaaacag agattcgaag 720
ccaacaacaa cagttggtag aatcattgca taaagttttg ggaggaaacc agaccctttac 780
tgtaaatgta gaggggcacta aaacattgcc agatgatcag acagaagttg ttatttatgt 840
tgttgagcgt tcgccaaatg gtacttcaag aagagttcca gctacaacgc tatatgccca 900
ttttgaacaa gccaatataa aaacacaatt gcagcaactt ggtgtaaccc tttctatgac 960
tagaacagaa ctttctcctg cacagatcaa acagctttta cagaatcctc ctgctggtgt 1020
tgatcctatt atctgggaac aggccaaggt agataaccct gattctgaaa agttaattcc 1080
tgtaccaatg gtgggtttta aggaacttct ccgaagactg aaggttcaag atcagatgac 1140
taagcagcat caaaccagat tagatatcat atctgaagat attagtgagc tacaaaagaa 1200
tcaaactaca tctgtagcca aaattgcaca atacaagagg aaactcatgg atctttccca 1260
tagaacttta caggtcctaa tcaaacagga aattcaaagg aagagtggtt atgccattca 1320
ggctgatgaa gagcagttgc gagttcagct ggatacgatt cagggtgaac taaatgcacc 1380
tactcagttc aaggggccgac taaatgaatt gatgtctcaa atcaggatgc agaatcattt 1440
tggagcagtc agatctgaag aaaggtatta catagatgca gatctgttac gagaaatcaa 1500
gcagcatttg aaacaacaac aggaaggcct tagccatttg attagcatca ttaaagacga 1560
tctagaagat ataaagctgg tcgaacatgg attgaatgaa accatccaca tcagaggtgg 1620
tgtctttagt tgacagttca caaacttgtg taaaggtttg tgaaatgcat cttcttactg 1680
catcagacct tcattaagaa tgaaaccgac cacatggagg gaaaaagaaa acaattcttt 1740
cttggatgg tttttgaga agtttactga caaattactg ttcatcaaat ctgaaatagt 1800
cacctcacag ctcttcaaag aaaacctttg aaagatttat atctaaaagc tgtatttact 1860
ttaaaagaag tgcataatta ccaaaattgt atgtactatt gtacatttttt acaacagcat 1920
```

```
tttcttaaac ataatctgtg tttaatgatt attgtccatt gagcctgtac tctgctttcc 1980
ataccaagta aatatgaaat aatctacttt gcacataaca gaacaaacta taattacttg 2040
gctgttggag atttgtactt gagtataaat gtacaccagt ttttgtattt gtgaactcat 2100
ctgtgggagg agtaaagaaa atccaaaagc atttaatgtt ttgttttttgt tctataaaga 2160
tatgaaaatg tatttttata ttatttttact tatttggaat ttacagagca cacctaagca 2220
attaggatat aacaaaacta cttaaccatt tttgcaacca ttttgttttt taagcctttt 2280
tatttctaaa aagatgaaaa cttataaata aattcttaat ttgtaattac ttttaaaaaa 2340
aaaaa                                                           2345

<210> 62
<211> 2085
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2758310CB1

<400> 62
cggagatgtg gcgaccgttt ctggcatcat tctgagactc ggcagttgct tctcactgct 60
gcggccgggc ctgttctgtgg gagctgcatc ctcctcatct gcaggcgctg gaaaaccaga 120
cacgatcgga catgcatgtg gttctgcggc caaagcacgc cctttggttg tgaacttcat 180
gatacctgtg tgcagctctg tcatttccac tctgctctgc tgcacagaag gcagaagccc 240
tggccgtccc ctgctgtgtt cttcaggaga aacgtcaggg gccttcctcc aaggttctcc 300
agccccacac ccctgtggag gaaggtgctc tccaccgcgg tagtgggggc gcccctgctc 360
ctcggagccc gctatgtcat ggcagaggca cgggagaaga ggaggatgcg gctcgtggtg 420
gatggcatgg ggcgctttgg caggtctctg aaggtcggcc tgcagatctc tgcagactac 480
tggtggtgca ccaatgttgt ccttcgaggg tggaagagcc caggctactt ggaggtgatg 540
tctgcgtgtc accagcgggc ggctgatgcc ctggtggcag gggccatcag caacgggggc 600
ctctacgtga agctgggcca ggggctgtgc tccttcaacc acctgcttcc ccccgagtat 660
acccggaccc tgcgcgtgct agaggacagg gccctcaagc ggggcttcca ggaggtggat 720
gagttgtccc ttgaggactt ccaggcctc ccccacgagc tcttccagga gtttgactac 780
cagccaattg ctgccgccag cctggcacag gtgcacagag ccaagctgca cgatggcacc 840
agcgtggctg tgaaggtgca gtacatcgac ctgcgggacc gctttgatgg ggacatccac 900
accctggagc tcctgctgcg ggtcgttgag gtcatgcacc ccagctttgg cttcagctgg 960
gtcctccagg acctgaaggg gaccctggcc caggagctgg acttcgagaa tgagggccgc 1020
aacgcagagc gctgtgcgcg ggagctggcg cactcccct acgtcgtggt gcccgcggtg 1080
cactgggaca agtccagcaa gcgcgtgctc actgccgact tctgcgccgg ctgcaaggtc 1140
aacgatgtgg aggccatcag gagccagggg ctggcagtgc atgacatagc agaaaagctc 1200
atcaaggcct ttgctgagca gatattttac accggcttca tccactcgga ccacatcct 1260
ggcaacgttc tggtgcggaa aggcccggac gggaaagcgg agctggtgct gctggaccac 1320
gggctctacc agttcctgga ggagaaggac cgcgcagccc tctgccagct gtggcgggcc 1380
atcatcctgc gggacgacgc cgccatgagg gcgcacgcag ccgcactggg ggtgcaagac 1440
tacctcctgt tcgccgagat gctcatgcag cgccccgtgc gcctgggcga gctgtggggc 1500
tcgcacctac tgagccgcga agaggcggcc tacatggtgg acatggcccg cgagcgcttc 1560
gaggccgtca tggcggtgct cagggagctg ccgcggccca tgctgctggt gctgcgcaac 1620
atcaacaccg tgcgcgctat caacgtggcc ctcggcgccc ccgtggaccg ctacttcctt 1680
atggctaaaa gggctgtccg gggctggagc cgcctggcgg gcgccacgta tcgggggtgtc 1740
tacggcacca gcctcctgcg ccacgccaag gtcgtctggg agatgctcaa gtttgaagtg 1800
gcgctcaggc tggagacctt ggccatgcgg ctgaccgccc tcctggctcg tgctctggtc 1860
cacctgagcc tcgtgccccc agcggaggag ctctaccagt acctggagac ctagggtgca 1920
gccgcccagg gccggcgggg ccctttcac cttgggctga cggaggtggc ggggctagag 1980
gtgtagacac cccgagcccc gtgggcactc gcactgggag gctgtgacag cagctgggcc 2040
aggaggccgt gtaatgacca cacactcctc tcaagcaaaa aaaaa                2085

<210> 63
<211> 3014
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2762348CB1

<400> 63
ggaggcaaag gccaggctga ggatcagggt ggcccgggtg gcagcgggga ggcgctgcat 60
gctggaggct gtgctgagtg cccggtgcag gtgagccggt cctgcggagt tgtgccgagt 120
gcctgctgca gaccgaggct gggccaagat ggcgtctgtg tttcgaagcg aggagatgtg 180
```

```
tttgtcacaa ctgtttctcc aggtggaagc tgcatattgc tgtgtggctg agctcggaga 240
gctcggattg gttcagttca aagatttaaa tatgaatgtg aacagctttc aaaggaaatt 300
tgtgaatgaa gtcagaaggt gtgaatcact ggagagaatc ctccgttttc tggaagacga 360
gatgcaaaat gagattgtag ttcagttgct cgagaaaagc ccactgaccc cgctcccacg 420
ggaaatgatt accctggaga ctgttctaga aaaactggaa ggaggttac aggaagccaa 480
ccagaaccag caggccttga aacaaagctt cctagaactg acagaactga aatacctcct 540
gaagaaaacc caagacttct ttgagacgga aaccaattta gctgatgatt tctttactga 600
ggacacttct ggcctcctgg agttgaaagc agtgcctgca tatatgaccg gaaagttggg 660
gttcatagcc gggtgtgatc caacagggaa gaggatggct tcctttgagc ggttactgtg 720
gcgagtctgc cgaggaaacg tgtacttgaa gttcagtgag atggacgccc ctctggagga 780
tcctgtgacg aaagaagaaa ttcagaagca catattcatc atattttacc aaggagagca 840
gctcaggcag aaaatcaaga agatctgtga tgggtttcga gccactgtct acccttgccc 900
agagcctgcg gtggagcgca gagagatgtt ggagagcgtc aatgtgaggc tggaagattt 960
aatcaccgtc ataacacaaa cagagtctca ccgccagcgc ctgctgcagg aagccgctgc 1020
caactggcac tcctggctca tcaaggtgca gaagatgaaa gctgtctacc acatcctgaa 1080
catgtgcaac atcgacgtca cccagcagtg tgtcatcgcc gagatctggt tcccggtggc 1140
agatgccaca cgtatcaaga gggcactgga gcaaggcatg gaactaagtg gctcctccat 1200
ggccccatc atgaccacag tgcaatctaa aacagcccct ccacattta acaggaccaa 1260
taaattcaca gctggcttcc agaatattgt tgatgcctat ggtgtcggca gctaccggga 1320
gataaaccca gccccctaca ccatcatcac tttccccttc ctgttcgctg tgatgtttgg 1380
agactgtggt catggaaccg tgatgctcct ggctgcactt tggatgattc tgaatgagag 1440
acgcttgctc tcccagaaga cagacaatga gatttggaac acttttcttc acgggcgcta 1500
tctgatccta cttatgggca tctttctcat ctacacgggt ttgatctaca atgactgctt 1560
ctccaagtcc ttgaacatct ttggctcttc ttggagtgtc caacccatgt tcagaaacgg 1620
cacatggaat actcatgtaa tggaggaaag tctatatctg cagctggacc cagccatacc 1680
aggagtgtat tttggaaatc catacccgtt tggggattgat ccgatttgga acttggcttc 1740
aaacaaactc acatttctga actcgtataa aatgaagatg tcggtgatcc tgggaattgt 1800
ccagatggtt tttggtgtca tcctcagcct tttcaatcac atatacttca gaagaactct 1860
caacatcatt ctgcaattta tccctgagat gatttttatc ctgtgtctgt ttggatacct 1920
ggttttcatg atcattttca aatggtgctg ctttgacgtc cacgtatctc agcacgcccc 1980
cagcatcctc atccacttca tcaacatgtt tctgttaac tacagtgact cttccaacgc 2040
acccctctac aaacatcagc aagaagtcca aagtttcttt gtggttatgg ctttgatttc 2100
tgtgccgtgg atgcttctga ttaagccgtt tattcttaga gccagtcatc ggaaatccca 2160
gctgcaggca tccaggatcc aagaagatgc cactgagaac attgaaggtg atagctccag 2220
cccttctagc cgttctggcc agaggacttc tgcagatacc cacggggctc tggacgacca 2280
tggagaagag ttcatctttg gagacgtctt tgtccaccaa gccatccaca ccatcgagta 2340
ctgcctgggc tgcatttcaa acacagcctc ctacctgcgg ctctgggccc tcagcctggc 2400
tcatgcacaa ctgtctgaag tgcttctggac tatggtgatg aacagcggcc ttcagacgcg 2460
aggctgggga ggaatcgtcg gggttttat tatttttgcc gtatttgctg tcctgacagt 2520
agccatcctt ctgatcatgg agggcctctc tgctttcctg cacgcctctg gactgcactg 2580
ggttgagttc cagaacaagt tctatgtcgg ggatggttac aagttttctc cattctcctt 2640
taaacacatc ctggatggca cagccgagga gtaggctgag ggctgcacct cccacggtgg 2700
tcaccatgcc aatgaaggaa gttcagtctt gtctttgata tcagcccctg caaggcgctc 2760
aatgggaagg ttgttcttgg ctcacctgaa gcatgaaact gtgtattatt tggacgtcag 2820
cctgtggatt tgatacgact taaccacgtc agaggaagga ctttggcaag tgatattgtc 2880
ttcatgtggg gtattaattc tcaaataata aagtaattga caaatgaggg gagaatgcta 2940
aacagatgtc ttcttgcaat attttaaata ttgtatttga gaaaataaac atctgagtca 3000
ttcaaaaaaa aaaa                                                   3014

<210> 64
<211> 1726
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3715961CB1

<400> 64
tgaaaatgcc tgctgcgtac caaggtatgt actagggcat ctggggtaag taaaaacaaa 60
cacatagagc ctgcctggag aagctcatgg tctgatggaa agataagcaa gaagagttaa 120
tttctaatca atatgataaa aaggtcagag agcagtttct gaaaaacatg tttttgagtt 180
gagtcctgaa agacaaggag atgttagtaa agcagagaag ggagaattca ttctagaaag 240
atcagacagt gtgtgggaag ggcagagtct gaaaagagca tgccccattt ggagaagcat 300
caagaagccc acgtgttaga agcaccggcc ccatgagaca aagacacagc tagagagatt 360
gactaggcca tgtcggaatg tcctcttatt ttatacatac ataagcatat agatacatat 420
agccaaagtt acctttttaa tgatcttttt tacccagtgt attctggagg tcgaatggtc 480
acatatgaac atctccgaga ggttgtgttt ggcaaaagtg aagatgagca ttatcccctt 540
```

```
tggaaatcag tcattggagg gatgatggct ggtgttattg gccagttttt agccaatcca 600
actgacctag tgaaggttca gatgcaaatg gaaggaaaaa ggaaactgga aggaaaacca 660
ttgcgatttc gtggtgtaca tcatgcattt gcaaaaatct tagctgaagg aggaatacga 720
gggctttggg caggctgggt acccaatata caaagagcag cactggtgaa tatgggagat 780
ttaaccactt atgatacagt gaaacactac ttggtattga atacaccact tgaggacaat 840
atcatgactc acggttatc aagtttatgt tctggactgg tagcttctat tctgggaaca 900
ccagccgatg tcatcaaaag cagaataatg aatcaaccac gagataaaca aggaagggga 960
cttttgtata aatcatcgac tgactgcttg attcaggctg ttcaaggtga aggattcatg 1020
agtctatata aaggcttttt accatcttgg ctgagaatga ccccttggtc aatggtgttc 1080
tggcttactt atgaaaaaat cagagagatg agtggagtca gtccatttta aacccctaaa 1140
gatgcaaccc ttaaagatac agtgttcagt attattgaaa tatgggcatc tgcaacacat 1200
acccctctatt atttctacct ctttaggaag acacctattc cacagagact gatttatagg 1260
gggcagcact ttatttttttt ctggaaaccc aagttctctt tgactcctct ttttgtccaa 1320
aagtgatctg gtcggatctc acaaggccat ccaatgagac cccgcacagc attttctaaa 1380
gaagaatcga agcctgacca ctttcacctt gggcaagaag gtttggcctt tgagttgcta 1440
ttctatgctg aagagcctgc ttagaggagg agtaccagga gggagccagc atttcagatc 1500
tgaagtagac gataggaatg tggaagaaca catacatagt gcttaagaaa tacatttaac 1560
ctgttatgtc agtatttatc aatgaagttt gataattcac ttttctgtca ttgttaaagc 1620
gtacatactg taaattaaag ggaggtgaat ggaaattaat gaataaacat tttgagtttc 1680
cctagtgttg aaggaaggtg tacttttttt tgtcagaaag ataaaa                1726

<210> 65
<211> 899
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5108194CB1

<400> 65
gcggcggcga cgcgtccggg ccggtgaggg ggcgcggggg gcgccggggg ggccccaagcg 60
tcagcgcccg cgcctgtcgg gctgaactga ggaccgagtc tcctgccatt ccgagcaggc 120
ctggtatggg taatggtgtg aaggaaggcc cggtgcgatt gcatgaggat gctgaggctg 180
tcctgtcctc gtccgtctca tcaaagcgtg accacaggca agtgctcagc tccctgctgt 240
ctggggccct ggctggtgcc cttgccaaaa cagcggtagc tccctggac cgaaccaaaa 300
tcatcttcca agtgtcttca aaaagatttt ctgccaagga ggccttccgg gtcctctact 360
acacctacct caacgaggga tttctcagct tgtggcgcgg gaactccggc accatggtgc 420
gcgtggtgcc ctacgccgcc atccagttca gcgcacacga ggagtacaag cgcatcctgg 480
gcagctacta tggcttccgt ggagaagccc tgccccctg gcctcgcctc ttcgccggcg 540
cactggctgg aacgacagcc gcttcactga cctaccccct ggacctggtc agagcgcgga 600
tggccgtaac cccgaaggaa atgtacagca acatctttca tgtcttcatc cgcatctcga 660
gagaagaggg gctgaagact ctctaccatg gatttatgcc caccgtgctg ggggtcattc 720
cctacgctgg cctgagcttc ttcacctatg agacgctcaa gagcttgcac agagagtaca 780
gcggccgcaa gcttattccc tttagtgagg gttaatttta gcttggcact ggccgtcgtt 840
ttacaacgtc gtgactggga aaaccctggc gttacccaac ttaatcgcct tgcagcaca  899

<210> 66
<211> 643
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5503122CB1

<400> 66
ctttaagctg tagctgtggt ttctgcagca attttgtttt tgccttgaaa gaggtgctct 60
ggattatcac acctccatgt atgacaattt gtacctgcat ggaattgaag actcggaggc 120
tggttcagcg gattcctaca caagcaggcc gtctgactcc gatgtctctt tggaagagga 180
ccgggaagca attcgacagg agagagaaca gcaagcagct atccagcttg agagagcaaa 240
gtccaaacct gtagcatttg ccgtgaagac aaatgtgagc tactgcggcg ccctggacga 300
ggatgtgcct gttccaagca cagctatctc ctttgatgct aaagactttc tacatattaa 360
agagaaatat aacaatgatt ggtggatagg aaggctggtg aaagagggct gtgaaattgg 420
cttcattcca agtccactca gattggagaa catacggatc cagcaagaac aaaaaagagg 480
acgttttcac ggagggaaat caagtggaaa ttcttcttca agtcttggag aaatggtatc 540
tgggacattc cgagcaactc ccacatcaac aggtgagggt tgtagttaaa ctctttttca 600
tacactgtat tcttttaaa aatatttgaa cacacatgca agc                    643
```

<210> 67
<211> 2574
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5517972CB1

<400> 67
gcgcctccca cgccggccgc cgccgacgtg atcgctcggg cgcgccgggc gtggttgggg 60
gaaggggttg tgccgcgcga cggtctgcgt gctgtgccca ctcaaaaggt tccgggcgcg 120
caggacggaa gacgcagtgc tcgccactcc cactgagatt gagagacgcg gcaaggaggc 180
agcctgtggg ggaactgggt aggatttagg aacgcaccgt gcacatgctt ggtggtcttg 240
ttaagtggaa actgctgctt tagagttcgt ttggaaggtc cgggtgactc atcccaacat 300
ttacatcctt aattgttaaa gcgctgcctc cgagcgcacg catcctgaga tcctgagcct 360
ttggttaaga ccgagctcta ttaagctgaa aagatagaaa ctctccagat gtcttccagt 420
aatgtcgaag tttttatccc agtgtcacaa ggaaacacca atggcttccc cgcgacagct 480
tccaatgacc tgaaggcatt tactgaagga gctgtgttaa gttttcataa catctgctat 540
cgagtaaaac tgaagagtgg ctttctacct tgtcgaaaac cagttgagaa agaaatatta 600
tcgaatatca atgggatcat gaaacctggt ctcaacgcca tcctgggacc cacaggtgga 660
ggcaaatctt cgttattaga tgtcttagct gcaaggaaag atccaagtgg attatctgga 720
gatgttctga taaatggagc accgcgacct gccaatttca aatgtaattc aggttacgtg 780
gtacaagatg atgttgtgat gggcactctg acggtgagag aaaacttaca gttctcagca 840
gctcttcggc ttgcaacaac tatgacgaat catgaaaaaa acgaacggat taacagggtc 900
attcaagagt taggtctgga taaagtggca gactccaagg ttggaactca gtttatccgt 960
ggtgtgtctg gaggagaaag aaaaaggact agtataggaa tggagcttat cactgatcct 1020
tccatcttgt tcttggatga gcctacaact ggcttagact caagcacagc aaatgctgtc 1080
cttttgctcc tgaaaaggat gtctaagcag ggacgaacaa tcatcttctc cattcatcag 1140
cctcgatatt ccatcttcaa gttgtttgat agcctcacct tattggcctc aggaagactt 1200
atgtcccacg ggcctgctca ggaggccttg ggatactttg aatcagctgg ttatccactg 1260
gaggcctata ataaccctgc agacttcttc ttggacatca ttaatggaga ttccactgct 1320
gtggcattaa acagagaaga agacttttaaa gccacagaga tcatagagcc ttccaagcag 1380
gataagccac tcatagaaaa attagcggag atttatgtca actcctcctt ctacaagag 1440
acaaaagctg aattacatca actttccggg ggtgagaaga agaagaagat cacagtcttc 1500
aaggagatca gctacaccac ctccttctgt catcaactca gatgggtttc caagcgttca 1560
ttcaaaaact tgctgggtaa tccccaggcc tctatagctc agatcattgt cacagtcgta 1620
ctgggactgg ttataggtgc catttacttt gggctaaaaa atgattctac tggaatccag 1680
aacagagctg gggttctctt cttcctgacg accaaccagt gtttcagcag tgtttcagcc 1740
gtggaactct ttgtggtaga gaagaagctc ttcatacatg aatacatcag cggatactac 1800
agagtgtcat cttatttcct tggaaaactg ttatctgatt tattacccat gaggatgtta 1860
ccaagtatta tatttacctg tatagtgtac ttcatgttag gattgaagcc aaaggcagat 1920
gccttcttcg ttatgatgtt tacccttatg atggtggctt attcagccag ttccatggca 1980
ctggccatag cagcaggtca gagtgtggtt tctgtagcaa cacttctcat gaccatctgt 2040
tttgtgttta tgatgatttt ttcaggtctg ttggtcaatc tcacaaccat tgcatcttgg 2100
ctgtcatggc ttcagtactt cagcattcca cgatatggat ttacggcttt gcagcataat 2160
gaatcttgag gacaaaactt ctgcccagga ctcaatgcaa caggaaacaa tccttgtaac 2220
tatgcaacat gtactggcga agaatatttg gtaaagcagg gcatcgatct ctcacccctg 2280
ggcttgtgga agaatcacgt ggccttggct tgtatgattg ttatttccct cacaattgcc 2340
tacctgaaat tgttatttct taaaaaatat tcttaaattt ccccttaatt cagtatgatt 2400
tatcctcaca taaaaaagaa gcactttgat tgaagtattc aatcaagttt ttttgttgtt 2460
ttctgttccc ttgccatcac actgttgcac agcagcaatt gttttaaaga gatacatttt 2520
tagaaatcac aacaaactga attaaacatg aaagaaccca agaaaaaaaa aaaa 2574

<210> 68
<211> 1571
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5593114CB1

<400> 68
ggcgcggcga cagctagggt tcacggccac tggggcagag gagccgcgag aagatgtggg 60
ttttggtta cgggtccctg atctggaagg tggatttccc ctatcaggac aagctggtcg 120
gatacatcac caactacagc aggcgcttct ggcagggcag cacggaccac cgcggggtcc 180
ccggcaagcc tggaagagtt gtgactcttg ttgaagatcc tgcgggatgt gtatggggtg 240

```
ttgcttacag attgccagta ggaaaggaag aagaagtaaa agcatacctt gacttcagag 300
aaaaaggagg ctacagaacc acaacagtca ttttttatcc aaaagatccc acaacaaaac 360
cattcagtgt attgctatat attggaacat gtgataatcc tgattatctt ggtcctgcac 420
ctctggaaga cattgctgaa caaatttta atgcagctgg tccaagtgga agaaatacag 480
aatatctttt tgaacttgca aattctatta ggaaccttgt gccagaagaa gcagatgagc 540
atcttttcgc tttggaaaaa ttagtaaagg aacgtttaga agggaaacag aaccttgatt 600
gcatataatt tagtcttcag agaattaact tcagtgcaca atgacaatat gatttggaaa 660
tacgtttact taaagatctt atttttaatg tagtgaggat attatttaaa cttttatttt 720
aactggaaat gtcctgaaac acatatttaa aatattggga tacagtgaaa gaaaaattca 780
aattttaata acataaagat ttcctaactt tatgttattg aacacttact cactagaagt 840
gagttcttta gaaaaataca gtgaaggact cagttcagtc ttgtttttat cagagtgata 900
atcatccttgt ttcacatccc aatactattt tgaaattcta aacaattaaa ccaaaattcc 960
aataaatata aggttatgcc ttcaatatat tcctatacaa ttctgtaacc atggtttaaa 1020
atacacaagc ttaaaataac atgcttagaa atacacaata atatgaacag tatttcagcc 1080
ttaattgtga atttccttgt tattcaagta ttaaatgaaa tcttttgagt ttttagccaa 1140
aaattggcat ttttaaaata cgaaaatttc cttggaatta taatgtactg tacctcttct 1200
tttttaaata aaggcatttt actatatgga aaataactca ctaaagcata aattacatta 1260
tacaaatcat gatcactaat gatgtagtct gtcattcact ttgtattaat cttatcacaa 1320
aactgaaaaa gatgggctga tactacaaat taatggcaca tataatgaaa atttagtttt 1380
taaaacagct tttggaattc tttgtctgtc actatctcaa tttgtgtgtg tgtgtgtgta 1440
tatacataaa tatacatata aaatttttct tttctttgca gcctgcgtct ggccatccca 1500
caggctggaa agtgtaacct ctggcagaag ccaagaacag gcacctcctg gaattataat 1560
tttgttttgt t                                                      1571

<210> 69
<211> 1549
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 044775CB1

<400> 69
cgcgcttagg caggcggtgg cgcggctgga gtgccgcggg gagggctgtg ccggttgctt 60
tctgcagccg catctcggcc agctctcctc gccgtccccg gggcgctgtg cgtctccagt 120
ccgggaccga agccgcctgc cgtagcgggc ggccagatcc gcgtcccgcc tcagcggccg 180
gaggacatgc gggagagaga atgagccaga gggacacgct ggtgcatctg tttgccggag 240
gatgtggtgg tacagtggga gctattctga catgtccact ggaagttgta aaaacacgac 300
tgcagtcatc ttctgtgacg ctttatatt ctgagttcta gctgaacacc atggctggag 360
ccagtgtcaa ccgagtagtg tctcccggac ctcttcattg cctaaaggtg atcttggaaa 420
aagaagggcc tcgttccttg tttagaggac taggccccaa tttagtgggg gtacgcccctt 480
ccagagcaat atactttgct gcttattcaa actgcaagga aaagttgaat gatgtatttg 540
atcctgattc tacccaagta catatgattt cagctgcaat ggcaggcatt tactgtacat 600
ttctcccgag aaaagagtga gatcgtgtca tctcatgctc cccatccgca ggtcacttcc 660
tgtagaaata tggactaact taaacctcgt tttactgcaa tcacagcaac caaccccatt 720
tggcttataa agactcggtt acagcttgat gcaaggaacc gcgggggaaag gcgaatgggt 780
gcttttgaat gtgttcgtaa agtgtatcag acagatggac taaaaggatt ttataggggc 840
atgtctgctt catatgctgg tatatcagag actgttatcc attttgttat ttatgaaagt 900
ataaaacaaa aactactgga atataagact gcttctacaa tggaaaatga tgaagagtct 960
gtgaaagaag catcagattt tgtgggaatg atgctagctg ctgccacctc aaaaacttgt 1020
gccacaacta tagcatatcc acatgaagtt gtaagaacaa gactacgtga agagggaaca 1080
aaatcagat ctttttttca gactctatct ttgcttgttc aagaagaagg ttatgggtct 1140
ctttatcgtg gtctgacaac tcatctagtg agacagattc caaacacagc cattatgatg 1200
gccacctatg aattggtggt ttacctactc aatggatagc agcacgagga ctgctgtact 1260
gcaaaaaaag aagaccaaaa gattacagtg gaccatggga tacagaagcc agcatggcag 1320
acagaagaaa aatagtttgg gaacatgtaa ctattctaag tggaagtttt gttgtaggaa 1380
ttatagtaat cacaccacat tacttggcct ttcggtaatg tgaaaaaaaa aaaaaacct 1440
cagagcctcc aaggaaatgc ctttagaagc actcctctct caaaattgcc attttctcta 1500
ccatgtcccc cagacacagt tgggttttgt tgatttatgg cagtcttct             1549

<210> 70
<211> 2237
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
```

<223> Incyte ID No: 116588CB1

<400> 70
gtcactggtg ccacggggcc tcagcgcact tctgtcttaa gctcctgggc ctccttattt 60
tccccttgc gatcgattcc agccacacct gtggatgttg ctagttactc cgcgtccgga 120
acgtggaggt cgaggactg agctgggcga gttttgtggc actcctttgc tcttcagcag 180
ctatttttgc tatgataatc ctgctgccct tcagactcaa gttaaacgag atatgcaagt 240
gaatacacag aaattcatgc tgctgtatgc ctggtattct tggcccaatg tagttttgtg 300
tttcttggt ggcttttga tagaccgagt atttggaata cgatggggca caatcatttt 360
tagctgcttt gtttgcattg gacaggttgt ttttgccctg ggtggaatat ttaatgcttt 420
ttggctgatg gaatttggaa gatttgtatt tgggattggt ggcgagtcct tagcagttgc 480
ccagaataca tatgctgtga gctggtttaa aggcaaagaa ttaaacctgg tgtttggact 540
tcaacttagc atggctagaa ttggaagtac agtaaacatg aacctcatgg gatggctgta 600
ttctaagatt gaagctttgt taggttctgc tggtcacaca accctcggga tcacacttat 660
gattgggggt gtaacgtgta ttctttcact aatctgtgcc ttggctcttg cctacttgga 720
tcagagagca gagagaatcc ttcataaaga acaaggaaaa acaggtgaag ttattaaatt 780
aactgatgta aaggacttct ccttaccccc gtggcttata ttatcatct gtgtctgcta 840
ttatgttgct gtgttccctt ttattggact tgggaaagtt ttctttacag agaaatttgg 900
attttcttcc caggcagcaa gtgcaattaa cagtgttgta tatgtcatat cagctcccat 960
gtccccggtg tttgggctcc tggtggataa aacagggaag aacatcatct gggttctttg 1020
cgcagtagca gccactcttg tgtcccacat gatgctggcc tttacgatgt ggaaccctg 1080
gattgctatg tgtcttctgg gactctccta ctcattgctt gcctgtgcat tgtggccaat 1140
ggtggcattt gtagttcctg aacatcagct gggaactgca tatggcttca tgcagtccat 1200
tcagaatctt gggttggcca tcatttccat cattgctggt atgatactgg attctcgggg 1260
gtatttgttt ttggaagtgt tcttcattgc ctgtgtttct ttgtcacttt tatctgtggt 1320
cttactctat ttggtgaatc gtgcccaggg tgggaaccta aattattctg caagacaaag 1380
ggaagaaata aaattttccc atactgaatg agaagttaaa atgaatgtgt catgagaatg 1440
ggcttaacac atcgttggtt tgaaaacttc catttttaaa aatttagagt ttagtcatta 1500
gaaaaaataa tggactggaa agttatattt atatccaaat atacctattt caaagtgtat 1560
ttgtgaggcc tgttttagcc tgtgtctttt gtattgtgtg ttgctaaaga attctacttt 1620
tagtaggcta atcaacaatg aaagggttag aaaattgctg tggaacatcc aggtgaactt 1680
caggaaagac agtgaaaaat ggaaaacgtt ggagcttctg ttgagataat cttcattagg 1740
tatatatctt agggatacag cctttcttt atcttatagc aggaaaaaaa aactttgag 1800
ggaaatagaa gggctgcgtt acacaaaata aacaatggca ttgtcatagg ccttctcttt 1860
actagtaggg catcaatgcta gggaatatgt gaagatgttt ttatgaagtc tctttctgat 1920
cacgaacaat agcttgcgct ctactctgta gttatgtgga ttgccgagca atgacccttt 1980
tcaatttctt atttctgtgt tactgaggac cctaatcact tagggatgta attttatagt 2040
ataaactttc tgtacagttt ttcttatagt ctaataagta aaaagtgtcc ttcaaattat 2100
gataattgcc tatgtacatg gataaattaa aacactgcac acggagtaaa aaaaaaaaaa 2160
aaaaaaaaaa aaaaaatgag cggccgcaag cttattccct ttagtgaggg ttaattttag 2220
cttggcactg gccgtcg 2237

<210> 71
<211> 1114
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 875369CB1

<400> 71
tgggaacgga gcagccccgg gggccccctt gaggcggcga ggccgcgaag ggcgcggggc 60
tggagggtag gagagcgcgg gaaagcgccc cagacgccac tcgcggcgga cggcggccag 120
ttcccagggg tttggagccg gcccgcggcg ccatggctca cgtcggctcc cgcaagcgct 180
cgaggagtcg cagccggtcc cggggacggg ggtcggaaaa gagaaagaag aagagcagga 240
aagacacctc gaggaactgc tcggcctcca catcccaagg tcgcaaggcc agcacggccc 300
ctggggcgga ggcctcacct tctccctgca tcacagagag aagcaagcag aaggcccgga 360
ggagaacaag atccagctcc tcctcctctt cttccagttc ttctagctcc tcttcttcct 420
cctcgtcctc ctcctcttcc tccagtgatg gccggaagaa gcgggggaag tacaaggaca 480
agaggaggaa gaagaagaag aagaggaaga agctgaagaa gaagggcaag gagaaggcgg 540
aagcacagca ggtggaggct ctgccgggcc cctcgctgga ccagtggcac cgatcagctg 600
gggaggaaga ggatggccca gtcctgacgg atgagcagaa gtcccgaatc caggccatga 660
agcccatgac caaggaggag tgggatgccc ggcagagcat catccgcaag gtggtggacc 720
ctgagacggg gcgcaccagg cttattaagg gagatggcga ggtcctagag gaaatcgtaa 780
ccaaagaacg acacagagag atcaacaagc aagccacccg aggggactgc ctggccttcc 840
agatgcgagc tgggttgctt ccctgagggc ccccgctggc caaggcctgt ggacgacgct 900
ggcggcccag cctgggcagg tttcagggtg ccagtgggaa gcctgatggg tgctggtggc 960

```
ctttcccccg tggattggtc tctggcccag cccagtctct tctcaggggc agggggtgga 1020
ggttggggtc accggcctgc ttggcacccc catctgaaag agcagcactt ctcagctatt 1080
aaaggccccc tggatagaca aaaaaaaaaa aaaa                            1114

<210> 72
<211> 998
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1325518CB1

<400> 72
gactaaaaaa gccatgtatt ctttcgtttc tctctaaaag aagaaaaata taatttaaaa 60
atacattgcg tatttttctaa aacaataaat ttatagtgtt aatattcata gggtcaatca 120
aaatgaagct tctcctttgg gcctgcattg tatgtgttgc ttttgcaagg aagagacggt 180
tcccctttcat tggtgaggat gacaatgacg atggtcaccc acttcatcca tctctgaata 240
ttcctatgg catacggaat ttaccacctc ctctttatta tcgcccagtg aatacagtcc 300
ccagttaccc tgggaatact tacactgaca cagggttacc ttcgtatccc tggattctaa 360
cttctcctgg attcccctat gtctatcaca tccgtggttt tcccttagct actcagttga 420
atgttcctcc tctccctcct agggggtttcc cgtttgtccc tccttcaagg ttttttcag 480
cagctgcagc acccgctgcc ccacctattg cagctgagcc tgctgcagct gcacctctta 540
cagccacacc tgtagcagct gagcctgctg cagggggcccc tgttgcagct gagcctgctg 600
cagaggcacc tgttggagct gagcctgctg cagaggcacc tgttgcagct gagcctgctg 660
cagaggcacc tgttggagtg gagccagctg cagaggaacc ttcaccagct gagcctgcta 720
cagccaagcc tgctgcccca gaacctcacc cttctccctc tcttgaacag gcaaatcagt 780
gaaattctct agaagagtac catgggttca tttctatact gatgcagaaa taagtgaaat 840
ctacaaaagt tttctttctt ttccaaagac tatttcattc tgttgtattc agagtattca 900
tctcactaca ttgatttgtt tgtggtagtt tttccttgga cttaatttat attgaaaaaa 960
cattgataat taaataaata aaatagataa tttagaca                        998

<210> 73
<211> 2348
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2060987CB1

<400> 73
gggccagccg gctcgcccgg gggccatggc agcagcggct actgcagccg agggggtccc 60
cagtcggggg cctcccgggg aagtcatcca tctgaatgtg ggaggcaaga gattcagtac 120
ctctcgccag actctcacct ggatcccaga ctccttcttc tccagtcttc tgagcggacg 180
catctcgacg ctgaaagatg agaccggagc aatcttcatc gacagggacc ctacagtctt 240
cgcccccatc ctcaacttcc tgcgcaccaa agagttggat cccaggggtg tccacggttc 300
cagcctcctc catgaagccc agttctatgg gctcactcct ctggttcgtc gcctgcagct 360
tcgagaggag ttggatcgat cttcttgtgg aaacgtcctc ttcaatggtt acctgccgcc 420
accagtgttc ccagtgaagc ggcggaaccg gcacagccta gtggggcctc agcagctagg 480
aggacggcca gcacctgtcc gacggagcaa cacgatgccc cccaacctta gcaatgcagg 540
gctgctgggc cgaatgctgg atggagaaac ccctccctca ccctcaggac aacctgagga 600
gccgggaatg gtgcgcctgg tgtgtgggaca ccataaattgg atcgctgtgg cctataccca 660
gtttctagtc tgctacaggt tgaaggaagc ctctggctgg cagctggtgt tttccagccc 720
ccgcctggac tggcccatcg aacgactggc gctcacagcc cgggtgcatg gtgggctttt 780
gggtgaacat gacaagatgg tggcagcagc caccggcagc gagatcctgc tatgggctct 840
gcaggcggaa ggcggtggct ccgagatagg ggtctttcat ctgggggtgc ctgtggaggc 900
cttgttcttc gtcgggaacc agctcattgc tacaagccac acagggcgca tcgggggtgtg 960
gaatgccgtc accaagcact ggcaggtcca ggaggtgcag cccatcacca gttatgacgc 1020
ggcaggctcc ttcctcctcc tgggctgcaa caacggctcc atttactacg tggatgtgca 1080
gaagttcccc ttgcgcatga aagacaacga cctccttgtc agcgagctct atcgggaccc 1140
agcggaggat ggggtcaccg ccctcagtgt ctacctcacc cccaagacca gtgacagtgg 1200
gaactggatc gagatcgcct atggcaccag ctcaggcggc gtgcgggtca tcgtgcagca 1260
cccggagact gtgggctcgg ggcctcagct cttccagacc ttcactgtgc accgcagccc 1320
tgtcaccaag atcatgctgt cggagaagca cctcatctca gtctgtgccg acaacaacca 1380
cgtgcggaca tggtctgtga ctcgctttcg cggcatgatt tccacccagc ccggctccac 1440
cccactcgct tcctttaaga tcctggctct ggagtcggca gatgggcatg gcggctgcag 1500
tgctggcaat gacattggcc cctacggtga gcgggacgac cagcaagtgt tcatccagaa 1560
```

```
ggtggtgccc agtgccagcc agctcttcgt gcgtctctca tctactgggc agcgggtgtg 1620
ctccgtgcgc tccgtggacg gctcacccac gacggccttc acagtgctgg agtgcgaggg 1680
ctcccgggcg ctcggctctc ggccccggcg ctacctgctc actggccagg ccaacggcag 1740
cttggccatg tgggacctaa ccaccgccat ggacggcctc ggccaggccc ctgcaggtgg 1800
cctgacggag caagagctga tggaacagct ggaacactgt gagctggccc cgccggctcc 1860
ttcagctccc tcatggggct gtctccccag ccccctcacc cgcatctccc tcaccagcct 1920
ccactcagcc tccagcaaca cctccttgtc tggccaccgt gggagcccaa gccccccgca 1980
ggctgaggcc cggcgccgtg gtgggggcag ctttgtggaa cgctgccagg aactggtgcg 2040
gagtgggcca gacctccgac ggccacccac accagccccg tggccctcca gcggtctcgg 2100
cactcccctc acacctccca agatgaagct caatgaaact tccttttgaa caacgcagct 2160
gccatgatgc cttgggatgc cctggtcctg ggggactcag gtgcctccct gattcctgtg 2220
ggaaccccgg gttcagggcc agggcctcct tggaataaat ggttattgtt actaggtccc 2280
caccttccct cttttctgga agccaaagtc accctcccca ataaagtcct cactgccaaa 2340
aaaaaaaa                                                          2348

<210> 74
<211> 1139
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2172064CB1

<400> 74
ctcgagctgg gatgtgtggc aggttcctgc ggcggctgct ggcggaggag agccggcgct 60
ccacccccgt ggggcgcctc ttgcttcccg tgctcctggg attccgcctt gtgctgctgg 120
ctgccagtgg gcctggagtc tatggtgatg agcagagtga attcgtgtgt cacacccagc 180
agccgggctg caaggctgcc tgcttcgatg ccttccaccc cctctccccg ctgcgttcct 240
gggtcttcca ggtcatcttg gtggctgtac ccagcgccct ctatatgggt ttcactctgt 300
atcacgtgat ctggcactgg gaattatcag gaaaggggaa ggaggaggag accctgatcc 360
agggacggga gggcaacaca gatgtcccag gggctggaag cctcaggctg ctctgggctt 420
atgtggctca gctgggggct cggcttgtcc tggagggggc agccctgggg ttgcagtacc 480
acctgtatgg gttccagatg cccagctcct ttgcatgtcg ccgagaacct tgccttggta 540
gtataacctg caatctgtcc cgcccctctg agaagaccat ttcctaaag accatgtttg 600
gagtcagcgg tttctgtctc ttgtttactt ttttggagct tgtgcttctg ggtttgggga 660
gatggtggag gacctggaag cacaaatctt cctcttctaa atacttccta acttcagaga 720
gcaccagaag acacaagaaa gcaacccgata gcctcccagt ggtggaaacc aaagagcaat 780
ttcaagaagc agttccagga agaagcttag cccaggaaaa acaaagacca gttggaccca 840
gagatgcctg agttggagat gaactttggc caacttttct catcaccata cttaaaatcc 900
tgtccaagga ggagcttatt caccattttc tatacatgtg acatatgtag cagcataacc 960
gacaactggg actgcgctgc cttgactcca cctctacata caatgactca gctaaccaga 1020
ctaataaaag ccatgtttgc accattgctc agggaggcat tgctttgggg aattattccc 1080
agtgtcctcc ttacttatcg caagtaataa aaatcccctg ggaaatcctc aaaaaaaaa  1139

<210> 75
<211> 863
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2219267CB1

<400> 75
tcagagctag cttccgccgc agcctggcac ctcaggtgcc gaccttctac ctgccctact 60
tcctggaggc cggcctggag gcggcagcct tggtcttcct gctcctgacg gcagattgct 120
gtggacgccg ccccgtgctg ctgctgggca ccatggtcac aggcctggca tccctgctgc 180
tcctcgctgg ggcccagtat ctgccaggct ggactgtgct gttcctctct gtcctggggc 240
tcctggcctc ccgggctgtg tccgcactca gcagcctctt cgcggccgag gtcttcccca 300
cggtgatcag gggggccggg ctgggcctgg tgctgggggc cgggttcctg ggccaggcag 360
ccggcccccct ggacaccctg cacggccggc agggcttctt cctgcaacaa gtcgtcttcg 420
cctccttgc tgtccttgcc ctgctgtgtg tcctgctgct gcctgagagc cgaagccggg 480
ggctgcccca gtcactgcag gacgccgacc gcctgcgccg ctcccactc ctgcggggcc 540
gcccccgcca ggaccacctg cctctgctgc cgccctccaa ctcctactgg gccggccaca 600
cccccgagca gcactagtcc tgcctggtgg ccctgggagc caggatggga ccaaagtcaa 660
ggcctggggc atggctgagt accccagacg tctggtccag ggcagacaca ttcctctcag 720
aagcccgtgt ctcagtgcag gtggagccgt ggggacagcg tgaaggtgtc tccagccagg 780
```

ccccaggcac tgggaggccc tgggtctccc cccagccaca cccagtaggt gtggaggata 840
aaggcttctg tggaaaaaaa aaa 863

<210> 76
<211> 1322
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2308629CB1

<400> 76
ccgggggggcc ggcgcgcggg gaggccgggg cctgcaggcc cccggtacga caagatccgg 60
actccggccc ggactacgag gcgctgccgg ctggagccac tgtcaccacg cacatggtgg 120
caggcgccgt ggcagggatc ctggagcact gcgtgatgta ccccatcgac tgcgtcaaga 180
cccggatgca gagtctacag cctgacccag ctgcccgcta tcgcaatgtg ttggaggccc 240
tctggaggat tataagaacg gagggcctat ggaggcccat gaggggggctg aacgtcacag 300
caacaggcgc agggcctgcc cacgccctt atttgcctg ctacgaaaag ttaaaaaaga 360
cattgagtga tgtaatccac cctgggggca atagccatat tgccaatggt gcggccgggt 420
gtgtggcaac attacttcat gatgcagcca tgaaccctgc ggaagtggtc aagcagagga 480
tgcagatgta caactcacca taccaccggg tgacagactg tgtacgggca gtgtggcaaa 540
atgaaggggc cggggccttt taccgcagct acaccaccca gctgaccatg aacgttcctt 600
tccaagccat tcacttcatg acctatgaat tcctgcagga gcacttttaac ccccagagac 660
ggtacaaccc aagctcccac gtcctctctg gagcttgcgc aggagctgta gctgccgcag 720
ccacaacccc actggacgtt tgcaaaacac tgctcaacac ccaggagtcc ttggctttga 780
actcacacat tacaggacat atcacaggca tggctagtgc cttcaggacg gtatatcaag 840
taggtggggt gaccgcctat ttccgagggg tgcaggccag agtaatttac cagatccccct 900
ccacagccat cgcatggtct gtgtatgagt tcttcaaata cctaatcact aaaaggcaag 960
aagagtggag ggctggcaag tgaagtagca ctgaacgaag ccaggggttc agatgacact 1020
gctgcatcct ggtcacattc tctgtctcct ggaatgctcc cacctcaagt ggagttagaa 1080
ggaaggtaga ggggctctcc cccaggattt tggtgttttg actaacacca gttcctgcca 1140
acctctgttg ccaccacctt tccttccagg ccctaagcac gtgcagcaaa gcacaccaca 1200
gcaccttgga taacttcttct ccatcctggg cctgatgacc tgctctagac tgttatagag 1260
ggataagcag ctcattcccc tggttcctaa taaaaagcct ttaaattaaa aaaaaaaaaa 1320
aa 1322

<210> 77
<211> 1869
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2660038CB1

<400> 77
cagggacgct cattcctggc cagagtcctg acttcttttct cggatcgaga tctcgttgct 60
ggctccgagga aatcaccggc tcttctcccg gatccttttc ttctctcact tgctggcttt 120
cttcttcctg cctccctggc ttccatctcc caaccccgcg attccctcct ctactcccgt 180
gctcccgtcg cctccatcc tgagccatcc cacctgcaac cttctgtctt ttgccccctc 240
ttgacctcag agggtcctgc cttaagcttc tcaccagaat ctcctagatt tctatcttct 300
ccctgcttgc cagctcttga ctcccaaatt ccagctgacg tttgaccact tgacatttga 360
ccctgacacc cttgactgca aatctaaatt cttatcttct gcaacctgta ctgctgaaac 420
aggccttccc cctgtcttcc aaccccgctt tctgacaccc atttttactt tcttactctt 480
gggtcagttc ctgctacagc tatcccacca tggacttctt gatgagtggc ctggcagcct 540
gcggggccctg tgtattcacc aatcccctgg aggtggtgaa gaccaggatg cagttgcaag 600
gagaactgca ggcccctggc acataccagc ggcactaccg aaatgtcttc catgccttca 660
tcaccatcgg caaggtggat ggccttgctg ccctgcagaa aggcctggcc cccgccctct 720
tgtaccagtt cctgatgaat ggcatccgac tgggcaccta tgggctggct gaggctgggg 780
gctacctgca cagagccgaa gcgacccaca gtcctgcccg cagcgcagca gctgggggca 840
tggctggggt catgggagcc tacttgggga gccccatcta catggtgaag acacacctgc 900
aggcacaggc agcctcagaa attgctgtag ggcaccagta taagcatcag ggcatgtttc 960
aggcgctaac cgagattggc cagaaacatg gtctggtggg gttatggcgt ggggctctgg 1020
gcggcctgcc ccgagttatc gtcggttcct ccacccagct gtgcaccttc tcatccacca 1080
aggacctcct gagccagtgg gagatctttc ctccccagag ctggaagttg gcgctggtgg 1140
ctgccatgat gagtggcatt gcagttgtct tggccatggc acccttgat gtggcctgca 1200
caaggctcta caaccagccc acagatgcac agggcaaggg cctcatgtac cgggggatac 1260

tggacgctct gctgcagaca gctcggaccg agggcatttt tggcatgtac aagggtatag 1320
gtgcctccta cttccgcctc ggccccaca ccatcctctc cctcttcttc tgggaccagc 1380
tgcgctccct ctactacaca gacactaaat aacagccgct ttcccagtct ccaccaaatg 1440
agcactcctt ggccacttgt gcctccacca ctatgtcctg gtgactactg attaggtgac 1500
ctttcatcca tccatggggg acagccaacc ccactcccca tctgttctca gggttgaatc 1560
actacaagag atgagtttcc cttctttcct tgggtgttgc tttaaacctt ccctacccat 1620
tccctgggta actcacaccc ctctctcagg gctgaacgag tcatcccaaa gtgtatttcc 1680
tcccactcac cactgccacc cttgagtccc tcctgctccc atgcacagtt ttaaactcct 1740
ccctccaaaa ccaaagggaa tcgagagacc caattcccag gcgtctggga cccaggtgtc 1800
ctgttagatt caaaggcaca gagattatat tgattataaa gcaagtttat tctgaaaaaa 1860
aaaaaaaaa 1869

<210> 78
<211> 1881
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2670745CB1

<400> 78
gaagaaccga gcttggctgt gtttatctcg ttggggacta aggcgtcggt tggcgcgcaa 60
cgggttctag gctgcaggca gctcgaggac ccgcggcccc gccccggctc ggcctggcag 120
atagcagagg cagcaggccg tgccgggggg gcatgttgct gtaaccagtg gcccaggggg 180
tgttacggtg gacagtgcac ctggagggcg ggccccgcag ggtgaaccat gctgcagtgg 240
ctgtcgggca tcgggtatac tccttcgggg gttactgctc tggtgaagac tatgagacac 300
tgcgtcagat agatgtgcac attttcaatg cagtgtcctt gcgttggaca aagctgcccc 360
cggtgaagtc tgccatccgt gggcaagctc ctgtggtacc ctacatgcgc tatggacact 420
caaccgccct catcgacgac acagtcctcc tttggggcgg gcggaatgac accgaagggg 480
cctgcaatgt gctctatgcc tttgacgtca atacgcacaa gtggttcaca ccccgagtgt 540
cagggacagt tcctgggccc cgggatggac attcagcctg tgtccttaggc aagatcatgt 600
acatttttgg gggctacgag cagcaggcgg actgtttttc caatgacatt cacaagctag 660
ataccagcac catgacatgg actcttatct gtacaaaggg cagccctgca cgctggaggg 720
acttccactc agccacaatg ctgggaagtc acatgtatgt ctttgggggc cgtgccgacc 780
gctttgggcc attccattcc aacaatgaga tttactgcaa ccgcattcga gtctttgaca 840
ccagaactga ggcttggctg gactgtcccc cgactccagt gctgcctgag gggcgccgga 900
gccactcggc ctttggctac aatggggagc tgtacatctt tggtggttat aatgcaaggc 960
tgaaccggca cttccatgac ctctggaagt ttaatcctgt gtcctttacc tggaaaaaga 1020
ttgaaccgaa ggggaagggg ccatgtcccc gccggcgcca gtgctgctgt attgttggtg 1080
acaagattgt cctctttggg ggtaccagtc catctcctga ggaaggcctg ggagatgaat 1140
ttgacttcat agatcattct gacttacaca ttttggactt tagccctagt ctgaagactc 1200
tgtgcaaact ggccgtgatt cagtataacc tagaccagtc ctgtttgcct catgatatca 1260
ggtgggagct gaatgccatg accaccaaca gcaatatcag tcgccccatc gtctcctccc 1320
atgggtagga ggaagtttct gccacctccc ctcctgagcc tgctgtcatc ttcactgccc 1380
ctgcccatct gtcacccacc tgctcctttg acccctggac ttggtatacc tccatgtgga 1440
gttgttgggc gagaggtgtt ctctgtgctg tgaattcagt ggggagctgt agcgggggtgg 1500
gggctaggtt cctcccccct tgggccgagg gccccttccc cttggtgctc tgtcccccatc 1560
cacctccttt cagctgctcc tgggcctcag ctctgcccag ggccagccag gttctgctgg 1620
gaagggaagg gaatggggag aagggagaag caagcagtgt ctgagcctca ggagcttccc 1680
cctccccctt tgcctatccc ctcccctctg cttgagcctt gagccttgac tgggagctga 1740
aaggagttgc agctgttggc atgagacctc cttctccccg tcttggggag gtggggacca 1800
gcagataaat cccacccttc cttgagctgt cgctgtactc tgaagttcag ccagctcaga 1860
ttttataaaa attaattaaa a 1881

<210> 79
<211> 2004
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2676443CB1

<400> 79
aatcgcaggg ggcgtggcct agcggtcccg cccccggggc gcgcgcgcgc attggctgtg 60
cggggtgcgg gcgcgcgggc ggcgctttga accgggcgcg gggcgcgggg cgcggggcgc 120
tgcggccggt acacgccggg gtagggccgg ggtcgggttg tggtcgggcc gggattgggc 180

```
tctcctgggc catggcagcc gaggcgcgcg tgtcgcgctg gtacttcggg gggctggcct 240
cctgcggggc cgcctgctgc acgcacccgc tggacctgct caaggtgcat ctgcagacgc 300
agcaggaggt gaagctgcgc atgacgggca tggcgctgcg ggtggtgcgt accgacggca 360
tcctggcact ctacagcggc ctgagcgcct cgctgtgcag acagatgacc tactccctga 420
ctcggttcgc catctacgag actgtgcggg accgcgtggc caagggcagc cagggggcctc 480
tccccttcca cgagaaggtg ttgctgggct ccgtcacggg tttagctgga ggcttcgtgg 540
ggacgcccgc agacttggtc aacgtcagga tgcagaacga cgtgaagctg ccccagggtc 600
agcggcgcaa ctacgcccat gcgctggatg gcctgtaccg cgtagctcgt gaagagggtc 660
tcaggagact gttctcgggt gcaaccatgg catccagccg aggggcctta gtcactgtgg 720
gccagctgtc ctgctacgac caggccaagc agctggtcct tagcaccggg tacctctctg 780
acaacatctt cactcacttt gtcgccagct ttattgcagg tggatgtgcc acgttcctgt 840
gccagcccct ggatgtgctg aagactcgcc tgatgaactc caaggggtag tatcagggcg 900
ttttccactg cgccgtggag acagcgaagc tcgggcctct ggccttttac aagggcctcg 960
tcccagctgg catccgcctc atcccccaca ccgtgctcac ttttgtgttt ctggaacagc 1020
tacgcaaaaa ctttggcatc aaagtgccat cctgaccagc cgtgggaatg gctgggctgc 1080
caggccagac acgctaggtt cttccaaaga gtcccaagcc cagcacctgc tcctggggcc 1140
acgactctcc tggccgtggc cacccatcct ccgcagcagg cccctgctgt ccccccacct 1200
gctggctgag ctcctcctgg cctcgtcccc tctcagctgt agctgcacca ccccctgttt 1260
ggctaccagg ctctcccggc tgggcactgc gtgggcttgc ccctctcccg ctggcagctc 1320
ctcaggggaa caggggctac cagaggctga tttctccctt ctcctgggcc aggggagggg 1380
tattatccct gcctcctgcc cccgatgccc aaagcagcat cttccagcac tttccatcga 1440
ggacttgggt ggcagagtgt gggtgcagcc tggctgttgc tcacccaagt gctagctctg 1500
cacttcgtgt ctgctgagag caaccagacc ttccatgtcc tcgggcagct gcaactccc 1560
gcgagacccc gcagctgggt gggatgaaca agcaacgcag accacaagcg agtgcctggg 1620
agggagtggc ccagggtggt tctggagcca ttgtgggtga gggtcgaggg ccaccgaggt 1680
cccgcgcacc gctgcctgcc ctgcagtggc tttaacagtt agttttgcca aagcctctcc 1740
actcaccagc aggcggtctc tgtcttcagg gattgtgcct gcgtccctcg ggcacctggg 1800
ccccccgct tggctccctg ggggaatggc ccaggcgggc cgcggttcct ccttagggcc 1860
ttctcccga caaggagtcc gacgggggcgg atgctgcatc ctctgcctcc ctggtcgctg 1920
ggcttcaccc cacctgggaa gggcagtgtg ctctgtgggg gctgcaatca ataaatgccg 1980
ggagctgcca aaaaaaaaaa aaaa                                       2004

<210> 80
<211> 3555
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3295764CB1

<400> 80
gaccgtgggc gagtccagaa cgtcctggcc ttacagggag aaggcgtcac tcgcggttac 60
aagtgcctga ccctcactcc agttggcgga ggaggagaag gaagggccg ggccgggtcc 120
cctcccctcg cgccccggat ggatgtgccc ggccccggtgt ctcggcgggc ggcggcggcg 180
gcggccactg tgctcctgcg gaccgctcgg gtccgtcgcg aatgctggtt cttgccgacc 240
gcgctgctct gcgcctacgg cttcttcgcc agcctcaggc cgtccgagcc cttcctgacc 300
ccgtacctgc tggggccgga caagaacctg accgagaggg aggtcttcaa tgaaatttat 360
ccagtatgga cttacttcta cctggtgcta ctgtttcctg tgttccttgc cacagactac 420
ctccgttata aacctgttgt tctactgcag gggctcagcc ttattgttac atggtttatg 480
ctgctctatg cccagggact gctggccatt caatttctag aatttttttа tggcatcgcc 540
acagccactg aaattgccta ttactcttat atctacagtg tggtggacct gggcatgtac 600
cagaaagtca caagttactg tcgaagtgcc actttggtgg gctttacagt gggctctgtc 660
ctagggcaaa tccttgtctc agtggcaggc tggtcgctgt tcagcctgaa tgtcatctct 720
cttacctgtg tttcagtggc ttttgctgtg gcctggtttt tacctatgcc acagaagagc 780
ctcttctttc accacattcc ttctacctgc cagagagtga atggcatcaa ggtacaaaat 840
ggtggcattg ttactgacac cccagcttct aaccaccttc ctggctggga ggacattgag 900
tcaaaaatcc ctctaaatat ggaggagcct cccgtggagg aaccggaacc caagccagac 960
cgtctccttg tattgaaagt actatggaat gatttcctga tgtgctactc ctctcgccct 1020
cttctctgct ggtctgtgtg gtgggcctc tctacctgtg gctattttca agttgtgaac 1080
tacacacagg gcctgtggga gaaagtgatg ccttctcgct atgctgctat ctataatggt 1140
ggcgtggagg ccgttccaac cttactgggt gctgttgctg tgtttgcagt tggttatata 1200
aaaatatcct ggtcaacttg gggagaaatg acattatctc tcttttctct cctgattgct 1260
gctgcagtgt atatcatgga cactgtgggt aacatttggg tgtgctatgc atcctatgtt 1320
gtcttcagaa tcatctacat gttactcatc acgatagcaa cttttcaaat tgctgcaaac 1380
ctcagcatgg aacgctatgc cctagtattt ggtgtaaata ccttcattgc cctggcactg 1440
cagacgctgc tcactctaat tgtggtagat gccagtggcc ttggattaga aattacaact 1500
cagtttttga tctatgccag ttattttgca ctcatcgctg tggttttcct ggccagtggt 1560
```

```
gcagtcagtg ttatgaagaa atgtagaaag ctggaagatc cacaatcaag ttctcaagta 1620
accacttcat aatatactgc tgaagggctt cttcttatag caagaacttt gcacagcaac 1680
tgcctggatg tatttgattt tttaaagcgt agacatatat ttatgaatgt gcatttcttg 1740
acttcacagc agccacttga ctaatacctt gtgttccggg aataacatga tactattcag 1800
aggagccaga agtaaagttt atttcatgga ttatttatga gagctaattt aaggatgact 1860
ttttttctga ttcaaaagtg aacttgattt taaaaaccag tcaagagcaa tcaaagcagc 1920
acatggtgtt gtatacttca ttagcaagtg agtttggtgt tttataggtc acatatgtct 1980
gtatctactt agccagatgc ttggcctggt gggaccaggg ctccacagag gccacaaaat 2040
gttgcaagtc atgatggatg gaaatatgtt ctaacagcat ctgcctctat tcaatttaat 2100
tcttatttct gtgttactca tgtacattgg tctttctaca tagttattct atcactggca 2160
atatttgttc tggtttagtg ttctgtattt taaggtgtac gtatcatttc taatttaag 2220
ttattttaaa aaaattcatc atatgaatgt tcttggttcc cattgtgacg attatttatt 2280
tctgtaaaat ttgtttagaa gtacgttttt gcattattca tatgcttccc agagaagctc 2340
atttagttag aaaataaggc aagttttgaa gcctgctaaa tgaagagact taagaaagct 2400
taaggtacgc ttgcttgtct ttaaatcttc aatatgaagg actattaatt ccaagattaa 2460
aagttcatat ataggctaaa gatgtaacta ggccatttgt atttgtattc ccttttattt 2520
ccaaaataaa atgaaaaatc ttttttttaat aatttcatcc ctatttatag tttttatatt 2580
aatttgtttt tcttatccaa gtaaagatgt caataggaat tgcattagtc caaggccttt 2640
ttcataaact gagcctcttt tcaatctatt caatgggaca ggaactagga tagatgtgat 2700
tcctgcattt ttttaccttа aatctgcctt tgtttctaaa ggtagatcat cttgaatatt 2760
tgcttaaaat tgctagtgat ttcattacca agttacttga aaaaatgttc tatatgcatt 2820
taattctgaa atcagtctac caaggggctg ctagtatatg tcagacatga aaactatttt 2880
aaagctgact ttgttgcctt atcttgaaaa gaatctagat aggtgctttt aactgggtga 2940
ttaacttttt tagaatgaca cagctgaaca gtgttaataa tagtgtgtca agattgcaaa 3000
gtcgacatac tcatttggtt taagcaggaa tcctagaagc aaatggatgg ggataagaat 3060
aggtcatttt ctattcacca tcctttacta ttaagggaaa ggaaaagaac actagctaag 3120
gaagggaaag ggaagtgata tcataaaagt agcaacctтc atttacatt ctgtctgttt 3180
ttctttttt gctttgtttt gtttgtgcta atttgggaat tgtgtactcc gaaacaagta 3240
gaaaagtgct gtttgaggga ttttattaaa tcttttttta atggaatgtg gtacaaattg 3300
ttcatgttac caaagcaata tttccctgga atttaattca aagtttgtgg catacaacct 3360
gagccttttc ttatataaga caagaatatg ttcacatctt ggtatgtggc catatttata 3420
gaatgctgaa ctcaatgtgc aagttgtact gtatgcagtt ttgtaaataa gtgaaaataa 3480
tttgttgtac tttttattca attctgtata gattataaaa ttatttttat taaataaata 3540
ttttacagta tattt                                                  3555

<210> 81
<211> 1293
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3438320CB1

<400> 81
atatgcccca cgcgggactc atactacgtt tcccgtgaac acgtgcagtc caaaccccgc 60
ccctgatatt tatctcagtg gacggtggcc ggaaaaggac aatggtttcc atgtcagcgg 120
ataaacgctc tcccctcggc tcccggacgc gacggaggtc gtagtagtag tgagtacgtg 180
ctgaggagca aaggagtaac caagagatcc agtgaccgac agagcaagag ccatgccgcg 240
ccggggcctg gtggctgggc cagactтgga gtattttcag cgtcgctatt tcacgccggc 300
ggaggtggcc caacataaca ggcccgaaga cctctgggta tcttacctgg gacgcgtgta 360
cgacctaacg tcattggcac aggaatacaa ggggaacctg cgtctgaaac ccatcgtgga 420
agttgcaggc caggatatca gccactggtt tgatccaaag accagagaca tccgcaagca 480
catagatccg ctgaccggct gcctgaggta ctgcacccag cggggccgct ttgtgcacgt 540
tccgcctcag ctgcctgtt cggactgggc caacgatttt gggaagccct ggtgcaggg 600
gtcgtattat gaggtggggc ggctgtctgc caagacccgg agcatccgca tcattaacac 660
gctcacgtcg caggagcaca cactggaggt gggggttctg gagtccatat gggaaatcct 720
acaccgctat ctcccctata actcacatgc tgccagctac acgtggaaat atgaagggaa 780
gaacctgaac atggatttta ccctggaaga gaatgggatc cgggatgagg aggaagaatt 840
tgactatctc agtatggacg gtacacttca cacacctgca atacttctgt acttcaatga 900
tgatctcacg gagttgtagg caaggagatg tacactcgtg tagactcaag acgtatttcg 960
agtttggctt tttctgtgcc ttgaggaaaa gtggtggggc cgaggggtgc ctggacccag 1020
atctccactc ctcctccagga gctagcctgt gcccttctga agtgtaaagg ccctattccc 1080
tgccttcatt acagtttgct ctgagaaaat tagtgaatta atcttgggga atgatacaag 1140
aagatcaagt accttggttt agggagatgt agaagaggat agtcagagtt caggcagaac 1200
tgtttgatag ttaagagaga gtagttctac aggggtgagg gatggaagga ctttttggc 1260
aatgatggaa atgagatgtc tgcaggagat ggg                              1293
```

<210> 82
<211> 1489
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3986488CB1

<400> 82
cggggctggc gggcggcgct cttctacggg acctgctcct tcctcatcgt gcttgtcaac 60
aaggcgctgc tgaccaccta cggtttcccg tcaccaattt tccttggaat tggacagatg 120
gcagccacca taatgatact atatgtgtcc aagctaaaca aaatcattca cttccctgat 180
tttgataaga aaattcctgt aaagctgttt cctctgcctc tcctctacgt tggaaaccac 240
ataagtggat tatcaagcac aagtaaatta agcctaccga tgttcaccgt gctcaggaaa 300
ttcaccattc cacttacctt actttctggaa accatcatac ttgggaagca gtattcactc 360
aacatcatcc tcagtgtctt tgccattatt ctcgggggctt tcatagcagc tgggtctgac 420
cttgctttta acttagaagg ctatatttttt gtattcctga atgatatctt cacagcagca 480
aatggagttt ataccaaaca gaaaatggac ccaaaggagc tagggaaata cggagtactt 540
ttctacaatg cctgcttcat gattatccca actcttatta ttagtgtctc cactggagac 600
ctgcaacagg ctactgaatt caaccaatgg aagaatgttg tgtttatcct acagtttctt 660
ctttcctgtt ttttgggggtt tctgctgatg tactcccacgg tttgtgcag ctattacaat 720
tcagccctga cgacagcagt ggtggagcc atcaagaatg tatccgttgc ctacattggg 780
atattaatcg gtggagacta catttctctt ttgttaaact ttgtagggtt aaatatttgc 840
atggcagggg gcttgagata ttccttttta acactgagca gccagttaaa acctaaacct 900
gtgggtgaag aaaacatctg tttggatttg aagagctaaa gagtctgcag caggattgga 960
gactgacttg tgactgcggg ctgggggggc attcccagta ggaatgtgaa gccagaggtt 1020
tcggattcgt gacatccacc ccctgggcaa gtgagagcat ctgcaaaatg caaagagaac 1080
tacctcatat gcaggatgag ccaatggcag tctcaagaaa tgtactcggg cgacacctta 1140
cctgtggaaa gcaaatcttt tcaaaataag ccactgggac tcggtaggtg gagccccagc 1200
tgctcttcta gggacctatg gggccttcgt ggcatctctg tgctgtgtgc tggggaggag 1260
gttgatgtaa tggtgactct tttctgatca gcaccttggc cgtgattccc aaggtcccag 1320
ccaaagcaaa gggccagttg tttcagttta aacagacatg tctttagtct aataaaatta 1380
gttaactgcc agtaaagtta tttgttagct ttgatgaaag ctatgttggt atctttccct 1440
aatcatcaaa gtaaataaaa aatcatttct atgtaaaaaa aaaaaaaaa 1489

<210> 83
<211> 927
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4378816CB1

<400> 83
ctccctgctt tcctctgccg catggtcctg ggccgttggc gtcggaagcc tgaagcatgg 60
gcgctgagtg ggagctgggg gccgaggctg gcggttcgct gctgctgtgc gccgcgctgc 120
tggcggcggg ctgcgccctg ggcctgcgcc tgggccgcgg gcaggggggcg gcggaccgcg 180
gggcgctcat ctggctctgc tacgacgcgc tggtgcactt cgcgctggaa ggccctttg 240
tctacttgtc tttagtagga aacgttgcaa attccgatgg cttgattgct tctttatgga 300
aagaatatgg caaagctgat gcaagatggg tttattttga tccaaccatt gtgtctgtgg 360
aaatttctgac cgtcgccctg gatgggtctc tggcattgtt cctcatttat gccatagtca 420
aagaaaaata ttaccggcat ttcctgcaga tcacccctgtg cgtgtgcgag ctgtatggct 480
gctggatgac tttcctccca gagtggctca ccagaagccc caacctcaac accagcaact 540
ggctgtactg ttggctttac ctgttttttt ttaacggtgt gtgggttctg atcccaggac 600
tgctactgtg gcagtcatgg ctagaactca agaaaatgca tcagaaagaa accagttcag 660
tgaagaagtt tcagtgaact ttcaaaacca taaacacat tatcttaact catgaaccag 720
aatgaatcaa atctttttgt ttggccaaaa tgtaatacat tccagtctac acttgtttt 780
tgtattgttg ctcctgaaca acctgtttca aattggtttt aaggcgacca gttttcgttg 840
tattgttgtt caattaaatg gtgatatagg gaaaagagaa caaatttgaa tttgtaataa 900
taaaatgttt aattatacaa aaaaaaa 927

<210> 84
<211> 970
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4797137CB1

<400> 84
ggatgcagca gagaggagca gctggaagcc gtggctgcgc tctcttccct ctgctgggcg 60
tcctgttctt ccagggtgtt tatatcgtct tttccttgga gattcgtgca gatgcccatg 120
tccgaggtta tgttggagaa aagatcaagt tgaaatgcac tttcaagtca acttcagatg 180
tcactgacaa gcttactata gactggacat atcgccctcc cagcagcagc cacacagtat 240
caatatttca ttatcagtct ttccagtacc caaccacagc aggcacattt cgggatcgga 300
tttcctgggt tggaaatgta tacaaagggg atgcatctat aagtataagc aaccctacca 360
taaaggacaa tgggacattc agctgtgctg tgaagaatcc cccagatgtg caccataata 420
ttcccatgac agagctaaca gtcacagaaa ggggttttgg caccatgctt tcctctgtgg 480
cccttctttc catccttgtc tttgtgccct cagccgtggt ggttgctctg ctgctggtga 540
gaatggggag gaaggctgct gggctgaaga agaggagcag gtctggctat aagaagtcat 600
ctattgaggt ttccgatgac actgatcagg aggaggaaga ggcgtgtatg gcgaggcttt 660
gtgtccgttg cgctgagtgc ctggattcag actatgaaga gacatattga tgaaagtctg 720
tatgacacaa gaagagtcac ctaaagacag gaaacatccc attccactgg cagctaaagc 780
ctgtcagaga aagtggagct ggcctggacc atagcgatgg acaatcctgg agatcatcag 840
taaagacttt aggaaccact tatttattga ataaatgttc ttgttgtatt tataaactgt 900
tcaggaagtc tcataagaga ctcatgactt ccccttttcaa tgaattatgc tgtaattgaa 960
tgaagaaatc 970

<210> 85
<211> 594
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5470806CB1

<400> 85
gacaggatgg cttccctttcg cctgttcctc ctctgcctcg ctgtactgat atttgcgtct 60
gaagctggcc ctgggggtgc tggagaatcc aagtgtcctc tgatggtcaa agtcctggat 120
gctgtccgag gcagccctgc tgttgatgtg gccgtgaaag tgttcaaaaa gactgcagac 180
ggaagctggg agccgtttgc ctctgggaag accgccgagt ctggagagct gcacgggctc 240
accacagatg agaagttcac ggaagggtg tacagggtag aactggacac caaatcgtac 300
tggaaggctc ttggcatttc cccattccat gaatacgcag aggtggtttt cacagccaat 360
gactctggtc atcgccacta caccatcgca gccctgctca gcccgtactc ctacagcacc 420
actgctgtcg tcagtaaccc ccagaactga gggacccagc ccagtaggac caggatcttg 480
ccaaagcagt agcttcccat ttgtactgaa acagtgttct tgctctataa accgtgttag 540
caactcggga agatgccgtg aaacgatctt attaaaccac ctgtgatgcc aaaa 594

<210> 86
<211> 618
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5473242CB1

<400> 86
gtgttgactc gcaacctcag gaacagacac catggtgcac ctaactgatg ctgagaaggc 60
tactgttaat ggcctgtggg gaaaggtgaa ccctgttgaa attggcgctg agtccctttgc 120
cagtctgctg attgtctacc cttggaccca gaggtacttt tctaaatttg gggacctgtc 180
ctctgtctct gctatcatgg gtaaccccca ggtgaaggcc catggcgaaa aggtgataaa 240
cgccttcgat gatggcctga aacacttgga caacctcaag ggcaccttcg ccagcctcag 300
tgaactccac tgtgacaagc tgcatgtgga tcctgagaac ttcaggctcc tgggcaatat 360
gattgtgatt atgatgggcc accacctggg caaggaattc accccgagtg cacaggctgc 420
cttccagaag gtggtggctg gagtggccag tgccctggct cacaagtacc actaaacctc 480
ttttcctgct cttgtctttg tgcaatggtc aattgttccc aagagagctt ctgtcagttg 540
ttgtcaaaat gacaaagacc tttgaaaatc tgtcctacta attaaagcat ttggttcaag 600
tgttctgttg agataccc 618